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Abstract
G protein-coupled receptors (GPCR) constitute by far the largest family of transmem-
brane cell-surface proteins involved in signal transduction and are the most important
targets for the development of novel therapeutic compounds. Many processes mediated
by GPCR signal transduction are still not well understood at the molecular level and
novel methods for their investigation are of general interest. The thesis presented here
describes investigations on the neurokinin-1 receptor (NK1R), a member of the GPCR
family, using ﬂuorescence techniques.
Fluorescence resonance energy transfer (FRET), the technique of preference in this
work, is used to measure ligand-protein and protein-protein interactions in living cells.
In order to reach this goal, the NK1R has been labelled with either ﬂuorescent proteins
or by using the novel post-translational ACP labelling technique.
A FRET-based method for monitoring speciﬁc ligand binding to NK1R is described.
In this context, a ﬂuorescent agonist for NK1R was synthesized and characterized. The
ACP labelling technique was shown to be superior for this kind of experiments compared
to labelling with ﬂuorescent proteins.
The same ACP labelling approach was shown to be ideally suited to study oligomer-
ization of membrane proteins by FRET. It was shown, that the NK1R does not form
homo-dimers, as many other GPCRs do. From these experiments we furthermore con-
clude, that the NK1R is present in small microdomains in the membrane.
Interactions between the NK1R and the diﬀerent subunits of the heterotrimeric
Gαqβ1γ2-complex were investigated by FRET using diﬀerent instrumentation. Prox-
imity of the NK1R and the G protein could be detected, but no change in FRET was
observed after activation of the receptor.
Total internal reﬂection ﬂuorescence (TIRF), was used to develop an assay for study-
ing ligand binding in vitro. Here, the NK1R was immobilized directly on a surface using
a cell membrane preparation. This method was shown to be highly sensitive.
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Les récepteurs couplés aux protéines G (RCPG) forment une famille particulièrement
riche de protéines transmembranaires essentielles pour la signalisation cellulaire et con-
stituent une des cibles principales pour le développement de nouveaux composés théra-
peutiques. Les diverses étapes de la transmission d’un signal de l’extérieur vers l’intérieur
de la cellule par activation de la protéine G ne sont généralement pas connues avec pré-
cision à l’échelle moléculaire. Le développement de nouvelles méthodes d’investigation
est donc nécessaire pour acquérir une meilleure compréhension du fonctionnement in-
time des RCPG. Cette thèse applique un large éventail de techniques basées sur la
ﬂuorescence à l’étude d’un membre important de cette famille de protéines, le récepteur
neuroquinine-1 (NK1R).
La technique de transfert d’énergie par ﬂuorescence résonnante (FRET) a été utilisée
de manière prépondérante dans ce travail car elle permet la mesure des interactions
entre protéines ou entre une protéine et son ligand au sein même d’une cellule vivante.
Ce type d’étude requiert un marquage préalable du récepteur soit avec des protéines
ﬂuorescentes soit en utilisant une nouvelle technique post-translationnelle basée sur une
protéine transporteuse d’acyles (PTA).
Cette thèse établit une méthode basée sur le FRET qui permet de mesurer la liaison
spéciﬁque d’un ligand au récepteur NK1R. Un agoniste ﬂuorescent du récepteur NK1R a
d’abord été synthétisé et caractérisé. La technique de marquage par PTA s’est imposée
dans le cadre de ces expériences.
La technique de marquage par PTA est particulièrement bien adaptée à l’étude de
l’oligomérisation des protéines membranaires par FRET. Il a ainsi été démontré que le
récepteur NK1R ne forme pas des homodimères contrairement à la plupart des RCPG
étudiés précédemment. Cette série d’expériences indique aussi que le récepteur NK1R
se trouve dans des domaines microscopiques de la membrane cellulaire.
Les interactions entre le récepteur NK1R et les diﬀérentes sous-unités du complexe
heterotrimérique Gαqβ1γ2 ont été étudiées par FRET dans plusieurs conﬁgurations
xi
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instrumentales. La proximité du NK1R et de la protéine G a pu être détectée mais
aucun changement n’a été observé par FRET lors de l’activation du récepteur.
La ﬂuorescence induite par réﬂexion interne totale (TIRF) est au cœur d’un essai
qui quantiﬁe la liaison d’un ligand à son récepteur in vitro. De manière innovante, le
récepteur NK1R a été immobilisé sur une surface directement à partir d’une préparation
cellulaire. Cette méthode se distingue par sa très haute sensibilité.
Chapter 1
General Introduction to GPCR
Signaling
1.1 Transmembrane Signaling
The ability of organisms, or individual cells, to react to external signals is crucial for
their survival. These various signals can be either physical (e.g. light, temperature and
pressure) or chemical stimuli (e.g. organic odorants, nucleotides, nucleosides, peptides,
lipids and proteins). Regardless of the nature of the signal, the target cell responds
by means of speciﬁc receptors. In most cases, these receptors are transmembrane cell-
surface proteins, because the signal has to overcome the plasma membrane separating
the extracellular environment from the interior of the cell.
A basic deﬁnition of a receptor is that it must recognize a distinct extracellular
stimulus and translate that information into an intracellular signal to which the cell
can respond. Receptors are typically composed of three domains (Figure 1.1): a signal
receiving domain, a transducing domain and an eﬀector domain , which can be either
comprised all within a single protein (e.g. ion channels) or separated into diﬀerent
proteins (e.g. G protein-coupled receptors and G proteins).
1.2 Receptor Classiﬁcation
The three largest classes of cell-surface receptors are ligand-gated ion channels, enzyme-
linked receptors and G protein-coupled receptors. They are deﬁned according to the
transduction mechanism used [1, 2].
Ligand-gated ion channels are involved in rapid synaptic signaling between elec-
trically excitable cells (Figure 1.2A). This type of signaling is mediated by a small
1
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R
T
E
Effect
Signal
Light
Odorants
Peptides
Hormones
Figure 1.1: Concept of transmembrane signaling. R, signal receiving domain; T,
transducing domain ; E, eﬀector domain.
number of neurotransmitters released from the presynaptic cell. The neurotransmitters
transiently bind to the receptor and thereby open an ion channel formed in the receptor,
which in turn brieﬂy changes the ion permeability of the plasma membrane and thereby
depolarizes the membrane potential of the postsynaptic cell.
Ligand
Ion flux
A
γ
β
Gα
G protein
CB
active catalytic
domain
signal molecule
 in form of a dimer
Figure 1.2: Receptor superfamilies. A, ligand-gated ion channels. B, Enzyme-linked
receptors (with an intrinsic enzyme). C, G protein-coupled receptors.
Enzyme-linked receptors, when activated, either function directly as enzymes or are
directly associated with enzymes that they activate (Figure 1.2B). The great majority
of these receptor are protein kinases (e.g. receptor tyrosine kinase) or are associated
with protein kinases (e.g. cytokine receptors). Enzyme-linked receptors are involved
in growth, proliferation, diﬀerentiation, and are important for the survival of the cell.
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They have a single transmembrane polypeptide chain and an extracellular ligand-binding
domain. The cytosolic domain has either an intrinsic enzyme activity or associates
directly with an enzyme.
G protein-coupled receptors (GPCR) act indirectly to regulate the activity of sep-
arate eﬀector proteins (Figure 1.2C). The interaction between the receptor and its
eﬀector is mediated by a third protein called the heterotrimeric GTP-binding protein
(G protein). The activation of the eﬀector, which can be either an enzyme or an ion
channel, can change the concentration of one or more intracellular mediators. These
mediators act in turn to alter the behavior of other signaling proteins in the cell.
1.3 GPCRs and Heterotrimeric G Proteins
G protein-coupled receptors constitute by far the largest family of transmembrane cell-
surface proteins involved in signal transduction. There are approximately 950 genes
in the human genome encoding GPCRs, of which 500 are odorant or taste receptors
and 450 are receptors for endogenous ligands [3]. GPCRs recognize signals as diverse
as light, odorants, hormones, growth factors and neurotransmitters. They interact
with heterotrimeric guanine nucleotide-binding proteins, so-called G proteins, which
transmit the receptor signal to diﬀerent eﬀectors. GPCRs are involved in a wide range
of physiological processes and, not astonishingly, are implicated in numerous diseases.
This makes GPCRs one of the most important target class of proteins for medicines [4].
1.3.1 Structure of GPCRs
GPCRs are integral plasma membrane proteins with a molecular mass ranging from
about 40 to 85 kD. All GPCRs sequenced so far share a common topology illustrated in
Figure 1.3, although they do not share any overall sequence homology [5]. They comprise
seven transmembrane helices (TM), which are connected by intracellular and extracel-
lular loops. The N-terminus is located on the extracellular side and the C-terminus
on the intracellular side of the plasma membrane [6, 7]. Only recently Palczewski et
al. [8] solved the crystal structure of the ﬁrst GPCR, rhodopsin, to 2.8Å resolution
(Figure 1.3A).
According to sequence homology, GPCRs can be further classiﬁed into 3 major
families (Figure 1.3B) [5, 9]. Family A, also named rhodopsin-like family, represents
the largest subgroup of these receptors and includes catecholamine, neuropeptides,
chemokine, glycoprotein, lipid and nucleotide receptors. The receptors share a set of
4 CHAPTER 1. GENERAL INTRODUCTION TO GPCR SIGNALING
BA
Family B
Family C
Family A
Figure 1.3: Structural properties of GPCRs. A, 2.8Å crystal structure of
rhodopsin [8]. B, topology model of G protein-coupled receptor families with extracel-
lular N-terminus, 7 transmembrane helices, intracellular C-terminus and the extra- and
intracellular loops (from [9]).
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∼20 highly conserved amino acids in the cytoplasmic side of the transmembrane core.
The high degree of conservation among these residues suggests an essential role for
structural and/or functional integrity of the receptors. The ligand binding sites are
formed by the extracellular loops and the transmembrane helices. The only residue
that is conserved in all family A receptors is the arginine in the Asp-Arg-Tyr (DRY)
motif at the cytoplasmic side of TM3. A palmitoylation site follows the last TM he-
lix. The hydrophobic palmitoyl inserts into the intracellular side of the membrane,
forming a “fourth" intracellular loop. Family B contains receptors for a large number
of peptides such as calcitonin-gene-related peptide (CGRP) and calcitonin. The most
prominent characteristics of family B receptors is a large (∼100 amino acids) extra-
cellular N-terminus containing several cysteins. It seems to play a key role for ligand
binding, although it is not suﬃcient and additional ligand interaction sites are found
on the extracellular loops connecting the TMs. The DRY motif, which is important
for family A receptors, is absent in family B receptors. Family C is the metabotropic
family comprising the metabotropic glutamate receptors (mGluRs), γ-amino butyric
acid receptors (GABAB) and the calcium-sensing receptor. They are characterized by
an exceptionally long N-terminus (500-600 amino acids) containing the ligand binding
site.
1.3.2 Structure of G proteins
Heterotrimeric GTP binding proteins (G proteins) are peripheral membrane proteins,
which are preferentially bound to the cytosolic face of the plasma membrane (Fig-
ure 1.4). They consist of an α-subunit and a βγ-complex, which is not dissociable
under non-denaturing conditions. Up to now, at least 23 α-subunits derived from 17
diﬀerent genes have been identiﬁed and are classiﬁed into four families (Gαi/o, Gαs,
Gαq/11, and Gα12). Concerning β- and γ-subunits, at least 6 and 12 diﬀerent molecular
species have been described, respectively. The molecular mass of Gα-subunits ranges
from 39-52 kD and they consist of two domains: the GTPase domain and the α-helical
domain. The GTPase domain contains the GDP/GTP binding site and exhibits a high
structural similarity with other small GTPases. The helical domain comprises 6 helices
and is believed to increase the aﬃnity for GTP. Furthermore, it seems to participate in
eﬀector recognition. Both the N- and C-terminus of the α-subunit are closely located to
the plasma membrane and the N-terminus of certain α-subunits is post-translationally
modiﬁed by lipid groups. The molecular mass of the β- and γ-subunit is about 36 kD
and 6-9 kD, respectively. Both β- and γ-subunits are post-translationally modiﬁed by
lipid groups and thus tether the βγ-complex to the plasma membrane. Several reviews
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about heterotrimeric G proteins are found in literature [10–14].
Plasma Membrane
Nt
Nt
Nt
Ct
Ct
Gαi1-subunit
Gβ1-subunit
Gγ2-subunit
Figure 1.4: Structure of a heterotrimeric G protein. Crystal structure at 2.3Å of
Gαi2 complexed with Gβ1γ2 (PDB:1GG2) [15]. Ct and Nt indicate C-terminus and N-
terminus, respectively.
1.4 Mechanism of GPCR Signal Transduction
1.4.1 Receptor - G protein Interaction
Extensive mutational analysis revealed some interaction sites of GPCRs with G pro-
teins. These include the intracellular loops i2, i3 and, to a lesser extent, i4 [6, 16]. The
same G protein subtype can be activated by diﬀerent receptors containing structurally
diﬀerent intracellular loops, thus, the prediction of the coupling speciﬁcity of a GPCR
cannot be deduced from its primary structure [17]. The extreme C-terminus of the Gα
subunit seems to be critical for its interaction with the receptor, especially for the speci-
ﬁcity of the receptor-G protein coupling [18, 19]. Also the extreme N-terminus of Gα
appears to speciﬁcally interact with the receptor [20]. This was shown in experiments
using chimeric G proteins. Furthermore, there are indications, that the Gβγ subunit
takes also part in binding to the receptor, but the structural elements involved in this
interaction are less well characterized [21]. There are now several independent lines of
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evidence that suggest that G protein activation may require a dimeric GPCR interacting
with a single heterotrimeric G protein [22]. It remains still an open question whether
receptors are pre-associated with G proteins before ligand binding or if they associate
upon receptor activation.
1.4.2 Principles of GPCR-G Protein Activation and Deactiva-
tion
The classic paradigm of the GPCR signal transduction is a simple linear model: a
ligand-activated receptor protein activates a G protein, which can activate or inhibit a
downstream eﬀector protein [23].
The G protein exists in two forms: The inactive, heterotrimeric form, in which
the Gα-subunit complexes the nucleotide guanosine diphosphate (GDP) and the active
form, in which Gα binds the nucleotide guanosine triphosphate (GTP). Binding of an
extracellular ligand to the receptor results in its conformational change, which promotes
the Gα-subunit to exchange GDP for GTP. The GTP-complexed and activated Gα dis-
sociates from the βγ-subunit, which then becomes activated as well. Gα and Gβγ then
interact with several diﬀerent eﬀector proteins, which modulate the intracellular concen-
tration of second messengers, leading to a cellular response. Eventually, GTP hydrolysis
occurs on the α-subunit. This step is often accelerated by the binding of another protein,
called a regulator of G protein signaling (RGS). The inactivated, GDP-bound α-subunit
re-associates with the βγ-complex, thereby turning oﬀ other downstream events [24–26].
Recent ﬁndings indicate that the classical model of G protein coupling and acti-
vation of second-messenger-generating eﬀectors do not fully explain their remarkably
diverse biological actions. Among them are GPCR oligomerization [27] and the discov-
ery that many proteins, e.g. chaperons, interact with GPCRs [28]. Also the paradigm
of G protein subunit dissociation has been challenged [29–31].
1.4.3 GPCR Activity States
Molecular pharmacology divides ligands into full, partial and inverse agonists as well
as neutral antagonists [32]. Full agonists are those ligands, which elicit the maximal
observed response upon receptor binding, whereas partial agonists only evoke a partial
response. Inverse agonists counteract with an existing basal activity of the free receptor.
Neutral antagonists inhibit the action of agonists but do not change the activity state
of the receptor. An extensive description of the diﬀerent allosteric receptor models is
found in [33,34].
8 CHAPTER 1. GENERAL INTRODUCTION TO GPCR SIGNALING
The extended ternary complex model
In the ternary complex model a receptor, an agonist and a heterotrimeric G protein
form a complex which leads to the activation of the G protein (Figure 1.5A). This
L+R+G
L+R  G
L  R+G
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L+R+G
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C
Figure 1.5: Diﬀerent models for GPCR activation. A, Ternary complex model,
and B, extended ternary complex model, which includes an activated receptor state R*
(taken from [35]). C, Taking into account that the potency of agonists acting on one
particular receptor depends on the G protein which couples to it, two activated states of
the receptor have to be assumed, R* and R** (adapted from [36]).
model implicitly states that an allosteric transition occurs upon agonist binding which
induces G protein activation - otherwise, the receptor would be constitutively active.
The discovery of mutations in β-adrenergic receptor which result in constitutive activity,
and the subsequent ﬁnding that antagonist could counteract these mutations, led to a
revised model of receptor activation, the extended ternary complex model (Figure 1.5B)
[35]. In this model, the receptor exists in an equilibrium between an inactive and an
active conformation, R and R*. Only the latter can interact with the G protein, but
both can interact with ligands. Agonists have a preference for the R* state, i.e. they
show higher aﬃnity for the R* than for the R state, thus, their binding leads to a shift of
the R R* equilibrium to the right, increasing the rate of G protein activation. Inverse
agonists have a high aﬃnity for R and shift the equilibrium to R. Partial agonists prefer
R* over R, but do not fully shift the equilibrium to the former. Neutral antagonists
bind to both, R and R*, and thereby exclude the binding of agonists, but do not change
the conformational equilibrium of the receptor.
The extended ternary model can explain why GPCRs often show two diﬀerent aﬃni-
ties for agonists. According to this theoretical model the receptor exists in equilibrium
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between two diﬀerent conformations, R and R*. Only the latter can interact with the
G protein, but both can interact with ligands. Agonists show higher aﬃnity for the R*
than for the R state. In native membranes, only the higher aﬃnity is observed. In vitro
in absence of G proteins, or if the system is treated with GTPγS (irreversibly activating
G proteins), only the low aﬃnity state is observed. Thus, G proteins can also induce
the R* state of the receptor.
This is of importance for recombinant expression systems [37], because overexpressed
GPCRs are generally present in excess in their host cells, and only a small fraction is
complexed to G proteins. In these cells and in plasma membranes harvested from
them, a bi-phasic isotherm for agonist binding is measured, which is the result of a
superposition of the two (high and low aﬃnity) binding curves.
A thermodynamically more complete version of the extended ternary complex model
is the cubic ternary complex model [38–40]. It allows non-activated receptors to interact
with G proteins to produce non-signaling species. This non-signaling complex is required
to complete the system, but might be not relevant physiologically.
Multiple activity states
Leﬀ et al. suggested that the extended ternary model is still too simpliﬁed to account
for some experimental results (Figure 1.5C) [36]. Receptors which can couple to diﬀer-
ent G protein subtypes, i.e. activate diﬀerent transduction cascades, have been found
to show diﬀerent relative potencies of their agonists, depending on which transduction
cascade is available. This is in disagreement with the assumption that the same receptor
conformation activates diﬀerent G proteins. If this is the case, the eﬃcacies to evoke a
response for the two pathways would be diﬀerent for a given agonist, but the relative
potencies between the diﬀerent agonists would be the same, irrespectively which trans-
duction cascade is activated. Therefore, it has been proposed that at least two, if not
more, activated forms of a GPCR exist, each of which preferentially interacts with a
subset of agonists and the appropriate G protein.
1.5 Signal Transduction Pathways
G proteins act as transducing units and transmit the signal from the receptor to the
eﬀector. The α- as well as the βγ-subunits can interact with diﬀerent eﬀectors and
thereby activate diﬀerent signaling pathways (Table 1.1). In the following a description
of the two most important G protein-coupled signaling pathways is presented.
10 CHAPTER 1. GENERAL INTRODUCTION TO GPCR SIGNALING
Subunit Family Main subtypes Primary eﬀector
α αs Gαs, Gαolf Adenylate cyclase ↑
αi/o Gαi1, Gαi2, Gαi2 Adenylate cyclase ↓
GαoA, GαoB K+ channels ↑
Gαt1, Gαt2 Ca2+ channels ↓
Gαz Cyclic GMP phosphodiesterase ↑
αq Gαq, Gα11, Gα14, Phospholipase C ↑
Gα15, Gα16
α12 Gα12, Gα13 ?
β β1-5 (6?) Diﬀerent assemblies Adenylate cyclase ↑/↓
of β- and γ-subunits Phsopholipase ↑
Phosphatidylinositol 3-kinase ↑
γ γ1-11 (12?) Protein kinase C ↑
Protein kinase D ↑
GPCR kinases ↑
Ca2+, K+ (and Na+) channels
Table 1.1: Heterotrimeric G proteins and their eﬀectors. The arrows indicate up-
or down regulation of the eﬀector (from [41]).
1.5.1 The cAMP Pathway
Cyclic AMP (cAMP) is synthesized from ATP by a plasma-membrane-bound enzyme
adenylyl cyclase (AC), and is rapidly and continuously degraded by cyclic AMP phos-
phodiesterases [42]. There are at least 8 isoforms of AC in mammals, most of which are
regulated by both G proteins and calcium. The receptors that act through cAMP can
either stimulate the AC via a stimulatory G protein (Gαs or Gαolf) or inhibit it via a
inhibitory G protein (Gαi). But also the βγ-subunit of the heterotrimeric G protein can
stimulate or inhibit AC (Table 1.1). Both Gαs and Gαi are targets for bacterial toxins.
Cholera toxin from the bacteria that causes cholera, catalyzes the ADP ribosylation
of the Gαs-subunit and inhibits the hydrolysis of bound GTP. The α-subunit retains
its bound GTP and remains in an active state. Pertussis toxin from the bacteria that
causes pertussis (whooping cough), catalyzes the ADP ribosylation of the Gαi-subunit
and therefore preventing it from interacting with the receptor. The α-subunit retains its
bound GDP and remains in an inactive state. Activation of AC leads to a rapid increase
of the cAMP level in the cytosol. This directly activates protein kinase A, which in turn
phosphorylates a variety of proteins and thereby modulates their activity.
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1.5.2 The DAG/IP3 and Calcium Signaling Pathway
Many GPCRs exert their eﬀects via G proteins, mainly Gαq, that activate the plasma-
membrane-bound enzyme phospholipase C-β (PLCβ) [43]. PLCβ cleaves the lipid
phosphatidyl-inositol-4,5-bisphosphate into diacylglycerol (DAG) and the cyclic alco-
hol inositol-trisphosphate (IP3). Both, DAG and IP3, are second messengers. IP3 acts
directly on calcium channels in the endoplasmatic reticulum. This leads to a fast in-
crease in the cytosolic calcium concentration. DAG acts via protein kinase C to open
L-type calcium channels in the plasma membrane. The inositol phospholipid signaling
pathway is illustrated in Figure 1.6.
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Figure 1.6: Inositol phospholipid signaling pathway through Gαq. (1) Receptor
activation by external signal. (2) Activation of G protein. (3) Hydrolysation of phosphat-
idylinositol-4,5-bisphosphate (PIP2) to IP3 and DAG by Phospholipase C (PLC). (4) IP3
acts on calcium channels in the endoplasmic reticulum releasing calcium to the cytosol.
(not shown in ﬁgure) DAG acts via protein kinase C to open L-type calcium channels in
the plasma membrane (adapted from [44]).
1.5.3 Other Pathways
Some G proteins directly activate or inactivate ion-channels in the plasma membrane
(Table 1.1). G protein activated inward rectiﬁer potassium channels (GIRK) are e.g.
12 CHAPTER 1. GENERAL INTRODUCTION TO GPCR SIGNALING
found in the heart. The Gβγ subunit has been shown to directly bind to these channels
and to gate their pore [45]. Additional eﬀector systems that were classically believed to
be activated by growth-factor receptors via tyrosine kinase activation were also shown
to be modulated by GPCRs. In particular, the ERK, p38 and mitogen-activated protein
kinase (MAPK) signaling pathways were shown to be activated by G proteins of the
Gαq, Gαi and Gαs families. In addition, G protein-independent signaling has been
documented, such as Na+/H+-exchanger regulatory factor (NHERF) or activation of
the Janus kinases (JAK) [46,47].
1.5.4 Diversity, Selectivity and Multiplicity
Complex cell behaviors, such as cell survival and cell proliferation, are generally stim-
ulated by speciﬁc combinations of extracellular signals rather than by a single signal
acting alone. Therefore it is not surprising that the concept of signal transduction
pathways in a linear fashion (one receptor coupling to one G protein that activates one
eﬀector) is inadequate to explain all experimental ﬁndings.
The same ligand can activate many diﬀerent receptor family members. The same
receptor can couple to diﬀerent combinations of heterotrimeric G protein subunits and
thereby act through diﬀerent signaling pathways and generate multiple intracellular
signals. All this leads to a complex signaling network (reviewed in [7, 16, 24, 41, 48]).
The stability and speciﬁcity of a receptor-G protein-eﬀector complex could be enhanced
by the presence of a scaﬀolding protein [28].
1.6 GPCR Desensitization
Activation of a GPCR by its agonist also initiates the process of receptor desensitization,
a negative feedback reaction to prevent potentially harmful eﬀects due to persistent
receptor stimulation.
Desensitization includes the uncoupling of the receptor from the G proteins in re-
sponse to receptor phosphorylation, the internalization of cell surface receptors to in-
tracellular membranous compartments, and the downregulation of the total cellular
complement of receptors due to reduced receptor mRNA and protein synthesis, as well
as the lysosomal and plasma membrane degradation of pre-existing receptors. The
time frames over which these processes occur range from seconds (phosphorylation) to
minutes (endocytosis) and hours (down-regulation). [49]
Phosphorylation occurs at residues within the intracellular loops and C-terminus of
the receptor and is mediated by both second messenger-dependent protein kinases and
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G protein-coupled receptor kinases (GRKs). Second-messenger dependent kinases, such
as protein kinase A and C (PKA, PKC), are activated in response to GPCR-stimulated
increases in second-messengers (e.g. calcium, cAMP, and diacylglycerol). Thus, the
activation of PKA or PKC can lead to a general desensitization of GPCRs. GRKs
selectively phosphorylate agonist-activated receptors, thereby promoting the binding of
arrestins, which sterically uncouple the receptor from the G protein. [49,50]
G protein-coupled receptor internalization is mediated by arrestins [51]. Arrestins
are involved in both the physical uncoupling of GPCRs from heterotrimeric G proteins
(desensitization) and the targeting of GPCRs to clathrin-coated pits for endocytosis
that leads to the loss of the receptor on the cell surface (internalization). Arrestins
bind preferentially to agonist-activated and GRK-phosphorylated GPCRs as opposed
to second-messenger protein kinase-phosphorylated or non-phosphorylated receptors.
Studies on the translocation of β-arrestin 1 and β-arrestin 2 to GPCRs have shown
that GPCRs can be divided into two classes, A and B, on the basis of their internalization
properties [52]. Complexes between class A receptors and β-arrestin 1 or β-arrestin 2 are
relatively unstable, dissociate at or near the plasma membrane, and the arrestins are
excluded from receptor-containing vesicles. Complexes between class B receptors and
β-arrestin 1 or β-arrestin 2 are stable and internalize together into endocytic vesicles.
Classical and new roles of β-arrestins have been reviewed by Pierce and Lefkowitz [53].
Just as GPCR desensitization provides a mechanism protecting cells against receptor
overstimulation, GPCR resensitization protects cells against prolonged receptor desen-
sitization, which would leave a cell unable to respond appropriately to extracellular
stimuli. The mechanism by which the resensitization of GPCRs is achieved is thought
to be the agonist-stimulated internalization of receptors to an intracellular membrane
compartment (endosomes) enriched in a GPCR-speciﬁc phosphatase activity. GPCRs,
dephosphorylated in endosomes, are subsequently recycled back to the cell surface.
1.7 Oligomerization of GPCRs
GPCRs were for a long time presumed to function as monomers according to the pre-
vailing model: one ligand molecule-one receptor-one G protein [23]. But recently, the
existence of dimeric or higher oligomeric structures for some GPCRs has been found by
biochemical and biophysical methods (for reviews [9, 22, 46, 54–58]). There is no con-
sensus on the role of GPCR oligomerization, but several potential roles are suggested
(Figure1.7).
Oligomerization is seen either between the same receptor subtype (homo-oligomer-
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Figure 1.7: Potential roles of GPCR dimerization during GPCR life cycle. (1)
In some cases, dimerization has been shown to have a primary role in receptor maturation
and allows the correct transport of GPCRs from the endoplasmic reticulum (ER) to the cell
surface. (2) Once at the plasma membrane, dimers might become the target for dynamic
regulation by ligand binding. (3) It has been proposed that GPCR hetero-dimerization
leads to both positive (+) and negative (-) ligand binding cooperativity, as well as (4)
potentiating (+)/attenuating (-) signaling or changing G-protein selectivity. (5) Hetero-
dimerization can promote the co-internalization of two receptors after the stimulation of
only one protomer. Alternatively, the presence of a protomer that is resistant to agonist-
promoted endocytosis, within a heterodimer, can inhibit the internalization of the complex
(from [27]).
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ization) or between diﬀerent receptor subtypes (hetero-oligomerization). Furthermore,
one can distinguish between constitutive oligomerization and ligand-dependent oligo-
merization. Preformed oligomers of some GPCRs may serve as a signaling platform
that retains its multimeric status throughout the GPCR life cycle. Other GPCRs may
cycle through monomeric and multimeric states in a ligand-regulated process that itself
is part of the signaling pathway. GPCR hetero-dimerization can result in altered lig-
and selectivities and distinctive coupling to signal transduction pathways, providing an
additional source of complexity and richness for the ﬁne-tuning of cellular signaling.
1.8 Neurokinin-1 Receptor
In this thesis we will focus on the G protein-coupled receptor neurokinin-1 (Substance P
receptor or NK1 receptor, NK1R). The human NK1 receptor consists of 407 amino acids
and has a calculated relative molecular mass of 46 kD. Like all GPCRs it comprises 7
predicted transmembrane helices with an extracellular N-terminus and an cytosolic C-
terminus. It is a neuropeptide receptor and belongs to the tachykinin receptor subfamily,
which are family A or rhodopsin-like receptors. Other members of the tachykinin re-
ceptor subfamily are the neurokinin 2 (NK2R) and neurokinin 3 (NK3R) receptors.
All three receptors bind the three most abundant tachykinins, which they distinguish
with only moderate selectivity; substance P (SP) is preferred by the NK1R whereas
the NK2R and NK3R have a higher association constant for neurokinin A (NKA) and
neurokinin B (NKB), respectively. The aﬃnities are in the low nanomolar range. [59]
Tachykinin receptors are found in central and peripheral nervous system [60, 61].
The NK1 receptor is involved in a variety of diﬀerent processes, e.g. neural signal
transmission, regulation of the intestine, hematopoiesis, nociception and neurogenic
inﬂammation, and is therefore an important pharmacological target [62].
Tachykinins, the naturally occurring agonists for the neurokinin receptors are small
peptides, which share a common C-terminal sequence (Phe-X-Gly-Leu-Met-NH2) and
a similar spectrum of biological activities [63–65]. The classical natural agonist with
highest aﬃnity for the NK1 receptor is the undecapeptide SP. The existence of SP
was described as early as 1931 by Von Euler and Gaddum [66]. The three classical
members of the mammalian tachykinin family SP, NKA and NKB are encoded by the
two genes preprotachykinin 1 (TAC1) and preprotachykinin 2 (TAC2) [64]. Recently,
a third mammalian tachykinin gene (TAC4) has been discovered coding for hemokinins
and endokinins [67,68]. Structure-activity studies have led to the development of several
peptide and non-peptide ligands for the NK1 receptor [59], some of which are commer-
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cially available.
The interaction of SP with the NK1 receptor mainly activates the G protein Gαq,
leading to the activation of phospholipase C, the increase of the intracellular concen-
tration of IP3 and DAG, and ﬁnally calcium [69]. Furthermore, NK1R can interact
with Gαs and act via the cAMP pathway [70] and there is evidence that it interacts
also with Gαo [71]. Studies on NK1R Gαq and Gαs fusion proteins revealed two active
molecular phenotypes, representing complexes with either Gαq or Gαs [72]. The authors
proposed that these molecular forms do not interchange readily, which could be due to
the presence of microdomains within the cell membrane. Very recently, Monastyrskaya
et al. [73] showed localization of NK1R in plasma membrane microdomains by biochem-
ical methods, and that its functionality depends on these microdomains, supporting the
previous ﬁndings.
Activation of NK1R stimulates translocation of GRKs and β-arrestins from the cy-
tosol to the membrane within seconds. GRKs phosphorylate NK1Rs and β-arrestins
then interact with the GRK-phosphorylated receptors [74, 75]. This leads to desensiti-
zation and internalization of NK1R, which was shown to take place within 3 minutes
of SP incubation at 37◦C [76], but also occurred within minutes after SP application at
18◦C [77]. The internalization can be prevented by C-terminal truncation of NK1R [78].
Martini et al. [79] fused β-arrestin 1 to the C-terminus of NK1R. The fusion protein
was almost totally silenced with respect to agonist-induced signaling through Gαq/11
and Gαo pathways. The NK1R-βarr1 fusion bound non-peptide antagonist with in-
creased aﬃnity, but surprisingly also bound agonists, SP and NKA, with high, normal
aﬃnity.
Furthermore, it was shown that the NK1R belongs to the class B receptors, because
(i) it forms stable complexes with β-arrestin 1 or β-arrestin 2 and (ii) they internalize
together into endocytic vesicles [52]. Recently, Bennett et al. [80] suggested that NK1R
internalization is not required for desensitization but is important in resensitization.
Interestingly, the pathway of internalization seems to be SP concentration dependent
[81]. High SP concentration (> 10nM) leads to translocation of NK1R into perinuclear
acidiﬁed endosomes, where they remain for several hours. Low SP concentration (1 nM)
leads to translocation into early endosomes and rapid recycling.
Also the oligomerization of NK1R was investigated, but so far only hetero-dimeriza-
tion with the µ-opioid receptor was shown [82]. Until now, there is no evidence for
homo-dimerization.
Chapter 2
Aim and Scope of this Thesis
The aim of this thesis is to investigate by ﬂuorescence (microscopic) techniques the
function of the NK1 receptor in whole cells. We focus on observing ligand-activated
biochemical interactions between the NK1 receptor and corresponding components of
its signal cascade. The chosen system serves as an example for developing methods to
monitor complex biochemical networks under physiological conditions, which might be
the basis for novel screening assays.
Chapter 4 describes the FRET methodology used throughout this thesis. FRET
occurs when an excited donor ﬂuorophore transfers its excitation energy non-radiatively
to an acceptor ﬂuorophore with an eﬃciency that depends strongly on their relative
distance. Therefore, FRET can quantify molecular association. Here, two ways to
determine FRET are used: The ﬁrst method is based on the evaluation of spectra
recorded either from cell suspensions using a common photospectrometer or from single
cells using a microscope equipped with a CDD camera coupled to a spectrometer. The
second method is based on ﬂuorescence micrographs of single cells recorded with a laser
scanning confocal microscope (FRET imaging).
Chapter 5 deals with the ﬂuorescence labelling of NK1R for investigations in living
cells. The NK1R is labelled with either ﬂuorescent proteins (e.g. EGFP) or by using the
novel ACP labelling technique. The design and cloning of the NK1R fusion constructs
and the conﬁrmation of functionality of the NK1R fusion proteins by means of calcium
signaling are described.
Chapter 6 deals with the synthesis and characterization of ﬂuorescent derivatives of
NK1R agonists to act as acceptors for the donor-labelled NK1R. Preliminary investiga-
tion of speciﬁc ligand binding using a FRET-based approach are presented.
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In Chapter 7 the ACP labelling method is used to simultaneously label the NK1R
with donor and acceptor in a well deﬁned ratio. FRET imaging is applied to investigate
the oligomerization degree and compartmentalization of NK1Rs.
Chapter 8 deals with the ﬂuorescence labelling of the heterotrimeric G protein and
FRET-based studies to investigate interactions between receptor and G protein subunits
or between Gα- and Gβγ-subunits.
In Chapter 9, a novel approach to immobilize minute amounts of recombinant, bi-
otinylated membrane receptor proteins in a uniform orientation on streptavidin-coated
sensor surfaces is described. Very sensitive total internal reﬂection ﬂuorescence (TIRF)
is used to investigate ligand binding on immobilized NK1Rs.
Chapter 3
Experimental Techniques and
Procedures
This chapter deals with the materials and general methods used throughout this work
unless otherwise stated. It includes the standard techniques for cell cultures, transient
and stable expression, calcium ion signaling, ﬂuorescence confocal microscopy, and ACP
labelling.
3.1 Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM), fetal calf serum (FCS) and Dulbecco
phosphate-buﬀered saline (D-PBS) were from Invitrogen (Breda, NL); hygromycin B
was from Calbiochem (Darmstadt, D); bovine serum albumin (BSA) and EDTA was
from Fluka (Buchs, CH); Substance P was from K. Servis (UNIL, Lausanne, CH);
bacitracin was from Serva; CoA-Cy3, CoA-Cy5 and AcpS from were a kind gift from
Nathalie George and Kai Johnsson of the Institute of Chemical Sciences and Engineer-
ing, Lausanne, Switzerland; tetramethylrhodamine-conjugated substance P (SP-TMR)
was from Molecular Probes (Eugene, OR, USA); NK1R antagonist L-732,138 was from
Tocris Cookson (Langford, UK).
3.2 Cell Cultures
Adherent human embryonic kidney cells (HEK293 cells) and Gq/11-deﬁcient mouse ﬁ-
broblasts were cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented
with 2.5% and 10% fetal calf serum (FCS), respectively, in a humidiﬁed 5% CO2 at-
mosphere at 37◦C. Cells were sub-cultivated twice a week at ratios between 1:10 and
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1:100. For confocal microscopy HEK293 cells were seeded (1 · 1015 cells/ml) into 8-well
plates (Nalge Nunc International, UK) or into 6-well plates (TPP, Trasadingen, CH)
containing a 25mm diameter glass coverslip (Assistent, D), in 200µl and 2ml culture
medium, respectively.
3.3 Transient and Stable Expression
HEK293 cells (45-75% conﬂuent) were transfected 16 to 20 hours after splitting, with
calcium phosphate-precipitated DNA as described [83]. Per 1ml of medium 2.5µg of
plasmid DNA was diluted in 50µl calcium buﬀer (250mM CaCl2) and was added to
50µl phosphate buﬀer (140mM NaCl, 1.4mM Na2HPO4, 50mM HEPES, pH 7.05 at
23◦C). After 1 minute incubation at room temperature the transfection solution was
added to the cell culture medium. After 4 hours incubation at 37◦C, the transfection
solution was replaced by fresh medium. Experiments were performed 24-55 hours after
transfection. Stable HEK293 cell lines were produced from cells transiently transfected
with the desired constructs in pCEP4 expression vectors by selection with 200µg/ml
hygromycin B.
3.4 Calcium Ion Signaling
Activation of NK1R leads to the releases of calcium from internal stores and thereby
increases the intracellular calcium concentration. This increase can be monitored with
calcium-sensitive dyes. The increase of the intracellular calcium concentration is related
to the increase in ﬂuorescence of the calcium-sensitive dye and can be measured on a
FLEX station.
HEK293 cells stably expressing wtNK1R, ACP-NK1R or NK1R-ECFP were seeded
into a 96 well plate (Greiner) in DMEM supplemented with 2.5% FCS and incubated
at 37◦C and 5% CO2. After 24 hours the cells were loaded with a calcium-sensitive
dye (Calcium 3 assay kit, Molecular Devices) during 30 minutes at 37◦C. The change
in ﬂuorescence intensity of the calcium dye upon addition of SP in buﬀer (50mM Tris-
HCl pH 7.5, 150mM NaCl, 5mM MnCl2, 0.1% BSA (w/v), 100µg/ml Bacitracin) was
recorded on a FLEX station (Molecular Devices) with excitation at 485 ± 4.5nm and
ﬂuorescence detection at 525± 4.5 nm. The ﬁnal concentration of SP was 0.003-10 nM.
The amplitude of the “calcium peak" versus log[SP] was ﬁtted with the Hill-equation:
EL = E0 +
Emax − E0
1 + 10(logEC50−log[L])·nH
(3.1)
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where EL is the amplitude of the intensity increase (eﬀect) for a given ligand concentra-
tion [L]; log[L] is the logarithm of the ligand concentration; logEC50 is the logarithm of
the EC50 value (concentration that produces 50% of the maximal possible eﬀect); E0 is
the baseline; Emax is the maximal response or eﬀect; and nH is the Hill coeﬃcient.
3.5 Fluorescence Confocal Microscopy
Laser-scanning confocal micrographs were recorded by using a 453/488nm Ar-Kr laser
line or a 543 or 633 nm He-Ne laser line on a Zeiss LSM 510 microscope (Zeiss) with an
63x water (1.2 numerical aperture) objective. Detection and distinction of ﬂuorescence
signals was achieved by appropriate ﬁlter sets using a multi-tracking mode. Table 3.1
lists the ﬁlter sets when using one ﬂuorophore in single-tracking mode and Table 3.2
lists the ﬁlter sets when using two ﬂuorophores in multi-tracking mode. If possible, an
additional dichroic mirror has been used for the multi-tracking mode to split emission
into two channels.
Excitation Dichroic Emission
Line Mirror Filter
ECFP 458nm HFT 458 LP 475
EGFP, EYFP 488nm HFT 488 LP 505
TMR, Cy3 543nm HFT 543 LP 560
Cy5 633nm HFT 633 LP 650
Table 3.1: Filter sets for one ﬂuorophore and single-tracking mode.
Excitation Dichroic Beam Emission
Line Mirror (HFT) Splitter (NFT) Filter
Cy3 and 543nm BP 560-615
Cy5 633nm
UV/488/543/633 635 vis
LP 650
ECFP and 458nm 458 - BP 465-495
EYFP 488nm 488 - BP 510-560
EGFP and 488nm BP 505-550
TMR 543nm
488/543 545
LP 560
Table 3.2: Filter sets for two ﬂuorophores and multi-tracking mode.
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3.6 ACP labelling
Before labelling the cells were washed once with D-PBS. The labelling was performed in
D-PBS with 10mM MgCl2, 1µM AcpS and 5µM CoA substrate. For double labelling
with Cy3 and Cy5 the substrates, CoA-Cy3 and CoA-Cy5, were mixed beforehand at a
desired ratios to a total concentration of 5µM. The labelling was performed at 19-23◦C
for 40 minutes. After incubation the cells were washed three times with D-PBS.
Chapter 4
Fluorescence Resonance Energy
Transfer (FRET)
Fluorescence resonance energy transfer (FRET) has been described ﬁrst theoretically
by Perrin in 1932 [84] and was fully elucidated by Förster in 1948 [85]. Since then it
has been used as a method to investigate various physical and biological systems. A
good introduction to FRET and ﬂuorescence spectroscopy in general can be found in
Principles of ﬂuorescence spectroscopy by Lakowicz [86].
In this chapter we give a short overview of the physical principles of FRET (Sec-
tion 4.1), of the diﬀerent methods to measure the FRET eﬃciency (Section 4.2), and
of some biological applications of FRET mainly with respect to signal transduction
(Section 4.3). Furthermore, FRET spectroscopy and microscopy are explained in more
detail and how it was used within this work (Chap. 4.4).
4.1 FRET Theory for a Donor-Acceptor Pair
FRET denotes a process by which the excited-state energy from a excited donor molecule
(D) is transferred to an acceptor molecule (A). FRET occurs when the emission spec-
trum of the donor overlaps with the absorption spectrum of the acceptor, and when
donor and acceptor are in close distance (typically 10-100Å). FRET does not involve
emission of light by the donor, but the energy of a photon absorbed by the donor
molecule is transferred non-radiatively to the acceptor molecule by a dipole-dipole in-
teraction. The Energy level diagram (Jabłonski diagram) in Figure 4.1 shows the tran-
sitions which inﬂuence FRET measurements.
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Figure 4.1: Jabłonski diagram showing the transitions which inﬂuence FRET.
The thick lines are the lowest vibrational levels of the particular molecular energy states,
and the thin lines represent the corresponding higher vibrational levels. S0, S1, and T1
refer to the ground and ﬁrst excited singlet states and the ﬁrst excited triplet state,
respectively. The donor is excited (kex) by a photon into higher vibrational levels of the
ﬁrst singlet state S1 of the donor D∗. Following vibrational relaxation (kr) to the lowest
vibrational state of D∗, the excitation energy is lost spontaneously by one of the following
conversions: (1) non-radiative internal conversion kc, (2) intersystem crossing to the triplet
state kisc, (3) collisional quenching kQ, (4) long-range resonance dipole energy transfer kT
to an acceptor molecule close to the excited donor molecule, and (5) radiative decay kf
to the ground state; k always denotes the rate constant of the indicated process (adapted
from Clegg [87]).
The donor is excited by a photon into a higher energy level and the decay lifetimes
of the excited donor in presence (τDA) or absence (τD) of acceptor are given by
τ−1DA = kc + kisc + kQ + kT + kf (4.1)
and
τ−1D = kc + kisc + kQ + kf, (4.2)
where the rate constants (k) are explained in Figure 4.1.
Noting that the quantum yield of any spectroscopic process is the ratio of the rate
constant of this process, divided by the sum of the rate constant of all processes occurring
from this state, then the quantum yield of energy transfer from the donor (ΦDT) is
ΦDT = kT/(kc + kisc + kQ + kT + kf) = kTτDA. (4.3)
The quantum yield of energy transfer from the donor (ΦDT) is the experimental variable
usually determined in FRET experiments, and can be deﬁned as the eﬃciency of energy
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transfer (E ≡ ΦDT). By using Eqs. 4.1 and 4.2, Eq. 4.3 can be written as
E = 1− τDA
τD
, (4.4)
where E is deﬁned as the quantum yield of energy transfer from the donor (ΦDT), or
in other words, the fraction of donor molecules de-excited via energy transfer to the
acceptor. It is obvious from Eq. 4.3 that this can be done only if the decay rates other
than kT are unaﬀected by the presence of the acceptor, and if the energy levels remain
the same in both circumstances. Another way to write Eq. 4.4 is in terms of ﬂuorescence
intensities of the donor:
E = 1− FDA
FD
, (4.5)
where FDA is the ﬂuorescence intensity of the donor in the presence of acceptor and FD
is the ﬂuorescence intensity of the donor in the absence of acceptor.
As mentioned before, the acceptor must absorb light at donor emission wavelengths
for FRET to occur, but it does not need to be ﬂuorescent. However, ﬂuorescent acceptors
are often used in FRET experiments. In these cases, light absorbed by the donor and
transferred to the acceptor appears as sensitized (or enhanced) acceptor emission and
the energy transfer eﬃciency is
E =
(
FAD
FA
− 1
)(
εA
εD
)
, (4.6)
where FAD is the emission of the acceptor in the presence of the donor (consisting of
ﬂuorescence arising from energy transfer and from direct excitation of the acceptor)
and FA is the ﬂuorescence of the acceptor-only labelled sample (direct excitation of
acceptor only); εA and εD are the molar extinction coeﬃcients of the acceptor and
donor, respectively, at the wavelength of excitation. Calculation of E from the sensitized
acceptor emission requires careful consideration of all interrelated intensities as will be
described in more detail in Section 4.4.
In 1948, Förster described a theoretical expression for kT in terms of spectroscopic
parameters, relating rate of transfer to distance between donor and acceptor [85]. The
transfer rate (kT) for a donor-acceptor pair separated by a distance r is given by
kT(r) =
φDκ
2
τDr6
(
9000(ln 10)
128π5NAn4
)
J(λ), (4.7)
where φD is the quantum yield of the donor in the absence of acceptor; n is the refractive
index of the medium, which is typically assumed to be 1.4 for biomolecules in aqueous
26 CHAPTER 4. FLUORESCENCE RESONANCE ENERGY TRANSFER
solution; NA is Avogadro’s number; τD is the lifetime of the donor in the absence of
acceptor; κ2 is a factor describing the relative orientation in space of the transition
dipoles of the donor and acceptor and is usually assumed to be 2/3 (discussed in [88]);
and J(λ) is the spectral overlap of donor emission with the acceptor absorption. The
degree of spectral overlap J(λ) is given by the overlap integral,
J(λ) =
∫ ∞
0
FD(λ)εA(λ)λ
4dλ (M−1cm−1nm4), (4.8)
where FD(λ) is the corrected ﬂuorescence intensity of the donor, with the total intensity
(area under the curve) normalized to unity and εA(λ) is the extinction coeﬃcient of the
acceptor at λ in units of M−1cm−1.
A number often encountered in FRET experiments is the Förster distance (R0). It
is deﬁned as the distance at which the transfer rate (kT) is equal to the decay rate of
the donor in the absence of acceptor (τ−1D ), or in other words, the distance at which
FRET is 50% eﬃcient. Using Eq.4.7, R0 is given by
R0 = 0.211[κ
2n−4φDJ(λ)]1/6 (in Å). (4.9)
It lies typically in the range of 20-60Å for standard DA pairs.
Once the Förster radius R0 is known, one can derive the rate of energy transfer from
Eqs. 4.7, 4.8 and 4.9:
kT(r) =
1
τD
(
R0
r
)6
. (4.10)
As mentioned before, the eﬃciency of energy transfer (E) is the fraction of photons
absorbed by the donor that are transferred to the acceptor and, using Eqs. 4.1, 4.2
and 4.3, can be written as
E =
kT
τ−1D + kT
, (4.11)
i.e. as the ratio of the transfer rate to the total decay rate of the donor. Eq. 4.11 can
be rearranged to yield
E =
R60
R60 + r
6
=
1
1 + (r/R0)
6 . (4.12)
Eq. 4.12 shows that the transfer eﬃciency is strongly dependent on distance when the
donor-acceptor distance is near R0. If r is twice the Förster distance (r = 2R0), then
the transfer eﬃciency drops to 1.6% (Figure 4.2). Any phenomenon that aﬀects the
donor-acceptor distance will aﬀect the transfer rate, allowing the phenomenon to be
quantiﬁed.
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Figure 4.2: Dependence of the energy transfer eﬃciency (E) on distance r.
It is important to note, that Eqs. 4.4, 4.5 and 4.6 are only applicable when in all
DA pairs the donor and the acceptor are separated by a ﬁxed distance. This is a
requirement often not matched in biological FRET experiments and it complicates the
determination of the energy transfer eﬃciency. An additional term must be added to
take the stoichiometry of donor and acceptor into account
Eapp =
(
1− FDA
FD
)(
1
fd
)
(4.13a)
Eapp =
(
FAD
FA
− 1
)(
εA
εD
)(
1
fa
)
, (4.13b)
where Eapp is the apparent FRET eﬃciency eﬀectively measured in experiments; fd is
the fraction of donor in complex with an acceptor; and fa is the fraction of acceptor in
complex with a donor. This will be discussed in more detail in Chapter 7, where the
oligomerization states are investigated.
4.2 Methods to Determine E
FRET results in several characteristic changes in the ﬂuorescence of the ﬂuorophores
involved. These characteristic changes are based on the three Eqs. 4.4, 4.5, and 4.6
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described in Section 4.1,
E = 1− τDA
τD
,
E = 1− FDA
FD
,
E =
(
FAD
FA
− 1
)(
εA
εD
)
,
and can be measured using appropriate methods. In the following a selection of the
diﬀerent methods is given.
First, the FRET eﬃciency E can be determined by measuring the ﬂuorescence life-
time of the donor in presence or absence of the acceptor (Eq. 4.4). The ﬂuorescence
lifetime can be measured in a time-resolved ﬂuorometer [87, 89]. This approach does
not depend on the concentration of the donor molecules but requires specialized light
sources and detectors capable of quantifying the nanosecond lifetimes. A more sophisti-
cated approach based on donor lifetime with additional spatial resolution is ﬂuorescence
lifetime imaging microscopy (FLIM) [90–94]. Another method connected to the ﬂuores-
cence lifetime of the donor is called donor photobleaching. This method is based on the
photobleachability of the donor. The donor photobleaches more slowly if energy transfer
to an acceptor is present. The fractional change in the photobleaching time constant
caused by energy transfer is the same as the fractional change in the ﬂuorescence life-
time of the donor [90,95–97]. FRET can also be observed by measuring the anisotropy
of the donor ﬂuorescence. The anisotropy depends on the extent of rotational diﬀusion
that the excited molecule undergoes before it emits a photon. Because τDA < τD the
anisotropy of the donor usually increases in presence of an acceptor [98].
Second, the FRET eﬃciency E can be determined by measuring the the ﬂuorescence
intensity of the donor in presence or absence of the acceptor (Eq. 4.5). As described
before, the donor ﬂuorescence intensity is quenched in the presence of the acceptor.
Removal or destruction of the acceptor then leads to donor dequenching. This is usu-
ally done by complete photobleaching of the acceptor in a spectrometer [99] or on a
microscope [100–102] by exciting the acceptor over a prolonged time.
Third, the FRET eﬃciency E can be determined by measuring the enhanced ﬂuo-
rescence intensity of the acceptor in presence of the donor (Eq. 4.6). Methods exploiting
this eﬀect are often referred to as methods based on sensitized acceptor emission. They
are mainly used in microscopy [103–110], but are also applicable on a spectrometer [87],
or on a ﬂow cytometer capable of dual wavelength excitation [111].
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4.3 Biological Applications of FRET
FRET typically occurs between distances of 10-100Å. This makes FRET very conve-
nient for the study of macromolecules such as proteins. The technique can be used
under physiological conditions with near angstrom resolution and with the sensitivity of
ﬂuorescence measurements. With the development of mutants of the green ﬂuorescent
protein (GFP) and advances in ﬂuorescence microscopy, FRET has rapidly been gaining
importance in the study of biological processes in living cells.
Its main applications include the study of interactions between diﬀerent proteins
tagged with either a donor or an acceptor ﬂuorophore (intermolecular FRET), or the
investigation of conformational changes within a single protein labelled with both a
donor and an acceptor (intramolecular FRET). The later includes the ﬁrst FRET-
based genetically encoded biochemical sensor using ECFP and EYFP [112]. The so
called cameleon undergoes a conformational change upon calcium binding resulting in
a dramatic change in FRET.
In the ﬁeld of GPCRs, intramolecular FRET has been used to monitor GPCR acti-
vation [113, 114]. Intermolecular FRET has been applied to investigate diﬀerent steps
in GPCR signaling, including ligand binding [115, 116], GPCR oligomerization [55],
receptor-G protein interaction [117], interactions between heterotrimeric G protein sub-
units [31, 118], GIRK channel activation by G proteins [119], and receptor-arrestin in-
teractions [120,121].
4.4 Experimental Procedures
FRET has been used as a technique to investigate molecular interactions in this the-
sis. In the following, the two main experimental methods used are explained in detail.
First, FRET spectroscopy, where emission spectra are recorded and the eﬃciency is
determined through sensitized acceptor emission. The method has been used in Chap-
ter 8. Second, FRET microscopy, where the FRET eﬃciency is calculated from single
cell images, also through sensitized acceptor emission. This method has been mainly
used in Chapter 7. It is important to note that both methods determine the apparent
FRET eﬃciency, which reﬂects both the intrinsic FRET for a DA pair and the fraction
of acceptor in complex with a donor (Eq. 4.13b).
All data treatment, including curve ﬁtting and image processing, was done with the
software IGOR Pro (Version 5.02, WaveMetrics Inc.).
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4.4.1 Sensitized Acceptor Emission: Spectroscopy
To use a spectrometer is the most straightforward way to measure FRET. Illuminating
at a wavelength appropriate to excite the donor results in an emission spectrum contain-
ing contributions of the donor emission and acceptor emission. The acceptor emission
is then the sum of emission due to direct excitation and due to FRET. To calculate
FRET eﬃciencies it is necessary to separate these three contributions.
Setup and Data Acquisition
Fluorescence spectra can be recorded either from a cell suspension using a conventional
spectrometer or from single cells using a microscope equipped with a spectrometer
coupled to a CCD camera.
Little instrumentation is needed when working with cell suspensions (∼200’000 -
1’000’000 cells/ml). Here, a SPEX Fluorolog II (Instruments S.A., Stanmore, UK)
was used, which contains a monochromator for emission and excitation. The sample
was placed in a 1ml quartz glass cuvette (Hellma, D) with a stirrer to keep cells in
suspension.
Measurements in a conventional spectrometer, where cell suspensions are used, can-
not reveal cell-by-cell diﬀerences, and a contribution from dead cells, cellular debris and
unbound, free ﬂuorescent molecules can be present in the signal. Therefore, a home-built
setup has been used for recording spectra from single cells (Figure 4.3).
The setup is based on a epiluminescence wide-ﬁeld microscope (Axiovert 100 TV,
Zeiss, D). Circularly polarized light of a diode laser (637 nm) or a tuneable single mode
Ar+ laser (457.9, 488, 514.5 nm) (both Coherent, USA) is directed by a dichroic mirror
into a microscope objective (C-Apochromat 63x W Korr, 1.2 NA, Zeiss, D) to illuminate
a 22µm diameter region of the sample. Fluorescence is collected by the same objective,
passed through an adequate ﬁlter (Table in Figure 4.3) and detected with a CCD camera
(LN/CCD-576 EUV, Spectroscopy Instruments GmbH, D) coupled to a spectrometer
(CP-140, Spectroscopy Instruments GmbH, D). Spectra are obtained by integrating the
ﬂuorescence of the whole cell during 0.5-1 s.
The method to calculate FRET eﬃciencies using a spectrometer is based on two
emission spectra of the same sample recorded at two diﬀerent excitation wavelengths,
regardless of the setup used. First, an emission spectrum extending over the whole
range of donor and acceptor ﬂuorescence is acquired by exciting the donor. Second,
an emission spectrum of the acceptor is recorded by exciting the acceptor only. In the
following equations the subscripts donor and acceptor indicate the spectra taken with
4.4. EXPERIMENTAL PROCEDURES 31
Shutter
Variable ODBeam expander
Condenser
Dichroic mirror
Microscope objective
Sample
Ocular or
CCD camera
CCD camera
Filter
Excitation
Fluorescence
Diode Laser
Ar+-Laser
Polarization controller
Spectrometer
Excitation Dicroic Emission
Line (nm) Mirror Filter
Cy3 514.5 FT530 LP550
Cy5 637 Q645LP HQ710/120
ECFP 457.9 Z458 LP480
EYFP/Citrine 514.5 FT530 HQ570/80M
Figure 4.3: Schematic view of the home-built setup and ﬁlter sets.
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donor and acceptor excitation, respectively.
ECFP and EYFP were used as DA pair to illustrate the method. The various spectra
were recorded with a SPEX Fluorolog II with donor excitation at 430 nm and emission
from 440-630 nm, and acceptor excitation at 510 nm and emission from 520-630 nm.
In order to ﬁt the measured spectra from the sample (S) as contributions of donor
and acceptor emission and calculate the FRET eﬃciency, corresponding spectra have
to be taken for the buﬀer only (SB), a cell suspension without donor and acceptor (SC),
the donor only (SD), and the acceptor only (SA) (Figure 4.4). The sample with only
cells is required for correction of light scattering and autoﬂuorescence.
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Figure 4.4: Example of spectra used for ﬁtting in FRET spectroscopy. ECFP
and EYFP were used as donor and acceptor, respectively. A, spectra used for ﬁtting of
Sdonor(λ) in Figure 4.5A. Excitation was set at 430 nm. B, spectra used for ﬁtting of
Sacceptor(λ) Figure 4.5B. Excitation was set at 510 nm.
Fitting and Calculation of E
As discussed before, the FRET eﬃciency E can be calculated using Eq. 4.6 for sensitized
acceptor emission,
E =
(
FAD
FA
− 1
)(
εA
εD
)
,
where FAD is the acceptor emission in presence of donor (consisting of ﬂuorescence
arising from energy transfer and from direct excitation of the acceptor) and FA is the
acceptor emission in absence of donor (direct excitation of acceptor only). The ratio
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εA/εD depends on the excitation wavelength of the donor and can be estimated from the
absorption spectra of donor and acceptor and the molar extinction coeﬃcients found in
literature, and is discussed in more detail in Section 4.4.3. The following calculations
to obtain the ratio FAD/FA from the emission spectra are illustrated in Figure 4.5 using
an ECFP-EYFP fusion protein.
The ﬁrst step to obtain FAD and FA is the decomposition of the spectrum of the
sample S into the separate contributions of donor and acceptor. Therefore, S is ﬁtted
using the spectrum of the buﬀer (SB), of the cells (SC), of the donor (SD), of the acceptor
(SA), and an oﬀset using
S(λ) = bSB(λ) + cSC(λ) + dSD(λ) + aSA(λ) + oﬀset, (4.14)
where b, c, d, and a are the ﬁt coeﬃcients for the spectrum of buﬀer, cells, donor, and
acceptor, respectively. If the various ﬁtting spectra are well separated the ﬁtting in IGOR
Pro is very robust and does not depend on the initial values for b, c, d, a and oﬀset. A
representative example of the ﬁtting is found in Figure 4.5A and 4.5B.
The donor and acceptor spectra can have a contribution from the cell autoﬂuores-
cence. This however did not inﬂuence the ﬁtting parameters d and a, for the donor
and acceptor, respectively. For the ﬁtting of the acceptor spectra, the ﬁt parameter d
could be set to zero, because the donor does not absorb at acceptor excitation. Subtrac-
tion of buﬀer (bSB(λ)), cells (cSC(λ)) and oﬀset from S for both sets of spectra (donor
excitation and acceptor excitation) results in
S ′donor(λ) = ddonorSD,donor(λ) + adonorSA,donor(λ) (4.15)
and
S ′acceptor(λ) = aacceptorSA,acceptor(λ), (4.16)
where S ′donor(λ) is the corrected spectrum of Sdonor(λ) and S ′acceptor(λ) is the corrected
spectrum of S ′acceptor(λ). The subscripts indicate the excitation used (donor or acceptor).
The term adonorSA,donor(λ) in Eq. 4.15 is the emission of the acceptor due to direct
excitation and energy transfer. It can be written as
adonorSA,donor(λ) = (adonor,direct + adonor,FRET)SA,donor(λ). (4.17)
In a sample with acceptor only (SA(λ)), the acceptor emission using donor exci-
tation (SA,donor(λ)) is proportional to the acceptor emission using acceptor excitation
(SA,acceptor(λ)) and depends on instrumental settings. In analogy, in a sample with
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Figure 4.5: Principle of FRET spectroscopy. Example of FRET spectroscopy for
the ECFP-EYFP fusion protein expressed in HEK293 cells. A, spectrum of ECFP-EYFP
fusion excited at 430 nm (Sdonor(λ)) ﬁtted with the spectra from Figure 4.4A (residu-
als of the ﬁt shown above), and the contributions from donor (ddonor SD,donor(λ)) and
from acceptor (adonor SA,donor(λ)). B, spectrum of ECFP-EYFP fusion excited at 510 nm
(Sacceptor(λ)) ﬁtted with the spectra from Figure 4.4B (residuals of the ﬁt shown above),
and the contribution of the acceptor (aacceptor SA,acceptor(λ)). C, enlargement of the spec-
trum in A, showing the two contributions to FAD, FA and adonor,FRET SA,donor(λ). The
calculated FRET eﬃciency for ECFP-EYFP was E = 0.44, with εA/εD = 0.046.
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donor and acceptor (S(λ)), the acceptor emission due to direct excitation using donor
excitation (adonor,directSA,donor(λ)) is proportional to the acceptor emission due to di-
rect excitation using acceptor excitation (aacceptor,directSA,acceptor(λ)) and depends on the
same instrumental settings. Because there is not contribution of FRET to the acceptor
emission using acceptor excitation, aacceptor,direct is equal to aacceptor. The unknown is
the acceptor emission in SA,donor(λ) due to direct excitation, and can be calculated as
adonor,directSA,donor(λ) = aacceptorSA,acceptor(λ)
SA,donor(λ)
SA,acceptor(λ)
, (4.18)
resulting in
adonor,direct = aacceptor. (4.19)
FAD is the ﬂuorescence of the acceptor in presence of the donor. In the spectrum
recorded with donor excitation, Sdonor(λ), FAD is equal to adonorSA,donor(λ). FA is
the ﬂuorescence of the acceptor in absence of the donor. In the spectrum Sdonor(λ),
recorded with donor excitation, FA is equal to the direct excitation of the acceptor,
adonor,directSA,donor(λ). And therefore, using Eq. 4.19,
FAD
FA
=
adonor
aacceptor
. (4.20)
Thus, the apparent FRET eﬃciency E can be obtained directly from the acceptor ﬁtting
parameters adonor and aacceptor (Figure 4.5C).
Advantages, Disadvantages, Problems
The determination of FRET eﬃciency using cell suspensions can be limited by the ex-
pression level of the protein of interest and more importantly the transfection eﬃciency.
If only a small percentage of cells are expressing the protein of interest, high cell con-
centrations (>1’000’000 cells/ml) are needed to yield a good ﬂuorescence intensity. The
signal to noise ratio can decrease dramatically due to light scattering and cell autoﬂu-
orescence This in turn can cause a problem with the ﬁtting procedures to decompose
the spectra. Moreover, high overexpression might lead to non-physiological conditions
and unwanted protein aggregation. Another disadvantage of cell suspensions is that
they require constant stirring to prevent cells from precipitation. Therefore it is often
necessary to work with large volumes of about 1ml. When working with antibodies or
other more sophisticated labelling techniques, such as ACP labelling, it is desired to
minimize the working volume to reduce the quantities of label reagents.
The determination of FRET eﬃciencies on single cells allows one to work with low
36 CHAPTER 4. FLUORESCENCE RESONANCE ENERGY TRANSFER
expression levels at physiological expression levels. The home-built setup is more sensi-
tive and cells can be selected before recording. A disadvantage of this setup is its ﬁeld
of illumination, where the two excitation wavelengths overlap only to a certain extent.
This does not cause any problems for single small cells, when they are positioned in the
center of the illumination ﬁeld [122]. But it gets critical for a cell or a group of cells,
which is larger than the illumination ﬁeld (∼ 20µm), leading to high variation in the
FRET signal depending on the position of the sample.
With both instruments it is possible to observe kinetics. On the SPEX this is done
by using two detectors one for donor emission and one for acceptor emission. On the
home-built setup whole spectra can be recorded at about 2-4Hz. In both cases only
changes in FRET can be detected unless the eﬃciency at the start of the measurement
is known.
An advantage of the SPEX over the home-built setup is the choice of excitation
and emission wavelength. A disadvantage is the time needed to record one spectrum.
It is usually in the order of several seconds to minutes as compared to 0.2-1 s on the
home-built setup.
4.4.2 Sensitized Acceptor Emission: Microscopy/Imaging
Sensitized acceptor emission imaging is becoming the most popular approach to FRET
imaging, as it can be implemented on wideﬁeld and confocal microscopes, it is non-
destructive, in contrast to acceptor photobleaching, and it allows measurements of
FRET changes in time. The sensitized ﬂuorescence of acceptor is detected through
an optical FRET ﬁlter set that selects acceptor emission during donor excitation. But
the image acquired with the FRET ﬁlter set contains several contributions beside the
FRET signal, which need to be corrected. These include direct excitation of the ac-
ceptor at the donor excitation wavelength (cross talk) and bleed-through of the donor
emission into the acceptor emission detection.
Several methods have been published for calculation of FRET from steady-state
images and for corrections of bleed-through and cross talk [104–110]. All these meth-
ods are based on three ﬁlter sets: (1) the donor ﬁlter set, where the donor emission is
recorded during donor excitation, (2) the acceptor ﬁlter set, where the acceptor emis-
sion is recorded during acceptor excitation, and (3) the FRET ﬁlter set, where acceptor
emission is recorded during donor excitation. To calculate correction factors, it is nec-
essary to record the three images not only for the sample with donor and acceptor, but
also with donor alone and acceptor alone.
In this Section the data acquisition, background and shading corrections, calculation
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of bleed-through and cross talk, and the ﬁnal calculation of the apparent FRET eﬃciency
is discussed in more detail.
Symbols
The symbols used for the various ﬂuorescence intensities in this and the following chap-
ters are the symbols introduced by Gordon et al. [105]. Two- and three-letter symbols
are deﬁned to denote the various signals depending on the type of ﬁlter set (Donor,
FRET or Acceptor), the ﬂuorophores present in the sample (donor only, acceptor only,
or both donor and acceptor) and the origin of the signal from either the donor or the
acceptor when both are present in the sample. Each symbol starts with an capital letter
representing the ﬁlter set, D for the Donor ﬁlter set, F for the FRET ﬁlter set, and
A for the Acceptor ﬁlter set. The second letter is lowercase and indicates which ﬂuo-
rophores are present in the specimen, d for donor only, a for acceptor only, and f for
both donor and acceptor present (FRET is possible). In the three-letter symbols, the
third letter is lowercase and indicates the signal from only one of the ﬂuorophores when
both ﬂuorophores are present (Table 4.1). The overline refers to the signal expected for
a mixture of donor and acceptor if no FRET were present.
Image Acquisition and Background Correction
Laser-scanning confocal micrographs were recorded on a LSM 510 microscope (Zeiss)
with an 63× (1.2 NA, W Korr, Zeiss) objective by using a 458/488 nm Ar+ laser,
and 543 nm and 633 nm HeNe lasers. Detection and distinction of ﬂuorescence signals
was achieved by appropriate ﬁlter sets using a multitracking mode. The excitation
wavelength and the ﬁlter set used for the DA pairs are given in Table 4.2. Under
these conditions each image was taken separately. Depending on the ﬁlters and dichroic
mirrors of the instrument, the donor and FRET image could also be taken at the same
time, since they are excited with the same wavelength. In the case of Cy3/Cy5 as
DA pair, the sample was excited at 543 nm and the emission beam was split with a
NFT 635 Vis dichroic mirror on two detectors with a BP 560-615 and a LP 650 ﬁlter,
respectively. This way the image acquisition gets faster, because the donor and the
FRET image are recorded at the same time.
The ﬁlter sets were chosen according to the ﬁlters available in the instrument and
to minimize bleed-through and cross talk. The donor ﬁlter set selects donor emission
during donor excitation, the acceptor ﬁlter set selects acceptor emission during acceptor
excitation, and the FRET ﬁlter set selects acceptor emission during donor excitation.
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Two-letter Filter Fluorochromes Meaning
Symbol Set Present
Dd Donor donor The signal from a donor-only sample
using the Donor ﬁlter set
Ad Acceptor donor The signal from a donor-only sample
using the Acceptor ﬁlter set
Fd FRET donor The signal from a donor-only sample
using the FRET ﬁlter set
Da Donor acceptor The signal from a acceptor-only sample
using the Donor ﬁlter set
Aa Acceptor acceptor The signal from a acceptor-only sample
using the Acceptor ﬁlter set
Fa FRET acceptor The signal from a acceptor-only sample
using the FRET ﬁlter set
Df Donor donor and acceptor The signal from a donor-acceptor sam-
ple using the Donor ﬁlter set
Af Acceptor donor and acceptor The signal from a donor-acceptor sam-
ple using the Acceptor ﬁlter set
Ff FRET donor and acceptor The signal from a donor-acceptor sam-
ple using the FRET ﬁlter set
Three-letter Filter Fluorochromes Meaning
Symbol Set Present
Dfd Donor donor and acceptor Refers to the donor signal only when
both donor and acceptor are present
Dfa Donor donor and acceptor Refers to the acceptor signal only when
both donor and acceptor are present
Ffd FRET donor and acceptor Refers to the donor signal only when
both donor and acceptor are present
Ffa FRET donor and acceptor Refers to the acceptor signal only when
both donor and acceptor are present
Afa Acceptor donor and acceptor Refers to the donor signal only when
both donor and acceptor are present
Afd Acceptor donor and acceptor Refers to the acceptor signal only when
both donor and acceptor are present
Dfd Donor donor and acceptor Refers to the donor signal that would
have been if no acceptor were present
and therefore no FRET occured
Afa Acceptor donor and acceptor Refers to the donor signal that would
have been if no donor were present and
therefore no FRET occured
Table 4.1: Two- and three-letter Symbols. The symbols used for the various ﬂuo-
rescence intensities in FRET imaging and their interpretation (Adapted from Gordon et
al. [105]).
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ECFP-EYFP Cy3-Cy5
Donor Channel Excitation 458 nm 543 nm
(Track 1) Dichroic HFT 458 HFT 543
Emission BP 465-495 BP 560-615
Acceptor Channel Excitation 488 nm 633 nm
(Track 2) Dichroic HFT 488 HFT 633
Emission BP 510-560 LP 650
FRET Channel Excitation 458 nm 543 nm
(Track 3) Dichroic HFT 458 HFT 543
Emission BP 510-560 LP 650
Table 4.2: Filter sets used for FRET imaging with the DA pairs ECFP-EYFP and
Cy3-Cy5. The settings for ECFP-EYFP were also used for ECFP-Citrine.
Figure 4.6 illustrates the three ﬁlter sets for the ECFP/EYFP FRET pair, the images
required to calculate correction factors and ﬁnally the FRET eﬃciency.
The images were recorded as 12-bit images to get a higher dynamic range for the
intensities. The laser power for the excitation and the gain of the detectors for the
emission were adjusted for each experiment to yield an image with a good signal to
noise ratio. The pinhole was set at the same value for all ﬁlter sets. Scan speed,
averaging of images and image size were usually set at 1.6µs, 2 and 512x512 pixels,
respectively, but could be changed depending on required image quality. The ampliﬁer
oﬀset was set to zero. Higher laser powers allow lower ampliﬁer gains. Together with
averaging of images and open pinholes, it increases the signal-to-noise ratio, but on the
cost of more photobleaching, longer imaging time and lower resolution.
In addition to the DA sample it is necessary to record images with exactly the same
settings for the donor, acceptor and FRET channel, of background (buﬀer or cells),
donor alone and acceptor alone. These images are used for background, bleed-through
and cross talk corrections.
The background of each image originates from the dark noise of the detector or the
CCD camera and the background ﬂuorescence from the buﬀer and the cells (autoﬂu-
orescence). Usually the background ﬂuorescence from buﬀer or cells was very small
compared to the dark noise. The background intensities were determined by recording
an image with all three ﬁlter sets (donor, acceptor, FRET) and the average intensity
was determined. In the case of cell autoﬂuorescence the average intensity in a ROI
within the cell was taken as the background intensity. The average for the background
was then subtracted from all images taken with the same ﬁlter set. The background
had to be determined for all diﬀerent settings used.
The eﬀect of shading or non-homogenous illumination can be seen by taking an image
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Figure 4.6: Principle of FRET microscopy. A, absorption (dashed) and emission
(solid) spectra of ECFP (grey) and EYFP (black) with indicated excitation wavelength
and emission band pass ﬁlters for donor, acceptor and FRET channel (Table 4.2). B,
the confocal micrographs for Dd, Ad, Fd, Da, Aa, Fa, Df , Af , and Ff required for
calculating FRET eﬃciency E. Colors in the micrographs are inverted to make the low
intensities in Fd and Fa visible. Scale bar represents 10µm.
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of a solution with donor or acceptor ﬂuorophores. With the Zeiss LSM 510 microscope
the intensity distribution was uniform over the whole image. No corrections for shading
were needed. In case of a wideﬁeld microscope the illumination is not homogenous and
shading corrections have to be done.
Calculation of the FRET eﬃciency
With every particular ﬁlter set one has more or less cross talk and bleed-through. The
acquired images are composite images that consist of multiple terms and have to be
corrected to ﬁnd the real FRET values. We separate three terms of emission intensi-
ties: donor emission (quenched), direct acceptor emission and acceptor emission due to
FRET: Intensity = Dquenched + Adirect + AFRET. The intensities in the images Df , Af
and Ff are thus given as
Df = (Dfd − FRET1 ) + S5 Afa + S6 G · FRET1 (4.21a)
Ff = S1 (Dfd − FRET1 ) + S4 Afa + G · FRET1 (4.21b)
Af = S2 (Dfd − FRET1 ) + Afa + S3 G · FRET1 (4.21c)
as described by Gordon et al. [105]. For all three equations, the ﬁrst term, Dfd−FRET1 ,
is the donor emission that would be in the absence of FRET, minus the loss of emission
due to FRET; the second term, Afa, describes the direct emission of the acceptor; and
the third term, G ·FRET1 , describes the emission of the acceptor due to FRET. S1 to
S6 correspond to the factors due to cross talk and bleed-through and are deﬁned as
S1 =
Fd
Dd
, S2 =
Ad
Dd
, S3 =
Ad
Fd
S4 =
Fa
Aa
, S5 =
Da
Aa
, S6 =
Da
Fa
(4.22)
G is a factor relating the loss of donor emission due to FRET in the Donor ﬁlter set to
the gain of acceptor emission due to FRET in the FRET ﬁlter set (see [105]).
The solution of the three unknowns Dfd , FRET1 and Afa is given by
Afa =
Af − S3Ff
1− S3S4 (4.23a)
FRET1 =
Ff − S1Df − Afa[S4 − S1S5]
G[1− S1S6] (4.23b)
Dfd = Df + FRET1 [1−GS5]− S5Afa (4.23c)
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The FRET ratio (FR = FAD/FA) is the value to be determined using sensitized
acceptor emission (Eq. 4.6). FR is equal to the fractional increase in acceptor emission
due to FRET:
FR =
FAD
FA
=
FA,direct + FA,FRET
FA,direct
, (4.24)
where the numerator is the emission of the acceptor in the presence of donor (consisting
of ﬂuorescence through the FRET ﬁlter set arising from direct excitation of the acceptor,
FA,direct, and from energy transfer, FA,FRET), and the denominator is the emission of the
acceptor in absence of the donor (direct excitation of acceptor, FA,direct). Noting that
FA,direct = Afa and FA,FRET = G · FRET1 the FRET ratio FR becomes
FR = 1 +
G · FRET1
S4Afa
. (4.25)
Substituting Afa and FRET1 from Eqs. 4.23a and 4.23b in Eq. 4.25, and noting
that S2 = S1S3 and S5 = S4S6, gives a general equation accounting for all possible cross
talk and bleed-through
FR =
Ff (1− S3S4)− Df (S1 − S2S4)
Af (S4 − S1S5)− Ff (S3S4 − S2S5) . (4.26)
Choosing the right DA pair with appropriate ﬁlter sets and excitation wavelengths,
Ad and Da become zero and the correction factors S2, S3, S5 and S6 can be neglected.
Therefore, Eq. 4.26 can be simpliﬁed to
FR =
Ff − S1Df
S4Af
. (4.27)
Masking and FR Histogram
The following steps, masking and FR histogram, are important mainly when the protein
of interest is a membrane protein. Membrane proteins are restricted to a small part of the
cell, the plasma membrane, and the intensity levels are usually not evenly distributed.
Figure 4.7A illustrates the process to calculate the FR value from the original images
of membrane proteins.
A threshold is applied before background subtraction on the Df or Af image and
is set high enough to select the membrane. All pixels below the threshold value are
removed from further calculations. The threshold was usually set at about twice the
background intensity. The threshold should not be applied on the Ff image, because
the intensity depends on FRET. Pixels with higher FRET ratios would be selected,
which can lead to overestimated FR values. With low donor and acceptor intensities,
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Figure 4.7: Masking and FR histogram. A, scheme of the process for determination
of the FR value. The correction factors S1 to S6 are calculated from background subtracted
images Dd, Da, Ad, Aa, Fd and Fa. A threshold is then applied on the Df or Af image
to mask the membrane. The FR value is calculated on a pixel-by-pixel basis according to
Eq. 4.26 or to the simpliﬁed Eq. 4.27, resulting in the FR image. The histogram over all
FR values is created and ﬁtted with a Gaussian to determine the average value for FR.
B, FR image and histogram was calculated with the same correction factors but without
applying a threshold to the original Df , Af and Ff images. C, FR image of HEK293
cells expressing ECFP-EYFP fusion protein. Scale bars represent 10µm.
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the threshold can be set only slightly above the background intensity, because otherwise
most pixels are removed. In this case, a threshold of about 105% of the background
intensity is applied to both images. This removes most of the background signal. Some
pixels in the background remain, because of the noise around the average background.
But because they will not be at the same position in all the three images and because
any pixel removed in one of the three images is not taken into account for further
calculations, the background is completely removed in the resulting FR image. This
process increases the quality of the resulting FR image.
To determine the FR value from the FR image, a histogram over all remaining pixels
is calculated. The histogram is then ﬁtted with a Gaussian. This procedure minimizes
the artifacts due to the threshold at low FR values and gives a better estimation of the
real FR.
Figure 4.7B illustrates the eﬀect of not applying a threshold before the calculation
of the FR image and histogram. In this case, the true FR value can still be found by
ﬁtting the second peak with a Gaussian. But if the total number of non-background
pixels is much smaller than the number of background pixels (eg. small cells or protein
expression in a small area) and the FR value is close to one, it will become almost
impossible to separate the true FR values from the background.
For soluble proteins, which are distributed all over the cell (eg. ECFP-EYFP fusion
protein) the application of a threshold is not necessary. A region of interest (ROI)
within the cell can be selected and the average of FR is determined (Figure 4.7C).
Misfocusing Deviations
As the calculation of FRET involves mathematical operations based on three raw im-
ages, it is of importance that these channels spatially overlap, both in lateral and axial
directions. The donor and acceptor images are eﬀectively taken from slightly diﬀerent
planes in the cell causing pixels with extreme high and low FRET. Source for misfocus-
ing deviations are chromatic aberrations and diﬀerences in the collimation of the laser
beams. Chromatic aberrations are due to the wavelength dependency of the refractive
index of the optical glasses (Table 4.3). In general, DA pairs with higher excitation
wavelengths are preferred.
4.4.3 The Factor εA/εD
When calculating E by sensitized acceptor emission (Eq. 4.6), the factor εA/εD directly
inﬂuences the dynamic range of the FR ratio. Assuming a 1:1 DA stoichiometry and an
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Laser line pair (nm) Distance (µm)
458/514 0.30
488/568 0.17
514/633 0.04
Table 4.3: Misfocusing deviations. Diﬀerences in focus distance between commonly
used laser line pairs using a standard 63x, 1.32 NA oil immersion objective (from [109]).
energy transfer of 100%, the maximal possible FRET ratio (FRmax) can be calculated
by FRmax = (εA/εD)−1 + 1. This means that a small εA/εD-ratio results in a larger
dynamic range for FR. With longer excitation wavelength, the direct excitation of
acceptor relative to the FRET is too high. Furthermore, it is diﬃcult to discriminate
the spectra. With shorter excitation wavelength the donor is hardly excited anymore.
The factor εA/εD is calculated from the absorption spectra of donor and acceptor
normalized to the molar extinction coeﬃcient of the ﬂuorescent dye. Figure 4.8 illus-
trates the εA/εD-ratio for the FRET pairs ECFP-EYFP and Cy3-Cy5. In the case of
ECFP-EYFP the εA/εD-ratio for excitation at 430 nm is much better than at 457 nm.
But this is often restricted by the instrument, especially when using laser excitation.
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Cy3-Cy5 543nm 0.11 10.1
Figure 4.8: Molar extinction and εA/εD factor. Molar extinction of the ﬂuorophores
ECFP and EYFP (A), and Cy3 and Cy5 (B) (εmax,ECFP = 23′900, εmax,EYFP = 83′400
from [123]; εmax,Cy3 = 130′000, εmax,Cy5 = 250′000 from Amersham), and corresponding
εA/εD factor, which deﬁnes the dynamic range of the measurable FRET ratio. Table:
the εA/εD factor for a given DA pair and excitation wavelength. FRmax is the maximal
possible FRET ratio assuming 1:1 DA stoichiometry and 100% transfer eﬃciency.
Chapter 5
Fluorescence Labelling of NK1R
5.1 Introduction
The main goal of this thesis was the investigation of processes involved in GPCR sig-
nal transduction in living cells using ﬂuorescent techniques. The NK1R, a prominent
member of the GPCR family and an important pharmaceutical target, was chosen for
this purpose. Was it for the investigation of ligand binding, receptor oligomerization
or receptor G protein interactions, in every case, it was of importance to construct a
functional, ﬂuorescently labelled receptor.
The classical way of protein labelling in living cells is by means of antibodies. In
recent years however, new techniques have been developed, e.g. incorporation of nonnat-
ural ﬂuorescent amino acids [124] or fusion to green ﬂuorescent proteins [125]. Even more
recently, post-translational in vivo labelling has been introduced, where the ﬂuorescent
label is covalently or non-covalently attached to a fusion tag or fusion protein [126–132].
In the ﬁeld of GPCR research EGFP has been used to study GPCR localization
and traﬃcking [133]. Vollmer et al. [115] investigated ligand binding kinetics to EGFP
labelled NK2R by FRET between a ﬂuorescent ligand and the EGFP. GPCR fusions
with variants of green ﬂuorescent protein or Renilla luciferase (RLuc) led to new ad-
vances in the understanding of GPCR oligomerization [55]. Incorporating ﬂuorescent
nonnatural amino acids at speciﬁc sites was used to investigate structure and function
of NK2R [124]. A combination of ECFP and EYFP or FlAsh has been used for a FRET
assay to determine GPCR activation in living cells [113,114].
In this work two approaches were chosen for labelling of NK1R in living cells: (i)
mutants of EGFP and (ii) the acyl carrier protein (ACP) for post-translational labelling.
In both cases a protein (EGFP or ACP) was genetically fused to either the N- or C-
terminus of the NK1R.
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This Chapter deals with the design and cloning of the NK1R fusion constructs and
the conﬁrmation of functionality of the NK1R fusion proteins by means of calcium
signaling. Furthermore, it explains the basics of the ACP labelling technique.
5.2 Experimental Procedures
5.2.1 Materials
pSFV1::NK1R-his was a gift from Kenneth Lundstrom (BioXtal, CH); CoA-Cy3, CoA-
Cy5 and AcpS were a kind gift from Nathalie George and Kai Johnsson (LIP-ISIC,
EPFL, CH); the vectors encoding for EGFP, ECFP, and EYFP were from Clontech (Palo
Alto, CA, USA); pCEP4 expression vector and Dulbecco’s phosphate-buﬀered saline (D-
PBS) were from Invitrogen (Breda, NL); pBluescript II KS+ was from Stratagene (La
Jolla, CA, USA); the synthetic oligo-nucleotides (primers) were from MWG-Biotech
(Ebersberg, D); L-723,138 was from Tocris Cookson (Langford, UK); EDTA was from
Sigma (Buchs, CH).
Cell culturing, cell transfection and preparation, calcium ion signaling, ACP la-
belling, and ﬂuorescence confocal microscopy were performed as described in Chapter 3.
5.2.2 Saturation of ACP Labelling
The ACP labelling saturation curve was obtained from HEK293 cells stably expressing
ACP-NK1R. The cells were grown in 24-well plates and labelled with Cy5 (200µl D-
PBS, 10mM MgCl2, 5µM CoA-Cy5, 1µM AcpS). After 5, 10, 20, 40 and 60 minutes
the cells were washed three times with D-PBS and detached with D-PBS supplemented
with 5mM EDTA, pelleted for 2min at 1000 g and resuspended in 1ml D-PBS. Flu-
orescence intensity of Cy5 was measured on a SPEX Fluorolog II (Instruments S.A.,
Stanmore, UK) with excitation and emission at 620± 1.8nm and 664± 2.7 nm, respec-
tively, and quantiﬁed using a CoA-Cy5 standard of known concentration determined
by absorbance (ε = 250′000M−1cm−1). Total protein content for the same sample was
determined using the Bradford protein assay system (Pierce, Rockford, Il, USA) with
BSA as standard.
5.3 cDNA Constructs of Neurokinin-1 Receptor
Polymerase chain reaction (PCR), DNA agarose gel preparation (analytic and prepara-
tive), restriction digest, ligation, DNA puriﬁcation, plasmid ampliﬁcation in E.coli XL1
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blue strain, bacterial medium (2TY), were done according to standard protocols de-
scribed in Molecular cloning, a laboratory manual [134]. The plasmid constructs were
conﬁrmed by restriction mapping and DNA sequencing.
Several NK1R fusion proteins were designed for diﬀerent purposes, which are ex-
plained in more detail in the corresponding Chapters. Three types of genetic NK1R
fusion constructs have been constructed. First, the gene encoding for ECFP or EYFP
was fused to the intracellular C-terminus of NK1R. These constructs were mainly used
to investigate interactions of NK1R with ﬂuorescently labelled heterotrimeric G proteins
by means of FRET (Chapter 8). Second, the gene encoding for EGFP was fused to the
extracellular N-terminus of the NK1R. As EGFP is not secreted by cells, the N-terminal
end of EGFP was further fused to the ﬁrst 32 amino acids of the mouse serotonin re-
ceptor type 3A comprising a signal peptide to promote translocation of the N-terminal
domain to the extracellular space. Diﬀerent subtypes were constructed, where either
EGFP or NK1R or both were truncated. This construct was used to investigate speciﬁc
binding of a ﬂuorescent ligand (Chapter 6). Third, the gene encoding for ACP was fused
to the extracellular N-terminus of the NK1R in the same way as EGFP. This construct
has been used to investigate speciﬁc ligand binding (Chapter 6) and oligomerization of
NK1R (Chapter 7). Both, the EGFP-NK1R and ACP-NK1R carry in addition a FLAG-
and a 10xHis-tag at their C-terminus. The wildtype NK1R (wtNK1R) was used as a
reference for the diﬀerent NK1R fusion constructs. Figure 5.1 illustrates the diﬀerent
NK1R constructs used in this thesis.
In the following we give a detailed description of the cloning steps to obtain the
diﬀerent NK1R plasmids used for this thesis. The original plasmid used for cloning
was a pSFV1 Semliki Forest virus vector containing the human neurokinin 1 receptor
cDNA with a C-terminal FLAG and 6xHis tag (pSFV1::NK1R-his). The primers used
for cloning are found in Table 5.1.
wtNK1R
The gene encoding for the human NK1R was ampliﬁed by PCR on the template
pSFV1::NK1R-his using the forward primer fw-NheI-NK1R and the reverse primer rv-
BamHI-NK1R introducing a NheI restriction site and a Kozak sequence [135] at the
5’ end, and a STOP codon and a BamHI restriction site at the 3’ end of the hNK1R
gene. The NheI /BamHI cut and puriﬁed fragment was ligated into the NheI /BamHI
cut pCEP4 expression vector yielding pCEP4::wtNK1R.
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Figure 5.1: Overview of genetic constructs of NK1R. wtNK1R, wildtype human
NK1R; Type 1, NK1R with C-terminal ECFP or EYFP (representing NK1R-ECFP and
NK1R-EYFP); Type 2 and 3, NK1R with N-terminal 5HT3 signal sequence and EGFP or
ACP and C-terminal FLAG- and 10xHis-tag (representing the four diﬀerent EGFP-NK1R
constructs and ACP-NK1R).
Primer Sequence
fw-NheI-NK1R 5’-G GCC GGG CTA GCC ACC ATG GAT AAC GTC CTC CCG GTG G-3’
fw-SpeI-NK1R 5’-GCG CGG ACT AGT ATG GAT AAC GTC CTC CCG GTG-3’
fw-SpeI-d15NK1R 5’-GCG CGG ACT AGT TCC ACT AAC ACC TCG GAA CCC-3’
fw-EagI-ssGFP 5’-CCG CGG CCG ATG CGG CTC TGC ATC CCG-3’
fw-NheI-ssGFP 5’-G GCC GGG CTA GCC ACC ATG CGG CTC TGC ATC CCG-3’
fw-EagI-NK1R 5’-GGG CGG CCG ATG GAT AAC GTC CTC CCG G-3’
fw-SpeI-EGFP 5’-CGC GGC ACT AGT GGA GGT GGA GGA ATG GTG AGC AAG GGC GAG-3’
rv-BamHI-NK1R 5’-CCG CCG GGA TCC CTA GGA GAG CAC ATT GGA GGA GAA G-3’
rv-BamHI-his 5’-CCG CGC GGA TCC TTA ATG GTG ATG GTG ATG ATG ATG ATG
ATG ATG GCT GCT GC-3’
rv-SpeI-EGFP 5’-GCG CCG ACT AGT CTT GTA CAG CTC GTC CAT GCC G-3’
rv-SpeI-trEGFP 5’-GCG CCG ACT AGT GAT CCC GGC GGC GGT CAC GAA CTC C-3’
rv-SpeI-NK1R(dS) 5’-CCG CCG ACT AGT GGA GAG CAC ATT GGA GGA GAA G-3’
rv-BamHI-EGFP 5’-GCC GCG GGA TCC TTA CTT GTA CAG CTC GTC CAT GC-3’
Table 5.1: Primers. Primers used for the cloning of NK1R constructs. Restriction sites
are underlined.
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EGFP-NK1R and Truncated Versions
The strategy was to use diﬀerent restriction sites on both ends for correct orientation
and to do the ﬁrst cloning steps in the pBluescript II KS+ cloning vector with a multiple
cloning site (MCS) containing EagI-SpeI-BamHI. First, four histidines were added to
the C-terminal end of the NK1R-his to enlarge the 6xHis-tag to a 10xHis-tag. The
resulting construct was inserted between the SpeI and BamHI site. In a second step
the EGFP was inserted between the EagI and SpeI site. In a third and last step the
EGFP-NK1R was ampliﬁed by PCR and inserted into the pCEP4 expression vector.
Furthermore, in some constructs the NK1R and/or the EGFP were truncated at the
N-terminal and C-terminal end, respectively, yielding EGFP-NK1R, EGFP-d15NK1R,
trEGFP-NK1R and trEGFP-d15NK1R (Figure 5.2). In trEGFP (truncated EGFP) the
AGITLGMDELYKTSMDNVLPVDSDLSPNISTN
AGI.........TSMDNVLPVDSDLSPNISTN
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Figure 5.2: Truncated EGFP-NK1R and Ligand. Schematic representation of
EGFP-NK1R fusion proteins with ﬂuorescently labelled ligand.
last 9 C-terminal amino acids were deleted. In d15NK1R the ﬁrst 15 amino acids of
the NK1R were deleted. All 4 constructs have as a signal sequence the ﬁrst 32 amino
acids of the mouse serotonin receptor type 3A (5HT3) in front of the EGFP and a
FLAG and 10xHis tag after the NK1R gene. The plasmid that served as a template for
the signal sequence fused to EGFP (pBS::ssGFP) was made during the diploma work
of Erwin Illegems. In the following EGFP-NK1R stands also for EGFP-d15NK1R,
trEGFP-NK1R and trEGFP-d15NK1R.
In the ﬁrst step the gene encoding for human NK1R with a C-terminal FLAG and
6xHis tag was ampliﬁed by PCR on the template pSFV1::NK1R-his using the forward
primer fw-SpeI-NK1R (or fw-SpeI-d15NK1R for the truncated NK1R (d15NK1R)) and
the reverse primer rv-BamHI-his introducing a SpeI restriction site at the 5’ end, and
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four histidines, a STOP codon and a BamHI restriction site at the 3’ end of NK1R-
his. The SpeI /BamHI cut and puriﬁed fragment was ligated into the SpeI /BamHI cut
pBluescript II KS+ cloning vector yielding pBS::NK1R (or pBS::d15NK1R).
In the second step the gene encoding for signal sequence fused to the N-terminal end
of EGFP (ssGFP) was ampliﬁed by PCR on the template pBS::ssGFP using the forward
primer fw-EagI-ssGFP and the reverse primer rv-SpeI-EGFP (or rv-SpeI-trEGFP for
the truncated EGFP (trEGFP)) introducing a EagI restriction site at the 5’ end, and a
SpeI restriction site at the 3’ end. The EagI /SpeI cut and puriﬁed fragment was ligated
into the EagI /SpeI cut pBS::NK1R (or pBS::d15NK1R) plasmid yielding pBS::EGFP-
NK1R.
In the third step the gene encoding for EGFP-NK1R (and truncated versions), in-
cluding the N-terminal signal sequence and the C-terminal FLAG and 10xHis tag, was
ampliﬁed by PCR on the template pBS::EGFP-NK1R using the forward primer fw-
NheI-ssGFP and the reverse primer rv-BamHI-his introducing a NheI restriction site
and the Kozak sequence [135] at the 5’ end, and a BamHI restriction site at the 3’ end.
The puriﬁed fragment was ligated into the NheI /BamHI cut pCEP4 expression vector
yielding pCEP4::EGFP-NK1R.
NK1R-ECFP and NK1R-EYFP
The strategy was to use diﬀerent restriction sites on both ends for correct orientation
and to do the ﬁrst two cloning steps in the pBluescript II KS+ cloning vector with a
multiple cloning site (MCS) containing EagI-SpeI-BamHI. Since ECFP and EYFP defer
only in a few point mutations towards the center of the nucleotide sequence, the same
forward and reverse primers could be used.
In the ﬁrst step the gene encoding for human NK1R was ampliﬁed by PCR on the
template pSVF1::NK1R-his using the forward primer fw-EagI-NK1R and the reverse
primer rv-SpeI-NK1R(dS) introducing a EagI restriction site at the 5’ end, and a SpeI
restriction site at the 3’. The Stop codon of NK1R was removed in the same step. The
EagI /SpeI cut and puriﬁed fragment was ligated into the EagI /SpeI cut pBluescript II
KS+ cloning vector yielding pBS::NK1R.
In the second step the gene encoding for ECFP (or EYFP) was ampliﬁed by PCR on
the template pECFP-N1 (or pEYFP-N1) using the forward primer fw-SpeI-EGFP and
the reverse primer rv-BamHI-EGFP introducing a SpeI restriction site and 4 glycine
as a spacer at the 5’ end, and a STOP codon and a BamHI restriction site at the 3’
end. The SpeI /BamHI cut and puriﬁed fragment was ligated into the SpeI /BamHI cut
pBS::NK1R plasmid yielding pBS::NK1R-ECFP (or pBS::NK1R-EYFP).
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In the third and last step the gene encoding for NK1R-ECFP (or NK1R-EYFP) was
ampliﬁed by PCR on the template pBS::NK1R-ECFP (or pBS::NK1R-EYFP) using the
forward primer fw-NheI-NK1R and the reverse primer rv-BamHI-EGFP introducing a
NheI restriction site and the Kozak sequence [135] at the 5’ end, and a BamHI restriction
site at the 3’ end. The puriﬁed fragment was ligated into the NheI /BamHI cut pCEP4
expression vector yielding pCEP4::NK1R-ECFP (or pCEP4::NK1R-EYFP).
5.4 Functionality of NK1R constructs
Agonist binding to NK1R leads to the activation of the DAG/IP3 and calcium sig-
naling pathway (see Section 1.5) and is usually determined by measuring the IP3 or
calcium concentration. Here, the functionality of wtNK1R, NK1R-ECFP, and ACP-
NK1R were veriﬁed by measuring the increase of intracellular calcium ion concentration
upon receptor activation by addition of the agonist SP. Therefore, HEK293 cell lines
stably expressing wtNK1R, NK1R-ECFP, or ACP-NK1R were produced and calcium
concentration response curves for SP were obtain on a FLEX station and ﬁtted with
the Hill equation (Figure 5.3). The pEC50 values were the same for all three constructs,
wtNK1R, NK1R-ECFP, and ACP-NK1R.
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Figure 5.3: Concentration response curves with pEC50 of SP for diﬀerent
NK1R constructs. Substance P concentration response curves for wtNK1R (A), NK1R-
ECFP (B), and ACP-NK1R (C) in absence (full circles) or in presence of 10µM antagonist
L-723,138 (empty circles). Data are means of 3-4 points ± S.D. in absence and means of 2
points in presence of L-723,138. pEC50 values were obtained by ﬁtting with Hill equation
(Eq. 3.1) ± 95% conﬁdence interval.
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The pEC50 measured here are in agreement with the literature, where variations
of one order of magnitude can be found depending on the cells used. Sagan et al.
[136] reported a pEC50 of 9.2 by measuring the IP3 accumulation for wtNK1R stably
expressed in CHO cells. Dery et al. [137] reported a pEC50 of 9.2 by measuring the
calcium increase with calcium-sensitive dyes for wtNK1R stably expressed in KNRK
cells. Holst et al. [72] reported a pEC50 of 10.1 by measuring the IP3 accumulation for
wtNK1R transiently expressed in COS-7 cells. Martini et al. [79] reported a pEC50 of
9.4 also by measuring the IP3 accumulation for wtNK1R transiently expressed in COS-7
cells.
We were not able to measure complete concentration-response curves for EGFP-
NK1R, because of high background signals from EGFP. EGFP absorbs and emits in
the same range as the calcium-sensitive dye from the Calcium 3 assay kit.
Nevertheless, the functionality of the EGFP-NK1R could be veriﬁed by measuring
the increase of intracellular calcium ion concentration by using ﬂuorescence confocal
microscopy. The same procedures were used for loading the cells with the calcium-
sensitive dye as for the experiments on the FLEX station. The ﬂuorescence increase
was recorded on single cells expressing the receptors. Figure 5.4 shows a representative
time trace of a calcium response for EGFP-NK1R. The ﬂuorescence signal increased
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Figure 5.4: Calcium response of EGFP-NK1R. Time course of the normalized
ﬂuorescence intensity of calcium sensitive probes inside the HEK 293 cells after stimulation
of NK1R by addition of 3 nM SP (at 20 seconds on the time axis).
steeply, reﬂecting an increase of the intracellular calcium ion concentration. These result
were not quantitative, because they did not provide an EC50 value, but they showed
that the EGFP-NK1R fusion protein is functional and able to activate the calcium
signaling pathway. The length of the response (∼100 sec) is consistent with literature
reports [78,138].
With respect to binding of antagonist (Figure 5.3, empty circles), there seemed to be
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a diﬀerence between wtNK1R and ACP-NK1R. Cells expressing ACP-NK1R responded
to SP even when preincubated with 10µM antagonist L-732,138. This indicates either a
lower aﬃnity of antagonist for ACP-NK1R as compared to wtNK1R or even a complete
loss of antagonist binding. It is insofar surprising, because ACP is fused to the N-
terminus of NK1R, which takes part in the binding of the agonist SP but not of the
non-peptide antagonist CP-96,345 [139, 140]. The same eﬀect has been observed for
EGFP-NK1R and needs further investigation.
5.5 ACP Labelling
Several methods for post-translational labelling of proteins have been developed re-
cently [127–132]. The method used for this work is based on the acyl carrier protein
(ACP) and has been described by George et al. [128]. The labelling method makes use
of the post-translational modiﬁcation of ACP by phosphopantetheine transferase (PP-
Tase), leading to the transfer of 4’-phosphopantetheine from coenzyme A (CoA) to a ser-
ine residue of ACP (Figure 5.5). The ﬂuorescent dyes Cy3 and Cy5 attached to the phos-
Figure 5.5: ACP labelling technique. The ﬂuorescent label (star) attached to CoA
is transferred together with 4’-phosphopantetheine by PPTase to ACP. The ACP is ge-
netically fused to the extracellular side of the protein of interest (from [128]).
phopantetheine on CoA are transferred to the ACP together with 4’-phosphopantetheine
during the labelling process. The ACP/PPTase pair used here is from Escherichia coli.
PPTase from E. coli (AcpS) can be easily puriﬁed and possess a relative narrow sub-
strate speciﬁcity with respect to ACP. [128]
The ACP labelling time course with Cy5 (Figure 5.6A) showed that 40 minutes
incubation at 19 ◦C is suﬃcient for the labelling of all receptors. Furthermore, the
ACP-NK1R could be labelled with Cy3 and Cy5 simultaneously by mixing the sub-
strates in a 1:1 ratio before adding to the cells (Figure 5.6). Only receptors that are
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correctly expressed in the plasma membrane are accessible for the labelling, which pre-
vents background ﬂuorescence arising from receptors inside the cells. In addition, all
the cells expressing ACP-NK1R were labelled with both ﬂuorophores.
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Figure 5.6: Labelling of ACP-NK1R fusion protein on cell surface. A, time
course of labelling with Cy5 on ACP-NK1R stably expressed in HEK293 cells. B-D,
ﬂuorescence confocal micrographs showing HEK 293 cells transiently expressing ACP-
NK1R labelled with Cy3 (B) and Cy5 (C). D, transmission image of the same area with
ﬂuorescence micrographs B and C superimposed. Scale bar represents 10µm.
5.6 Conclusion and Outlook
The NK1R has been labelled using two approaches. First, C- or N-terminal fusion of
EGFP, and second, N-terminal fusion of ACP and post-translational labelling with Cy3
or Cy5. All ﬂuorescent NK1R constructs were functional with respect to agonist binding
and calcium signaling. In the case of N-terminal EGFP and ACP fusions, the aﬃnity
of the non-peptide antagonist was changed dramatically or even lost, and further inves-
tigation is needed. Nevertheless, the constructs used in this thesis are functional with
respect to agonist binding and activation of the calcium signaling pathway. Further-
more, it has been shown that 40 minutes at 19 ◦C is suﬃcient for the complete labelling
of ACP-NK1R receptors expressed in HEK293 cells and that ACP-NK1R receptors can
be labelled simultaneously with at least two diﬀerent dyes.
The NK1R constructs can be used for several studies such as ligand binding, traf-
ﬁcking, oligomerization, and protein-protein interactions.
Chapter 6
Monitoring Speciﬁc Ligand Binding
by FRET
6.1 Introduction
GPCR mediated cellular signaling is initiated by the binding of a ligand to its cognate
receptor. Since the development of radiolabelled ligands many binding studies have
been performed leading to insight in binding aﬃnities, structures of binding pocket,
topography models of receptors, and (relatively slow) binding kinetics. Fluorescent
ligands have been used for the same kind of studies with the advantage, that they
are much more sensitive, that they can be applied to living cells using ﬂuorescence
microscopy, and therefore give access to spatial distributions in time, and in addition
they allow the detection of fast kinetics [141].
For GPCRs ﬂuorescent ligands have been used to probe binding domains [140,142], to
investigate ligand binding by ﬂuorescence anisotropy [143] or on immobilized receptors
by TIRF [144] (see Chapter 9), to follow receptor internalization [76,145], and to monitor
receptor diﬀusion by single molecule spectroscopy [146].
The NK1R comprises several binding aﬃnities for SP, which are attributed to dif-
ferent receptor states, depending on the coupling to heterotrimeric G proteins: (1)
uncoupled receptors, (2) receptors coupled with Gαq, and (3) receptors coupled with
Gαs [72, 147–149]. Ligand binding kinetics would give further insight into the diﬀerent
states of the receptor and its functionality.
FRET is a promising method to directly measure speciﬁc ligand binding with high
time resolution. It has been applied to measure fast kinetics of ligand binding to
tachykinin NK2 receptor [115, 116, 150], the chemokine CXCR4 receptor [151] and the
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muscarinic M1 receptor [152, 153]. Figure 6.1 shows a scheme of the principle of this
method, where a donor is fused to the extracellular end of the receptor and the ligand
is labelled with an acceptor. Upon ligand binding the donor-acceptor distance is suﬃ-
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Figure 6.1: FRET between ligand and receptor. Scheme showing the principle of
FRET between a ligand and its receptor. The donor (D) is fused to the N-terminal end
of the receptor, and the acceptor (A) is conjugated to the ligand.
ciently small to quench the donor ﬂuorescence and to sensitize the acceptor emission.
By recording the quenching of the donor one can directly measure the speciﬁc ligand
binding.
Here, we labelled the NK1R at its extracellular N-terminus by either fusion of the
ﬂuorescent protein EGFP or the ACP with subsequent labelling by Cy3 (see Chapter 5).
This Chapter deals with the synthesis and characterization of ﬂuorescent derivatives of
the NK1R agonist (SP) to act as an acceptor for EGFP or Cy3. Preliminary inves-
tigation of speciﬁc ligand binding, using FRET, revealed the advantages of the ACP
labelling over the EGFP labelling.
6.2 Experimental Procedures
Tetramethylrhodamine-labelled substance P (SP-TMR) was from Molecular Probes
(Eugene, OR, USA); NK1R antagonist L-732,138 was from Tocris Cookson (Langford,
UK); Ac-Substance P (AcSP) was synthesized by K. Servis (UNIL, Lausanne, CH);
Cy3B and Cy5 succinimidyl esters were from Amersham Biosciences (Buckinghamshire,
UK).
Cell culturing, cell transfection and preparation, calcium ion signaling, ACP la-
belling, and ﬂuorescence confocal microscopy were performed as described in Chap-
ter 3. The genetic constructs used in this chapter are wtNK1R, NK1R-ECFP, EGFP-
NK1R, EGFP-d15NK1R, trEGFP-NK1R, trEGFP-d15NK1R. Detailed description of
the molecular cloning and the construction of the plasmids can be found in Chapter 5.
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6.2.1 Synthesis of SP-Cy3B and SP-Cy5
2mg of N-terminally acetylated substance P (AcSP) in 0.5ml N,N -dimethylformamide
(DMF) and 50-100µl 100mM carbonate buﬀer at pH 8.2 was mixed with a solution of 0.9
molar equivalent of Cy3B or Cy5 succinimidyl esters in 100-500µl DMF. The reaction
was complete (> 90%) after 1 hour at room temperature. The solvents were evapo-
rated by lyophilization. The solid obtained was dissolved in 300µl of MeOH:H2O:5M
HCl (85:14:1) and puriﬁed by semi-preparative silica gel thin layer chromatography
(TLC, 0.25mm layer thickness), using 5% NH4OH in MeOH as the mobile phase.
The colored band on the top was the non-reacted ﬂuorophore, the large central band
was the product and the small other bands were impurities from the ﬂuorophore and
side-products. The part of the TLC with the product was detached and extracted
three times with MeOH:H2O:5M HCl (85:14:1). The ﬁnal volume was around 3-4ml.
The concentration of SP-Cy3B and SP-Cy5 was measured by absorbance spectroscopy
(εCy3B = 130′000M−1cm−1, εCy5 = 250′000M−1cm−1). The solution with the product
was aliquoted, dried and stored at -20◦C.
6.3 Results and Discussion
6.3.1 Synthesis of SP-Cy3B and SP-Cy5
The physiological agonist for NK1R is substance P (SP),
H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2,
a neuropeptide that belongs to the group of tachykinins and consist of 11 amino acids
with an amidated C-terminus [64]. C-terminal amidation occurs during biosynthesis.
All mammalian tachykinins known up to now share a common C-terminal amino acid
sequence (FXGLM-NH2), which is essential for its binding to the receptors. The N-
terminus seems to be less important for ligand binding and is therefore suitable for
conjugation of a ﬂuorophore, as was shown by Tota et al. [143] who labelled SP with
ﬂuorescein at Lys3 and retained high aﬃnity binding. Dansyl or ﬂuorescein were also
attached at residue 1, 3, 8 and 11 of SP, where labelling at residue 3 showed the smallest
decrease in aﬃnity as compared to non-labelled SP [140]. Molecular Probes, Inc. (Eu-
gene, OR, USA) oﬀers ﬁve ﬂuorophore-conjugated analogs of SP, where the ﬂuorophores
Alexa 488, BODIPY Fl, ﬂuorescein, Oregon Green 488 and tetramethylrhodamine were
conjugated to the third amino acid of SP, Lys3. Except for SP-Alexa488, all of them
were shown to bind to NK1Rs and induce a calcium response in living cells [154]. Also
60 CHAPTER 6. MONITORING SPECIFIC LIGAND BINDING BY FRET
Cy5 has been conjugated to SP at Lys3 and the resulting derivative retained high aﬃnity
for NK1R [155].
The peptide SP has two reactive amino groups, the N-terminal amino group and
the ε-amino on the lysine side chain. Both amino groups in SP have a similar pKa
value and could not be selectively labelled with succinimidyl esters of the ﬂuorophores.
In order to label SP with one ﬂuorophore only, we used a SP analogue, where the N-
terminal amine was replaced by a non reactive acetyl-group. Thus, the ﬂuorophores
were attached selectively to the lysine at position 3. Cy3B and Cy5 were chosen as
ﬂuorophores to act as acceptor for EGFP and Cy3, respectively (Table 6.1). Although
the commercially available tetramethylrhodamine (TMR) conjugated SP would be also
suitable as an acceptor for EGFP, the Cy3B was used because it shows a longer Förster
distance (R0).
Molar Absorption Emission Spectral Förster
Extinction Maximum Maximum Overlap Distance (R0)
Cy3B 130’000 566 580 4.14 · 1015 58.0
Cy5 250’000 646 664 6.79 · 1015 50.0
TMR 85’000 560 575 2.72 · 1015 54.1
Table 6.1: Properties of the ﬂuorophores conjugated to SP. Extinction coeﬃcient
in M−1cm−1 (Cy3B and Cy5 from Amersham, TMR from Molecular Probes), absorption
and emission spectra maxima in nm, calculated spectral overlap (in M−1cm−1nm4), and
Förster distance R0 (in Å) for EGFP-Cy3B and Cy3-Cy5, respectively. Donor quantum
yields used for the calculation of the spectral overlap were 0.6 and 0.15 for EGFP and
Cy3, respectively (from Clontech and Amersham). TMR, tetramethylrhodamine.
6.3.2 Speciﬁc Ligand Binding and Receptor Localization
Studies in Chapter 5 showed that EGFP-NK1R and ACP-NK1R are functional with
respect to SP binding and calcium signaling. Next, we wanted to know if the ﬂuo-
rescent SP derivatives also bind to these receptors. Therefore, the diﬀerent receptors
were expressed in HEK293 cells and speciﬁc ligand binding was monitored by confocal
microscopy.
As shown in Figure 6.2, all four EGFP-NK1R constructs were able to bind ﬂuorescent
derivatives of SP selectively, conﬁrmed by (i) removal of ﬂuorescent ligands with an
excess of unlabelled SP, and (ii) absence of SP binding on cells not expression EGFP-
NK1R. Furthermore, confocal micrographs of the four diﬀerent EGFP-NK1R fusion
constructs showed partial localization of EGFP-NK1R in the plasma membrane with a
considerable fraction of immature and incompletely processed proteins inside the cells.
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Figure 6.2: Expression of EGFP-NK1R constructs. Confocal micrographs show-
ing, ﬁrst column (green), EGFP-NK1R fusion constructs transiently expressed in HEK293
cells. Second column (red), binding of ﬂuorescent SP derivatives. Third column, white
light transmission image of the same area with ﬂuorescence images superimposed. A,
EGFP-NK1R with 100 nM SP-TMR; B, EGFP-d15NK1R with 100 nM SP-TMR; C,
trEGFP-NK1R with 50 nM SP-Cy3B; D, trEGFP-d15NK1R with 50 nM SP-Cy3B. Scale
bars represent 10µm.
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Because the ligand only binds to receptors expressed in the plasma membrane, the
ﬂuorescence signal of labelled SP colocalized only with the EGFP signal from receptors
in the plasma membrane. This can be seen very well in the micrographs in the third
column of Figure 6.2, where the overlay of red and green signal turns yellow. The
fraction inside the cells varied from day to day and is probably due to variations of the
cell cycle.
In comparision, Figure 6.3A and B show ligand binding to the Cy3-labelled ACP-
NK1R. The colocalization of SP-Cy5 with the labelled receptor indicates that only
receptors accessible to SP and therefore located at the cell surface are labelled with
the ACP labelling technique. The speciﬁc SP-Cy5 binding was further conﬁrmed by
competition with excess of unlabelled SP. Furthermore, the ACP-NK1R internalized
A B
C D
Figure 6.3: Expression of ACP-NK1R in HEK 293. A-B, ﬂuorescence confocal
micrographs showing HEK 293 cells transiently expressing ACP-NK1R labelled with Cy3
(A) and the agonist SP-Cy5 at 100 nM bound to the receptor (B). C-D, ﬂuorescent confocal
micrograph showing HEK293 cells stably expressing ACP-NK1R labelled with Cy3 (C)
after 15 minutes incubation with 100nM SP-Cy5 (D) at 20◦C. Arrows indicate internalized
NK1R and SP-Cy5. Scale bars represent 10µm.
together with SP-Cy5 within 15 minutes after ligand application at room temperature
(Figure 6.3C and D).
Similar to ACP-NK1R and SP-Cy5, internalization of SP-TMR was observed after
30 minutes incubation at room temperature. Surprisingly, hardly any signal arising from
the EGFP fused to the receptor could be detected inside the cells, whereas SP-TMR
was detectable (Figure 6.4). A reason for this eﬀect could be the acidic environment of
early endosomes. It is known that the ﬂuorescence emission of EGFP decreases at low
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pH [156–158], and EGFP fused to the extracellular side of the receptor is in the lumen
of the early endosomes after internalization.
CA B
Figure 6.4: EGFP-NK1R internalization. Confocal micrographs showing EGFP-
NK1R expressed in HEK293 cells, 1 (A) and 30 (B) minutes after addition of 100 nM SP-
TMR. C, removal of SP-TMR by antagonist L-732,138. First and second row, ﬂuorescent
signal from EGFP and SP-TMR in green and red, respectively. Third row, overlay of
EGFP and SP-TMR signal. Scale bar represents 10µm.
Addition of excess concentration of the antagonist L-732,138 removed partly the SP-
TMR on the cell surface. The remaining SP-TMR can be attributed to either ligands
with very slow oﬀ-rates or ligands bound to internalized receptors present in small
vesicles attached to the plasma membrane. SP-bound NK1Rs expressed in KNRK cells
internalized at 18◦C within minutes into small vesicles beneath the plasma membrane
[77].
The observed ligand binding and subsequent receptor internalization show that the
ﬂuorescent ligands act as agonists. In the following part detailed cellular calcium re-
sponse after receptor activation are presented.
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6.3.3 Calcium Response of Fluorescent SP Derivatives
As mentioned before, activation of NK1R leads to the releases of calcium ions from inter-
nal stores and thereby increases the intracellular calcium ion concentration. This eﬀect
can be monitored with calcium-sensitive dyes. The increase of the intracellular calcium
ion concentration is related to the increase in ﬂuorescence of the calcium-sensitive dye
and can be measured on a FLEX station. A concentration response curve is measured
plotting the amplitude of the intensity increase versus the agonist concentration. The
data points can be ﬁtted with the Hill equation (Eq. 3.1, Chapter 3).
Such experiments were performed for the newly synthesized ﬂuorescent SP analogues,
SP-Cy3B and SP-Cy5, as well as the commercial available SP-TMR. Figure 6.5 shows
the concentration response curves and the pEC50 values for the ligands SP, SP-Cy3B
and SP-TMR, using a HEK293 stably expressing NK1R-ECFP. SP-Cy3B and SP-TMR
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Figure 6.5: Concentration response curves with pEC50 of ﬂuorescent SP
derivatives. Concentration response curves of SP, SP-Cy3B, and SP-TMR on HEK293
cells stably expressing NK1R-ECFP. Data are means of 3-4 points ± S.D. pEC50 values
were obtained by ﬁtting with the Hill equation ± 95% conﬁdence interval.
were shown to act as agonists with a pEC50 in the same range as SP. As a control, cells
preincubated with 10µM antagonist L-732,138 showed no response at all.
The ability of SP-Cy5 to activate the calcium signaling pathway was also veriﬁed,
using HEK293 cell lines stably expressing wtNK1R and ACP-NK1R (Figure 6.6). The
pEC50 for SP on both wtNK1R and ACP-NK1R was the same, 10.6±0.3 and 10.7±0.3,
respectively. The pEC50 for SP-Cy5 on both wtNK1R and ACP-NK1R was also the
same, 9.2±0.6 and 8.9±0.5, respectively, but with about 50 times higher pEC50 values.
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Figure 6.6: Concentration response curves of SP and SP-Cy5 on wtNK1R and
ACP-NK1R. Concentration-response curve for SP on wtNK1R (triangles) and ACP-
NK1R (empty circles), and for SP-Cy5 on wild type NK1R (full circles) and ACP-NK1R
(empty squares). pEC50 values are shown in the Table. Data are means of 3-4 points ±
S.D. pEC50 values were obtained by ﬁtting with Hill equation (Eq. 3.1) ± 95% conﬁdence
interval.
6.3.4 Quenching of Fluorescently Labelled NK1R
GPCR mediated cellular signaling is initiated by the binding of a ligand to its receptor.
Ligand binding kinetics can be monitored in real-time by FRET, where the receptor
is labelled with a donor and the ligand carries the acceptor. Upon ligand binding the
donor ﬂuorescence is quenched due to FRET. With the ﬂuorescent NK1R constructs
and the ﬂuorescent ligands, the tools to investigate speciﬁc ligand binding by FRET
were available.
Two examples with the ﬁrst approach, where EGFP has been fused to the NK1R,
are shown in Figure 6.7. The best results were achieved with SP-Cy3B as ligand and
the two NK1R constructs, where the EGFP is truncated (trEGFP-NK1R and trEGFP-
d15NK1R). The time courses of EGFP intensities where calculated from a region of
interest (ROI) over a part of the plasma membrane. The intensities were background
subtracted and normalized. Selection of the membrane with a ROI was necessary,
because of the high intracellular background signal from incompletely processed EGFP-
NK1R.
Speciﬁc ligand binding could be observed through quenching of EGFP on trEGFP-
NK1R and on trEGFP-d15NK1R, conﬁrmed by the increase of the signal after appli-
cation of excess of non-labelled SP. The quenching was more pronounced for trEGFP-
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Figure 6.7: Quenching of EGFP-NK1R. 50nM SP-Cy3B were added to HEK293
cells transiently expression either trEGFP-NK1R (A) or trEGFP-d15NK1R (B). Curves
are time traces of the normalized ﬂuorescence from EGFP. First vertical line indicates time
when SP-Cy3B was applied (40 s and 45 s, respectively). Second vertical line indicates
application of excess (2.5µM) of non-labelled SP (130 s and 180 s). Fluorescence confocal
micrographs represent EGFP signal and ROI from which the intensity time curves were
calculated. Scale bars represent 10µm.
d15NK1R. This is probably due to a shorter distance between donor and acceptor. The
reason why the EGFP signal did not recover its intensity as before the quenching is not
clear. It could be due to photobleaching, internalization of receptors with agonist still
bound, or an additional slow dissociation rate of the agonist.
As mentioned before, the ACP method allows the speciﬁc labelling of receptors
at the cell surface and therefore does not create intracellular background ﬂuorescence
from incompletely processed receptors. In Figure 6.8, SP-Cy5 (116 nM) was applied
to HEK293 cells at 19◦C stably expressing Cy3-labelled ACP-NK1R. The ﬂuorescence
signal of Cy3 decreased simultaneously with the increase of Cy5 ﬂuorescence, indicating
speciﬁc binding of agonist SP-Cy5 to the receptor.
The mixing time for SP-Cy5 to reach the desired equilibrium concentration is in the
range of 3-4 seconds (Figure 6.8, top). The second trace in Figure 6.8 shows ﬂuorescence
changes with time constants in the range of 30-40 seconds. It is not obvious if the changes
observed in the short time regime is a combination of the mixing time and an additional
fast association time for SP-Cy5 to NK1R.
In contrary, the third trace in Figure 6.8 reveals speciﬁc binding of SP-Cy5 to Cy3-
labelled ACP-NK1R, because only bound ligands are able to quench the Cy3-labelled
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Figure 6.8: Quenching of ACP-NK1R. 116 nM SP-Cy5 was applied with the pipette
of a perfusion system a few micrometers away from the cell at 19 ◦C. Application durations
depicted by bars above the curves were 84 s (ﬁrst) and 63 s (second). Top curve represents
ﬂuorescence intensity (a.u.) of SP-Cy5 in the buﬀer next to the cells. Middle curve
represents ﬂuorescence intensity (a.u.) of SP-Cy5 binding to ACP-NK1R. Bottom curve
represents the time course of the normalized ﬂuorescence intensity of Cy3-labelled ACP-
NK1R over the same region of interest (ROI) as for SP-Cy5 binding. Fluorescence confocal
micrograph of HEK293 cells transiently expressing ACP-NK1R labelled with Cy3 with
white box indicating the ROI for the middle and bottom curves. Scale bar represents
10µm.
ACP-NK1R ﬂuorescence by FRET. Here, we can clearly distinguish two association
time constants: a short time constant in the range of 3-5 seconds, which might be
inﬂuenced by the mixing time, and a long time constant in the range of 30-40 seconds.
From the SP-Cy5 trace alone it is not possible to distinguish between speciﬁc and
unspeciﬁc binding, because this signal is the sum of the intensities of speciﬁc and un-
speciﬁc binding of SP-Cy5, the SP-Cy5 in solution, and internalized SP-Cy5. The
internalization of the SP-Cy5 remains in the trace after washing with buﬀer. However,
the quenching of Cy3 shows only the speciﬁc binding, since non-bound ligand cannot
quench the Cy3 bound to the receptor.
Applying the agonist SP-Cy5 for 84 seconds yielded 23% quenching of the Cy3.
After washing with buﬀer the agonist was only partially removed and Cy3 remained
quenched by 9%. After adding the ligand for another 63 seconds and then washing with
buﬀer, 13% of Cy3 remained quenched. We attribute the remaining ligand to a slow
dissociation process in the range of hours or internalization to small vesicles, which are
bound to the cytoplasmic side of the plasma membrane.
ACP-NK1R, trEGFP-NK1R and trEGFP-d15NK1R showed a similar degree of
quenching, considering the concentrations of ﬂuorescent SP added (116 nM and 50 nM
for SP-Cy5 and SP-Cy3B, respectively). Comparing the Förster distance (R0) for the
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DA pairs EGFP/Cy3B (58Å) and Cy3/Cy5 (50Å), and noting the fact that there was
no need for truncation in ACP-NK1R construct, suggest that ACP-NK1R is more suit-
able for these kind of experiments. Furthermore, there is no need to select part of the
membrane to evaluate the quenching, as it was the case for the EGFP-NK1R (micro-
graph in Figure 6.7). Using the ACP-NK1R, an area including all the cells (micrograph
in Figure 6.8) can be selected, because there is no background ﬂuorescence from incom-
pletely processed ﬂuorescent NK1Rs. This is especially advantageous if one wants to
work with cell suspensions instead of single cells.
6.4 Conclusions and Outlook
Two ﬂuorescent ligands for the NK1R, SP-Cy3B and SP-Cy5, were synthesized to inves-
tigate ligand binding by FRET. The ﬂuorophores were attached to the lysine at position
3 of the peptide, and the resulting SP derivatives bound speciﬁcally to the NK1R and
were shown to act as agonists.
SP-Cy3B turned out to be better for FRET measurements with EGFP-NK1R than
the commercially available SP-TMR. Futhermore, the truncation of EGFP was required
to obtain FRET. In the case of other GPCRs the N-terminus had to be truncated as
well to achieve good quenching signals [115, 152]. The ACP-NK1R fusion construct,
where no truncation was necessary, is a good alternative to EGFP-NK1R. Several
donor-acceptor combinations can be used on the same fusion protein, and no tedious
and time consuming cloning is required. In addition, the choice of good ﬂuorophores is
much larger than of ﬂuorescent proteins.
The tools are now available for further detailed investigations of ligand binding ki-
netics or endocytosis. It would also be interesting to try the labelling of the ACP-NK1R
with ﬂuorophores with a long ﬂuorescence life-time, such as lanthanides, to enhance the
signal-to-noise ratio for time-resolved FRET investigations. The internalization could be
studied with a FRET-based approach, using the Cy3-labelled ACP-NK1R and CypHer 5
conjugated SP. CypHer 5 is a pH sensitive ﬂuorophore that becomes ﬂuorescent at acidic
pH as it is present in intracellular endosomes [145].
Although EGFP-NK1R did not quite fulﬁl our hopes, it showed to be useful in other
studies. Lill et al. [146] used the stable EGFP-NK1R cell line for single molecule experi-
ments, were a reduction of receptor diﬀusion within the ﬁrst second after ligand binding
was shown. Guignet et al. [129] reversibly quenched the EGFP on the extracellular side
by binding NTA-I, a quencher conjugated to NTA, to the 10xHis-tag at the cytoplasmic
side of the receptor.
Chapter 7
Oligomerization and
Compartmentalization of NK1R
7.1 Abstract
Many G protein-coupled receptors (GPCRs) tend to form dimers or higher oligomers
which might be of importance for cellular signalling. Here we investigate the oligomer-
ization state of the neurokinin-1 receptor (NK1R) in single living cells by FRET using
an in vivo labelling method recently developed by our laboratories. The NK1R was ﬁrst
expressed in form of a fusion protein with an acyl carrier protein (ACP). Subsequently,
small ﬂuorophores were covalently bound to the ACP moiety of the ACP-NK1R. This
approach oﬀers several substantial improvements as compared to labelling by classical
ﬂuorescent protein derivatives: (i) The practically unlimited free choice of the label
molecule makes it possible to use ﬂuorophores optimized for FRET measurements. (ii)
Because labelling occurs exclusively at the cell surface, only correctly assembled receptor
proteins are accessed; in consequence no intracellular ﬂuorescence background appears
yielding yet unreached signal to noise ratios even at low receptor concentrations. (iii)
Simultaneous dual color labelling e.g. with donor and acceptor of precisely deﬁned and
controlled molar ratios between the two ﬂuorophores can be realized which is prereq-
uisite of reliable and quantitatively evaluable FRET measurements in living cells. Our
single cell FRET measurements exclude the presence of dimeric or higher oligomeric
NK1Rs but indicate that the NK1Rs tend to concentrate in microdomains.
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7.2 Introduction
G protein-coupled receptors (GPCR) were for a long time presumed to function as
monomers according to the prevailing model: One ligand molecule - one receptor -
one G protein [23]. But recently, dimeric or higher oligomeric structures have been
found for several GPCRs using biochemical (co-immunoprecipitation) and biophysi-
cal methods (BRET and FRET) [9, 22, 46, 54–58]. Oligomerization can occur between
the same receptor subtypes (homo-oligomerization) or between diﬀerent receptor sub-
types (hetero-oligomerization) and can be constitutive or ligand-dependent. Preformed
oligomers of some GPCRs may serve as a signaling platform that retains its multimeric
status throughout the process. Other GPCRs may cycle through monomeric and mul-
timeric states in a ligand-regulated process [27]. GPCR hetero-dimerization can result
in altered ligand selectivities and distinctive coupling to signal transduction pathways,
providing an additional source of richness for the ﬁne-tuning of cellular signaling.
BRET and FRET assays are presently often used to investigate GPCR oligomeriza-
tion [55], because they allow in-vivo measurements. As a particular advantage, FRET
and BRET measurements allow quantitative determinations of the presence and amount
of oligomerization by investigating the dependency of the BRET or FRET signals on
the donor-acceptor ratios and on the overall expression levels. Yet, there is only a few
reports on such quantitative cellular studies on GPCRs. Ayoub et al. [159] used BRET
competition assays with melatonin receptors to determine that the transfer of energy
resulted from the formation of dimers and not of higher oligomers. To investigate β1-
and β2-adrenergic receptor homo- and hetero-dimerization Mercier et al. [160] plotted
the percent maximal BRET level against the donor-acceptor (DA) ratio to distinguish
between dimers and trimers. Similar experiments were done with serotonin 5-HT2C
receptors [161] using a FRET assay.
A major limitation for quantitative FRET and BRET measurements is the quality
of the signals, which is directly related to the type of ﬂuorophore used. Most studies
use ﬂuorescent proteins, respectively luciferase for BRET, which both are accompanied
with background signals of incompletely processed proteins inside the cell and from the
unfavorable emission wavelengths in a spectral region where the autoﬂuorescence of the
cells is high. This and the diﬃculties to adjust DA ratios complicate quantitative esti-
mations. In contrast, post-translational labelling methods [127–132] are more versatile
and oﬀer substantially increased signal-to-noise ratios and control of DA ratios. In par-
ticular, we have shown previously the feasibility of ACP labelling [128] in FRET studies
and its advantages over labelling using ﬂuorescent proteins: The possibility to choose
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ﬂuorophores, an exclusive labelling of the receptors translocated to the membrane and
straightforward tunability of the acceptor-donor ratio. ACP labelling is based on the
enzymatic transfer of ﬂuorescently labelled 4’-phosphopantetheine from coenzyme A
(CoA) to an acyl carrier protein (ACP) fused to the protein of interest [128].
In the present studies we chosen the neurokinin-1 receptor (NK1R) as a prototypical
example of a GPCR. The NK1R mediates processes such as nociception, neural inﬂam-
mation or smooth muscle contraction. NK1R enjoys considerable attention as a drug
target for instance for treatments against depression. Therefore, it is of importance to
investigate the organization, i.e. oligomerization and localization of the NK1R in cell
plasma membrane, and to correlate it with its function. It has been shown previously
that the neurokinin-1 receptor can form hetero-dimers with the human µ-opioid recep-
tor [82]. However, to our knowledge, there is no report on whether the NK1R is also able
to form homo-dimers. Biochemical studies indicate that the NK1R is most probably
localized in rafts microdomains in the cell plasma membrane [73]. This has also been
proposed by Holst et al. [72] investigating NK1R Gαq and Gαs fusion proteins.
Here, we made use of the advantages of the ACP labelling technique to investigate
whether or not NK1R oligomerizes in living cells using sensitized acceptor emission based
FRET microscopy (Chapter 4). The NK1R fused with ACP (ACP-NK1R) was labelled
simultaneously with a deﬁned ratio of Cy3 and Cy5 as donor and acceptor, respectively.
High FRET eﬃciencies with a strong dependency on DA ratio were observed for receptor
expression levels around 300 receptors/µm2. The dependency was not linear, excluding
that the FRET signals was due to the presence of dimers. It was furthermore possible
to rule out the presence of oligomers from the sharp dependency of the FRET signal
on the expression level. In general, the FRET data can be explained as resulting from
stochastic encounters of the donor and the acceptor assuming that the eﬀective surface
density is about 100 times higher as expected as a result of the compartmentalization
of the NK1R into microdomains.
7.3 Experimental Procedures
7.3.1 Materials
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine labelled with Cy5 (DPPE-Cy5)
was a kind gift from Silke Mark of the Ludwig Institute for Cancer Research (Epalinges,
CH); 1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)] (DOPG) was from Avanti Po-
lar Lipids (Delfzyl, NL); methyl-β-cyclodextrin (MBCD) was from Sigma (Buchs, CH).
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Cell culturing, cell transfection and preparation, and ACP labelling were performed
as described in Chapter 3. The method to calculate sensitized acceptor emission has
been described in Chapter 4. Protein content was determined using the Bradford protein
assay (Pierce) with BSA as standard. Image treatment and data analysis were performed
using custom programs written in IGOR PRO 5 (Wavemetrics). Unless diﬀerently
stated, all errors indicated are 95% conﬁdence intervals. Error bars represent standard
deviations.
7.3.2 Lipid Vesicles Preparation and Estimation of Receptor
Surface Density on Cells
DOPG and DPPE-Cy5 dissolved in chloroform were mixed at a molar ratio of 0.03% and
0.06% DPPE-Cy5 to yield a Cy5 surface concentration of 500 and 1000 molecules/µm2,
respectively, assuming a lipid surface area of 60Å2. Lipid mixtures were dried over night
and rehydrated with PBS at 37 ◦C during 3 days. The lipid vesicles were placed on glass
coverslips and imaged with the same settings used for FRET imaging. A threshold was
applied to the background-subtracted images to select the membrane of the vesicles.
The average intensity for each single vesicle was determined and the receptor density,
σr (receptors/µm2) calculated according to
σr = σCy5
IC
IV
(
1
xA
)
, (7.1)
where IC is the average ﬂuorescence intensity of Cy5 on a cell; IV is the average ﬂuo-
rescence intensity of Cy5 on a vesicle (measured with same instrument settings as IC);
σCy5 is the surface density of Cy5-DPPE on the vesicle (molecules/µm2); and xA is the
acceptor mole fraction on the labelled cells.
7.3.3 Confocal FRET Microscopy
Laser-scanning confocal micrographs were recorded on a LSM 510 microscope (Zeiss)
equipped with a 63× water objective (1.2W Korr, Zeiss) either excited at 543 nm or
at 633 nm using Helium-Neon lasers. Detection of ﬂuorescence signals of acceptor and
donor/FRET was achieved by appropriate ﬁlter sets using two tracks. The settings for
the acceptor track were (excitation wavelength, dichroic mirror, emission ﬁlter): 633 nm,
HFT 633, LP 650 (acceptor ﬁlter set, denoted as acceptor channel). The donor and the
FRET images were recorded simultaneously with excitation at 543 nm and a dichroic
mirror HFT 543, the emission beam was split with a NFT 635 Vis mirror onto two
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detectors with a BP 560-615 ﬁlter for donor emission (donor ﬁlter set, denoted as donor
channel) and a LP 650 ﬁlter for acceptor emission (FRET ﬁlter set, denoted as FRET
channel), respectively. The laser power for the excitation and the gain of the detectors
for the emission were adjusted for each experiment to yield an image with a good signal
to noise ratio. Fluorescence intensities on the cell were calibrated using measurements of
ﬂuorescence intensities of solutions of the donor or the acceptor at known concentrations
at the same experimental settings, allowing to compare expression of various cells and
to calculate observed donor mole fractions from xD,obs = [D]/([D] + [A]).
7.4 Theory
7.4.1 Relationship between Donor Dequenching and Sensitized
Acceptor Emission
The true FRET eﬃciency, E, refers to the transfer of energy between a donor and an
acceptor molecule in a single DA pair or to the average over a large number of DA
pairs, excluding the molecules not contributing to FRET. The apparent eﬃciency, Eapp,
signiﬁes the eﬃciency of energy transfer in a large population of donors and acceptors,
where only a fraction contributes to FRET. The method to measure the eﬃciency is
based either on donor quenching, Eapp,dq = 1 − (FDA/FD), or on sensitized acceptor
emission, Eapp,se = (FAD/FA− 1)[εA(λ)/εD(λ)] (see Chapter 4). For a mixture of donor
and acceptor molecules, where only a fraction of them performs FRET, Eapp,dq and
Eapp,se are not necessarily identical.
It is possible to derive a simple relation between Eapp,dq and Eapp,se. Energy conser-
vation dictates that the excitations lost by energy transfer from the donor are gained by
the acceptor. Excitations directly correspond to detected ﬂuorescence through a propor-
tionality factor comprising the ﬂuorescence quantum yield and the detection eﬃciency.
Using the ﬂuorescence quantum yields, φD and φA, and the detection eﬃciencies, ηD
and ηA, for donor and acceptor, respectively, one gets
1
φDηD
(FD − FDA) = 1
φAηA
(FAD − FA). (7.2)
Fluorescence is proportional to number of molecules, extinction coeﬃcients, ﬂuores-
cence quantum yields and detection eﬃciencies: FD ∝ xDεDφDηD and FA ∝ xAεAφAηA.
FA
FD
=
xA
xD
εA
εD
φA
φD
ηA
ηD
. (7.3)
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Combining Eq. 7.2 and Eq. 7.3 gives
εA
εD
(
FAD
FA
− 1
)
=
(
1− FDA
FD
)
xD
xA
, (7.4)
or
or Eapp,se = Eapp,dq
xD
xA
, (7.5)
where Eapp,se is the apparent eﬃciency measured by sensitized acceptor emission; Eapp,dq
is the apparent eﬃciency measured by donor dequenching; xD and xA are the donor and
acceptor mole fractions.
7.4.2 Determining the Presence of Dimers and Higher Oligo-
mers by FRET
The apparent FRET eﬃciency (Eapp) is a function of the true FRET eﬃciency and the
donor or acceptor mole fraction. A model to relate donor dequenching (Eapp,dq) to the
true FRET eﬃciency (E) and the donor mole fraction (xD) was developed previously
[162,163],
1− FDA
FD
= E(1− xn−1D ), (7.6)
where n is the number of units in an oligomer. Eq. 7.6 expressed as Eapp,se, using Eq. 7.5
and noting that xA + xD = 1 gives
Eapp,se = E
xD
1− xD (1− x
n−1
D ). (7.7)
Incomplete Labelling
Adair and Engelman [162] extended their model for the case of incomplete labelling,
1− FDA
FD
= E(1− (x′DU)n−1), (7.8)
where x′DU is the mole fraction of donor labelled and unlabelled receptors together
(x′DU = x′D + x′U). If x′D and x′A are the mole fractions of donor- and acceptor-labelled
receptors and x′U is the mole fraction of unlabelled receptors, then x′D = xD(1 − x′U)
and x′A = xA(1 − x′U) , where xD and xA are the donor and acceptor mole fractions
used for labelling. Combining Eq. 7.5 and Eq. 7.8, the apparent eﬃciency measured by
sensitized acceptor emission for incomplete labelling is
Eapp,se = E
xD
xA
(1− (x′DU)n−1), (7.9)
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with x′DU = xD(1− x′U) + x′U.
Oligomers in Presence of Monomers
If we assume a population of oligomers in the presence of monomers, the apparent
eﬃciency would be reduced, with an increasing fraction of monomers. The equation for
Eapp,dq with a mixture of monomers and oligomers can be derived by writing Eapp,dq in
terms of molar ﬂuorescence, fDA and fD:
Eapp,dq = 1− FDA
FD
= 1− fDA
fD
. (7.10)
The molar ﬂuorescence for donor in presence of acceptor, fDA, can be expressed as the
sum of contributions of the molar fraction of monomers, xmono, and the molar fraction
of oligomers, xoligo:
fDA = xmonofDA,mono + xoligofDA,oligo = xmonofD + xoligofDA,oligo , (7.11)
where, fDA,mono and fDA,oligo are the molar ﬂuorescence of donor in presence of acceptor
for a monomer and an oligomer, respectively. Because monomers cannot undergo FRET,
fDA,mono = fD,mono = fD. Substituting Eq. 7.11 in Eq. 7.10 yields:
Eapp,dq = 1− xmonofD + xoligoFDA,oligo
fD
= xoligo
(
1− fDA,oligo
fD
)
(7.12)
= xoligo
(
1− FDA
FD
)
,
with xmono = 1 − xoligo and fDA,oligo = fDA, because all changes due to FRET occur in
the oligomer. The measured apparent eﬃciency is proportional to the true eﬃciency
with the proportionality factor xoligo.
7.4.3 FRET for Randomly Distributed Donors and Acceptors
For randomly distributed donors and acceptors in membranes, the energy transfer eﬃ-
ciency (with respect to donor dequenching) is a function of the Förster distance (R0),
the distance of closest potential approach of donor and acceptor (Rc), and the surface
density of acceptors [164].
Wolber and Hudson [165] derived an analytical approximation for the transfer eﬃ-
76 CHAPTER 7. OLIGOMERIZATION DEGREE OF NK1R
ciency for randomly distributed donors and acceptors:
FDA
FD
= A1e
−k1 cA + A2e−k2 cA , (7.13)
where cA is the reduced acceptor concentration (acceptor surface density normalized by
R20); A1,2 and k1,2 are constants which change for diﬀerent Rc/R0 ratios and given in
Wolber and Hudson [165]. It is important to note that this approximation holds only
for 0 ≤ cA ≤ 0.5.
We introduced a factor α to account for the fact that the receptors might not be
homogenously distributed but concentrated in microdomains. This factor increases the
local acceptor density. Using Eq. 7.5 we can relate the approximation in Eq. 7.13 to
Eapp,se as
Eapp,se = (1− (A1e−k1 cAα + A2e−k2 cAα)) xD
1− xD , (7.14)
where cA = σR(1− xD)R20.
7.5 Results
7.5.1 Controlled Labelling and FRET Imaging of ACP-NK1R
The NK1R was fused at its N-terminus with ACP for subsequent labelling with ﬂuo-
rescent analogs of Coenzyme A. Previous reports have shown that the fusion protein
ACP-NK1R expressed in HEK293 cells can be speciﬁcally labelled with Cy3 [128] and
keeps its ability to bind the agonist Substance P, eliciting a calcium response at a similar
eﬀective concentration than for the wild-type receptor (Chapter 5).
For FRET imaging, ACP-NK1Rs were double labelled with Cy3 (Donor) and Cy5
(Acceptor) by mixing the substrates at deﬁne ratios before applying to the cells. Fig-
ure 7.1A-C shows typical donor, acceptor and FRET images of a living cell labelled with
a donor (acceptor) mole fraction of 0.67 (0.33), revealing a rather heterogeneous distri-
bution of the NK1R in the cell membrane. Because only receptors correctly translocated
to the plasma membrane are accessible for labelling, there is no background ﬂuorescence
inside of the cells. The FRET ratio (FR) was calculated on a pixel-by-pixel basis from
the background-subtracted images after applying a threshold to select only the mem-
branes comprising the labelled ACP-NK1Rs (Figure 7.1D) and was 6.4 (0.01) yielding
a corresponding apparent FRET eﬃciency, Eapp,se, of 60% using Eq. 4.6 (in Chapter 4).
For quantitative FRET experiments, it is instrumental that the DA ratios in solution
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Figure 7.1: Controlled double-labelling and FRET imaging of a living cell.
A-B, Fluorescence confocal micrographs showing a HEK293 cell transiently expressing
ACP-NK1R, which was labelled simultaneously with Cy3 and Cy5 at a Cy3 mole fraction
(xD) of 0.67. The cell was imaged with the ﬁlter sets for donor (A), acceptor (B) and
FRET (C). Scale bar represents 10µm. D, The micrograph of the FRET ratio (FR) was
calculated from images (A), (B) and (C) on a pixel-by-pixel basis. The mean FR value was
6.4 (0.01), corresponding to an apparent FRET eﬃciency of 60% (see color bar). E, The
donor mole fraction, xD,cell, observed on the cells as a function of the donor mole fraction
in solution, xD,sol, used for the labelling. xD,sol is identical to xD,cell within experimental
error as shown by a linear regression yielding an intercept of 0.035± 0.073 and a slope of
0.94± 0.12 (± 95% conﬁdence interval). Each point is the mean (± S.D.) of 10 cells.
used for labelling precisely correspond to the real DA ratios obtained on the cells. To test
this, we labelled HEK293 cells expressing very low amount of ACP-NK1Rs using donor
mole fractions xD,sol ranging from 0.2-0.8. No FRET occurred at such low expression
levels meaning that average ﬂuorescence intensities in the donor and acceptor channels
(Df and Af , see Theory) were directly proportional to the respective concentrations.
Using a calibration procedure, the observed donor mole fraction xD,cell was calculated
and found to vary linearly with xD,sol (Figure 7.1E), conﬁrming that the DA ratio on the
receptors after labelling can be directly obtained from the DA ratio used for labelling.
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7.5.2 Oligomerization of NK1R
In the following we use the controlled dual color labelling to investigate the oligomer-
ization of the NK1R by FRET imaging. Veatch and Stryer [163] showed that the
oligomerization of a membrane protein can be determined from the dependency of the
apparent FRET eﬃciency (Eapp,dq) on the donor mole fraction (xD, Eq. 7.6). Here, we
adapted this model to measure the apparent FRET eﬃciency using sensitized acceptor
emission (Eapp,se). For dimers (n = 2) a linear increase in Eapp,se with increasing xD is
expected from Eq. 7.7.
ACP-NK1R transiently expressed in HEK293 cells was labelled at various mole frac-
tions of the donor (Figure 7.2, gray circles). Care was taken that all investigated cells
showed similar expression levels. A ﬁt of Eapp,se as a function of xD using Eq. 7.7 yielded
the true FRET eﬃciency E = 0.26±0.09, and the oligomerization degree n = 3.75±1.27.
For the ﬁt, an oﬀset was included in Eq. 7.7, which was found to be −0.022± 0.030, i.e.
zero within the experimental accuracy.
Remarkably, the number of units n in the oligomer was signiﬁcantly higher than
2 showing that the NK1R does not form dimers at these expression levels, but rather
higher oligomers. From the FRET eﬃciency, E, and the Förster distance for Cy3 and
Cy5 of R0 = 50Å [164], the average distance Rc between donor and acceptor in the
oligomer was calculated to be about 60Å, which is slightly larger than the estimated
diameter of a GPCR of 40-50Å [8,160].
In order to investigate whether the FRET eﬃciency varied with the expression level,
Eapp,se was measured in HEK293 cells stably expressing ACP-NK1R at expression levels
2.5 times lower than for transient expression (Figure 7.2, black circles). Strikingly, such
a small concentration diﬀerence resulted in the complete loss of FRET. Fitting the
data with E ﬁxed to 0.26 yielded an oligomerization degree n = 1.09 ± 0.28 and an
oﬀset = 0.018± 0.047, meaning that all NK1Rs were present as monomers at this lower
expression level. To exclude that this observation was only due to the stable expression
of the NK1R, FRET was measured on transiently expressing cells with 2.5 times lower
expression levels leading to the same result.
In order to interpret these ﬁndings, it is essential to assess the possible inﬂuence
of unlabelled receptors on the degree of oligomerization. Unlabelled receptors might
be present due to (i) incomplete labelling of the ACP-NK1R, (ii) free non-conjugated
CoA in the labelling solution, or (iii) presence of wtNK1R or other non-labelled GPCRs
forming oligomers with the NK1R. Saturation labelling experiments (Figure 5.6A in
Chapter 5 and [128]) revealed that the labelling eﬃciency at our conditions is better
than 95%, while analysis of the purity of conjugated CoA showed negligible amounts of
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Figure 7.2: FRET between NK1R at diﬀerent donor mole fraction. HEK293
cells expressing ACP-NK1Rs were labelled with a mixture of Cy3 and Cy5 ﬂuorophores at
diﬀerent ratios indicated by the donor mole fraction xD. The apparent FRET eﬃciency,
Eapp,se, is plotted versus xD, for two populations of cells: The grey circles represent
transiently expressing cells while the black circles stem from to stably expressing cells
showing a 2.5 times lower expression. Each point is a mean (± S.D.) of 10 cells. Fitting
the data with Eq. 7.7 plus an oﬀset (solid curves) yields for the higher expressing cells
oﬀset = 0.022± 0.030, E = 0.26± 0.09, n = 3.75± 1.27, and for the lower expressing cells
with E ﬁxed to 0.26 oﬀset = 0.018±0.047, n = 1.09±0.28 (± 95% conﬁdence interval). The
dotted curve represents Eapp,se calculated using Eq. 7.14, with A1 = 0.6327, k1 = 1.3686,
A2 = 0.3673, k2 = 0.4654, α = 81, σR = 256R/µm2 and xD as an independent variable.
non-conjugated CoA. HEK293 cells do not express endogenously NK1Rs but it cannot
be excluded that other GPCRs present might form hetero-oligomers with NK1R. The
eﬀect of unlabelled receptors can be estimated using the oligomerization model from
Adair and Engelman [162] adapted for sensitized acceptor emission (Eq. 7.9). Data
were ﬁtted using Eq. 7.9 for increasing mole fractions of unlabelled receptor (x′U). Even
assuming x′U of up to 35% did not noticeably change the resulting FRET eﬃciency E
and the number of units n, which remained within the 95% conﬁdence intervals of the
values obtained from the ﬁt at x′U = 0. Furthermore, n increased with x′U excluding
that the presence of unlabelled receptors might explain why n is higher than two. It
is worth noting that the possible co-existence of monomers (Eq. 7.12) is also unable to
account for n higher than two, as it would only change the apparent eﬃciency, which
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is proportional to the mole fraction of oligomers, and not to the number of units in an
oligomer.
Based on these results, we conclude that the NK1R does not form homo-dimers
and probably also no higher oligomers unless assuming a dramatic dependency of the
oligomer stability on the concentration of receptors. Moreover, such an oligomer would
be expected to consist of four NK1Rs, which is mechanistically diﬃcult to conceive.
7.5.3 Inﬂuence of the Agonist Substance P
Some GPCRs show an agonist-dependent dimerization [166]. In order to know whether
this is also the case for the NK1R, we investigated the stable cell line with lower ACP-
NK1R expression levels (450±48 fmol/mg of protein) closer to physiological conditions.
Addition of 100 nM SP did not result in a signiﬁcant increase of the apparent FRET
eﬃciency, indicating that the receptors do not oligomerize upon agonist binding (Fig-
ure 7.3).
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Figure 7.3: Modulation of FRET by SP. FRET eﬃciency of cells stably expressing
ACP-NK1Rs, labelled with a donor mole fraction of xD = 0.6, before and after addition
of 100 nM SP (mean of 7 cells ± S.E.). Data show that the NK1R does not form homo-
oligomers upon binding of the agonist.
7.5.4 Dependence of FRET on the Receptor Density at the
Cell Surface
In a next step, we addressed the question, whether FRET at high expression levels
might be due to high concentrations of donor and acceptor so that frequent stochastic
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encounters due to small average distances between ﬂuorophores (receptors) might allow
FRET. Therefore, we transiently expressed ACP-NK1R in HEK293 and labelled the
receptors with donor and acceptor at a constant donor mole fraction of 0.67, which is
in the range where we measured a high apparent FRET eﬃciency on cells with high
receptor density.
Transiently transfected cells usually provide a wide distribution of receptor expres-
sion levels, which in turn allows to measure FRET at diﬀerent receptor surface densities.
Using high detector gains we selected cells with low receptor expression levels. We chose
cells with good donor and acceptor signal but no saturation. By gradually decreasing
the detector gain we measured the apparent eﬃciency on cells with increasing expres-
sion levels. The expression levels were calibrated as described before. In addition we
used lipid vesicles with a deﬁned surface concentration of Cy5 to quantify the receptor
concentration on the cell surface.
Figure 7.4 shows Eapp,se both as a function of receptor surface density (σR) and
as a function of the concentration of acceptors per R20, cA = xAσRR20 (denoted also
as reduced acceptor concentration). Eapp,se strongly depends on the receptor surface
density and reaches saturation at Eapp,se,max = 0.626 ± 0.042 (Figure 7.4, ﬁne dotted
line). The maximum of the apparent eﬃciency is expected to be reached when the
NK1Rs are closely packed (each receptor surrounded by six neighbors, n = 7). Under
this condition the true eﬃciency can be estimated with Eq. 7.7 to be E = 0.34, which
corresponds to a distance of closest approach Rc = 55.9Å, assuming a Förster distance
for Cy3 and Cy5 of R0 = 50Å [164], slightly larger than the estimated diameter of a
GPCR of 40-50Å [8,160].
Knowing the reduced acceptor concentration cA, the apparent FRET eﬃciency re-
sulting from stochastic encounters between donors and acceptors can be estimated using
Eq. 7.14 (for details see legend of Figure 7.4 and Section 7.4.3). Wolber’s formula is an
analytical expression containing coeﬃcients which only depend on the ratio of Rc/R0,
i.e. 1.1 as obtained from the eﬃciency at densest packing. As depicted by the bold
dotted curve in Figure 7.4 stochastic encounters at low surface density of NK1R cannot
account for the experimentally observed high apparent FRET eﬃciencies.
A possible explanation for this discrepancy would be that the eﬀective density of
NK1Rs at the cell surface is higher than the one estimated from the calibration. This
would be the case if the NK1R would reside in microdomains. If for example the NK1Rs
homogenously distributed over the entire cell surface at a cell surface concentration of
400R/µm2 should reach a state of closest packing of 40’000R/µm2 at constant receptor
number per cell, then the NK1Rs have to be concentrated in only about 1% of the cell
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Figure 7.4: FRET dependence on cell surface receptor density. HEK293 cells
transiently expressing the ACP-NK1R were labelled at a donor mole fraction of xD = 0.67.
The apparent FRET eﬃciency, Eapp,se (grey circles), was measured and plotted as a
function of the reduced acceptor concentration, cA (bottom), and the receptor surface
density, σR (top). Each data point represents an image containing 1-3 cells. The bold
dotted curve at the bottom represents Eapp,se calculated with Eq. 7.14 assuming the
absence of microdomains (α = 1; coeﬃcients A1,2 and k1,2 from Wolber and Hudson [165]
for a Rc/R0-ratio of 1.1; A1 = 0.6327, k1 = 1.3686, A2 = 0.3673, k2 = 0.4654). The ﬁne
horizontal dotted line represents the maximal apparent eﬃciency measured by sensitized
acceptor emission: Eapp,se,max = 0.626 ± 0.042 (mean of the last 17 points ± S.D.). The
two vertical lines represent the receptor surface densities for the data in Figure 7.2. The
solid curve represents a ﬁt over the ﬁrst 47 points using Eq. 7.14 with α as the only free
parameter: α = 81.1± 0.3 (± 95% conﬁdence interval). The dotted curves represent the
calculated Eapp,se from Eq. 7.14 with α factors of 81.1± 50%.
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membrane. A more precise estimate can be gained by ﬁtting the initial part of the
data in Figure 7.4 using Eq. 7.14 and allowing only one free parameter, the "scaling"
factor α to account for the increased eﬀective concentration. The analytical expression
in Eq. 7.14 is known to be valid only for a limited range of cA = 0− 0.5 of the reduced
acceptor concentration [165]. The corresponding ﬁt (bold curve in Figure 7.4) yields
a scaling factor α = 81.1 ± 0.3. Taking into account the scatter of the data, the vari-
ation between cells of the scaling factor can be estimated to be around 50% (dashed
curves in Figure 7.4) implying that the receptors are concentrated in microdomains rep-
resenting only 0.8-2.5% of the total surface area of the plasma membrane. Interestingly,
a deviation from the ﬁtting curve can be observed at low apparent FRET eﬃciency,
which might indicate fusion of microdomains. However, it cannot be excluded that this
deviation is an artifact of the analysis procedure.
To verify that the model of Wolber can also explain the dependency of Eapp,se on
xD (Figure 7.2, black circles) for cells with the same total expression levels, σR, of
256R/µm2, we plotted Eapp,se, calculated with Eq. 7.14 using the parameters obtained
previously, as a function of xD (Figure 7.2, dotted curve). The dotted curve can repro-
duce the data in a reasonable way besides a deviation at low xD due to the fact that
Wolber’s approximation is not anymore valid at these high acceptor densities.
7.5.5 Inﬂuence of Cholesterol Depletion
Monastyrskaya et al. [73] recently showed that the NK1R is present in detergent-
resistant membrane fractions and that this localization is disrupted by cholesterol ex-
traction with methyl-β-cyclodextrin (MBCD). They further demonstrated that also sig-
naling by the NK1R is abolished upon cholesterol depletion. In order to test whether
the microdomains observed by FRET correspond to the detergent-resistant membrane
fractions, the dependency of the apparent FRET eﬃciencies on cholesterol extraction
was investigated on transiently expressed ACP-NK1R showing high NK1R densities
(Figure 7.5). After incubation with 2% MBCD at RT for 45 minutes (same condi-
tions as [73]), the apparent eﬃciency decreased signiﬁcantly (p ≤ 0.005) by 29% from
0.34± 0.048 to 0.24± 0.076 (mean of 9 cells ± S.E.), supporting a model where NK1Rs
are localized in microdomains.
7.6 Discussion
Here we have shown the power of the ACP labelling for quantitative FRET measure-
ments in living cells. Although the ACP labelling is limited to membrane proteins
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Figure 7.5: Modulation of apparent FRET eﬃciency by cholesterol extraction.
Apparent FRET eﬃciency of transiently expressed ACP-NK1Rs before (0.34±0.048) and
after (0.24 ± 0.076) cholesterol extraction (mean of 9 cells ± S.E.). Cholesterol was ex-
tracted by incubation with 2% methyl-β-cyclodextrin for 45 minutes at room temperature.
ACP-NK1R was labelled with a donor mole fraction of xD = 0.6.
comprising extracellular fusion of ACP, it has the advantage that only the proteins in-
corporated into the plasma membrane are labelled, thereby avoiding background signal
from incompletely processed receptors. Furthermore, the ACP labelling allows to choose
suitable ﬂuorophores for FRET and the control of DA ratios, which is a requirement for
precise FRET measurements on membrane proteins where the state of oligomerization
is not known.
Physiological NK1R expression levels reported in literature are 550 fmol/mg of mem-
brane protein in rat submaxillary gland membranes [147], 107 fmol/mg of membrane
protein in guinea pig lung membranes [167], and 254 fmol/mg of membrane protein
in rat brain membranes [168]. In our case, we measured a cell surface concentration
of stably expressed ACP-NK1R of 450 fmol/mg of protein. The physiological expres-
sion levels from literature were normalized to total membrane protein content. This
means that the ACP-NK1R stably expressed in HEK293 shows about 5-10 times higher
expression levels than under physiological conditions. Nevertheless, using the stably
expressed ACP-NK1R no FRET could be detected, meaning that the NK1R does not
form homo-oligomers at physiological expression levels.
At the present state, we cannot exclude that the N-terminus of the NK1R is in-
volved in oligomerization [55] and that the ACP when fused to the N-terminus abol-
ishes oligomerization. But, because the ACP-NK1R is functional with respect to cellular
calcium signaling this would mean that homo-oligomerization is not required for func-
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tionality of the NK1R.
Investigating SSTR5 homo-oligomerization in CHO cells expressing the receptor at
800 fmol/mg of protein showed signiﬁcant FRET. Five times lower expression levels
showed insigniﬁcant FRET, which however increased with increasing agonist concentra-
tion [166]. We also investigated the eﬀect of SP on FRET eﬃciencies for low expression
levels and did not measure a signiﬁcant change of FRET, excluding agonist-dependent
oligomerization. From these results we conclude that the NK1R does not form consti-
tutive homo-oligomers and does not oligomerize in an agonist-dependent manner.
BRET and FRET signals were reported to be stable for receptor expression levels
ranging from 1.4 to 26.3 pmol/mg of protein for β2-AR receptors [160], from 40 to
100 fmol/mg of membrane protein for CCR5 receptors [169], from 200 to 1000 fmol/mg
of membrane protein for opioid receptors [170], and from 580 to 6570 fmol/mg of protein
for β2/β3-AR hetero-oligomers [171]. On the other hand we observed a clear dependency
of the apparent eﬃciency on the donor mole fraction by increasing the expression level
from about 450 fmol/mg of protein by a factor of 2.5.
Because many GPCRs are reported to form homo- or hetero-dimers [54,55], and the
NK1R is known to form a hetero-dimers with the µ-opioid (MOR) receptor in HEK293
cells [82], it is surprising that the NK1R does not form homo-dimers, and that the FRET
measured was in fact strongly concentration dependent.
From the measured receptor density we could exclude FRET originating from high
incidence of random collisions. Nevertheless, we measured a strong dependency on
receptor density. Because we showed that the NK1R does not form homo-oligomers,
we suggest, that the FRET signal is arising from NK1R concentrated in sub-pixel-
sized microdomains. Furthermore, cholesterol extraction signiﬁcantly reduced FRET
eﬃciencies. This is consistent with the observations of Monastyrskaya et al. [73], who
reported the presence of NK1R in lipid rafts. Also Holst et al. [72] suggested the
existence of NK1R in plasma membrane microdomains based on binding experiments
with fusion proteins of NK1R with Gαq and Gαs.
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Chapter 8
FRET between NK1R and Gαβγ
Subunits
8.1 Introduction
A classical model of GPCR signaling states that agonist-activated receptors change their
conformation and thereby recruit heterotrimeric G proteins. Upon binding of the Gαβγ
complex to the activated receptor, a conformational change leads to the exchange of
GDP for GTP in the Gα-subunit, following a disassembly in Gα and Gβγ [1]. Recently,
this classical model of GPCR signaling has been challenged [30,47,172,173]. It has been
proposed that GPCRs and G proteins exist as persistent multimolecular complexes,
where activated G protein subunits do not disassemble from each other. Still little is
known about the dynamics of the interaction between receptor and G protein in living
cells and whether activated Gαβγ-complexes do indeed dissociate.
In vitro approaches using reconstituted model systems, such as surface plasmon
resonance [174, 175] or ﬂow cytometry [176] have been developed to measure real-time
interactions between GPCRs and their G proteins. These experiments were done in
solubilized systems or reconstituted in lipid bilayers and thus do not represent the
natural environment. Until very recently there was no report about real-time monitoring
of receptor-G protein interactions in living cells [117]. The authors describe a BRET-
based assay were they observe a basal BRET signal between receptor and Gαβγ without
activation of the receptor. Although they contribute this to constitutive active receptors,
the BRET signal increases upon activation and remains constant for several minutes,
indicating that activated G proteins do not dissociate from the receptor.
Also the question of the dissociation of Gβγ from activated Gα has recently been
addressed in living cells. FRET-based studies in Dictostelium discoideum and yeast con-
cluded that GPCR activation leads to the disassembly of the Gαβγ-complex [118,177].
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This ﬁnding in turn has been challenged by another FRET-based study on mammalian
G protein subunits, which led to the conclusion that a rearrangement rather than dis-
sociation occurred in response to receptor activation [31].
This Chapter deals with the experiments to investigate real-time receptor-G pro-
tein interactions in living cells using a FRET-based approach. The goal was to detect
changes in FRET between NK1R and the Gαqβγ-complex or between the G protein
subunits themselves upon activation of the receptor by its agonist. It is also known that
G proteins can be activated when the guanine nucleotide binding site of Gα is occupied
by AlF−4 which together with GDP mimics the activating eﬀect of GTP [178–180]. Be-
cause AlF−4 is membrane permeable it can be used to directly activate the Gα in living
cells.
For FRET experiments in living cells a commonly used DA pair is ECFP and EYFP.
Unfortunately, high concentrations of ﬂuoride anions in a preparations of AlF−4 leads to
artefacts in FRET, because EYFP is sensitive to halides [181, 182]. Therefore, a point
mutation was introduced into EYFP to reduce its halide sensitivity [183] and make it
suitable for our experiments. This ﬂuorescent protein, named citrine (Cit), and other
derivatives were then fused to the diﬀerent G protein subunits, and their functionality
was investigated. FRET experiments with diﬀerent combinations of labelled receptor
and G protein subunits were performed using three diﬀerent experimental conditions.
FRET could be measured but no changes upon addition of agonist or AlF−4 was observed.
8.2 Experimental Procedures
8.2.1 Materials
pSFV1::Gq was a gift from Kenneth Lundstrom (BioXtal, CH); pECFP-mem::Gαi2 was
a gift from Andrew Tinker (University College London, UK); vectors containing EGFP,
ECFP and EYFP were from Clontech (Palo Alto, CA, USA); pEYFP::Gβ1 (human)
and pEYFP::Gγ2 (bovine) were a gift from Susanna Cotecchia (UNIL, CH); ECFP-
EYFP fusion construct was a gift from Régis Grailhe (Institute Pasteur, Paris, F);
QuickChange site directed mutagenesis kit was from Stratagene (La Jolla, CA, USA);
NaF and AlCl3 were from Fluka (Buchs, CH).
Cell culturing, cell transfection and preparation, calcium ion signaling, and ﬂuores-
cence confocal microscopy were performed as described in Chapter 3.
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8.2.2 cDNAs
Polymerase chain reaction (PCR), DNA agarose gel preparation (analytic and prepara-
tive), restriction digest, ligation, DNA puriﬁcation, plasmid ampliﬁcation in E.coli XL1
blue strain, bacterial medium (2TY), were done according to standard protocols de-
scribed in Molecular cloning, a laboratory manual [134]. The plasmid constructs were
conﬁrmed by restriction mapping and DNA sequencing. Following is a detailed de-
scription of the cloning steps. The primers used for cloning are found in Table 8.1.
Primer Sequence
fw-Cit-mut 5’-C GTG ACC ACC TTC GGC TAC GGA TTA ATG TGC TTC GCC CGC
TAC CC-3’
rv-Cit-mut 5’-GG GTA GCG GGC GAA GCA CAT TAA TCC GTA GCC GAA GGT GGT
CAC G-3’
fw-Gq-mut 5’-CG CTC AAG ATC CCA TAC AAG TAT GGC GCC ATC CAT GGA GAA
CAC AAT AAG GCT CAT GC-3’
rv-Gq-mut 5’-GC ATG AGC CTT ATT GTG TTC TCC ATG GAT GGC GCC ATA CTT
GTA TGG GAT CTT GAG CG-3’
fw-XFP-mut 5’-C GGG GTG GTG CCC ATA CTA GTC GAG CTG GAC GGC-3’
rv-XFP-mut 5’-GCC GTC CAG CTC GAC TAG TAT GGG CAC CAC CCC G-3’
fw-NheI-Gq 5’-G GCC GGG CTA GCC ACC ATG ACT CTG GAG TCC ATC ATG GC-3’
fw-SpeI-Gq 5’-GCG CGG ACT AGT ATG ACT CTG GAG TCC ATC ATG GCG-3’
fw-BsrGI-Gq 5’-GG CCG GTG TAC AAG ATG ACT CTG GAG TCC ATC ATG GC-3’
fw-KasI-EGFP 5’-G CGG GGC GCC GGT ATG GTG AGC AAG GGC GAG G-3’
fw-SpeI-frCit 5’-G CCC ATA CTA GTC GAG CTG GAC GG-3’
rv-BamHI-Gq 5’-CCG CGC GGA TCC TTA GAC CAG ATT GTA CTC CTT CAG GTT CAG C-3’
rv-NotI-Gq 5’-A TAG TTT AGC GGC CGC TTA GAC CAG ATT GTA CTC CTT CAG
GTT CAG-3’
rv-NcoI-EGFP(dS) 5’-CG CGG CCC ATG GCC CTT GTA CAG CTC GTC CAT GCC-3’
rv-BsrGI-frCit 5’-GC GCT GTA CAG CTC GTC CAT GC-3’
Table 8.1: Primers. Primers used for the Gαq-constructs and citrine. Restriction sites
are underlined.
Citrine (Cit)
Citrine is a ﬂuorescent protein derived from EYFP by exchanging glutamine at position
69 for a methionine (Q69M) [183]. To achieve the mutation Q69M two point mutations
were introduced into the EYFP gene by site directed mutagenesis using the primers
fw-Cit-mut and rv-Cit-mut. In the same step, an additional AseI restriction site was
introduced by three further point mutations, where the nucleotide sequence was changed
but the amino acid sequence remained the same (silent mutation, Figure 8.1). This
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restriction site was used to select positive plasmids by restriction mapping. The Clontech
vector pEYFP-C1 was mutagenized yielding pCit-C1.
TAC GGC CTG CAG TGC TTC
ATG CCG GAC GTC ACG AAG
Tyr Gly Leu Gln Cys Phe aa
DNA
Q69M
+ AseI
TAC GGA TTA ATG TGC TTC
ATG CCT AAT TAC ACG AAG
Tyr Gly Leu Met Cys Phe aa
DNA
EYFP (66-71)
Cit (66-71)
Figure 8.1: Site directed mutagenesis. Introduction of Q69M mutation and an addi-
tional AseI restriction site (silent mutation). Bold letters indicate the mutated nucleotides.
wtGq
The gene encoding for mouse Gαq was ampliﬁed by PCR on the template pSFV1::Gq
using the forward primer fw-NheI-Gq and the reverse primer rv-BamHI-Gq introducing
a NheI restriction site and a Kozak sequence [135] at the 5’ end, and a BamHI restriction
site at the 3’ end of the Gαq gene. The NheI /BamHI cut and puriﬁed fragment was
ligated into the NheI /BamHI cut pCEP4 expression vector yielding pCEP4::wtGq.
Gq(EGFP)-BM
The gene encoding for mouse Gαq was ampliﬁed by PCR on the template pSFV1::Gq
using the forward primer fw-SpeI-Gq and the reverse primer rv-BamHI-Gq introducing
a SpeI restriction site at the 5’ end, and a BamHI restriction site at the 3’ end of the
mouse Gαq gene. The SpeI /BamHI cut and puriﬁed fragment was ligated into the
SpeI /BamHI cut pBluescript II KS+ expression vector yielding pBS::Gq.
Two new restriction sites, KasI and NcoI, were introduced into pBS::Gq between the
residues Tyr103 and Glu104 of the wild type mouse Gαq by site directed mutagenesis
resulting in pBS::Gq(mut). The primers were fw-Gq-mut and rv-Gq-mut.
The gene encoding for EGFP was ampliﬁed by PCR using the forward primer fw-
KasI-EGFP and the reverse primer rv-NcoI-EGFP(dS) introducing a KasI restriction
site at the 5’ end, and a NcoI restriction site at the 3’ end of the EGFP. The STOP
codon has been removed. The KasI /NcoI cut and puriﬁed fragment was ligated into
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the KasI /NcoI cut pBS::Gq(mut) plasmid yielding pBS::Gq(EGFP) with a Gly-Ala-Gly
spacer in front of and a Gly-His-Gly spacer after EGFP.
In a last step, the gene encoding for Gq(EGFP) was ampliﬁed by PCR on the tem-
plate pBS::Gq(EGFP) using the forward primer fw-NheI-Gq and the reverse primer
rv-BamHI-Gq introducing a NheI restriction site and a Kozak sequence [135] at the
5’ end, and a BamHI restriction site at the 3’ end. The NheI /BamHI cut and puri-
ﬁed fragment was ligated into the NheI /BamHI cut pCEP4 expression vector yielding
pCEP4::Gq(EGFP)-BM.
Cit-Gq and ECFP-Gq
The plasmid pECFP-mem::Gαi2 is based on the vector pECFP-mem (Clontech) con-
taining the dual palmitoylation signal from GAP43, fused in-frame with ECFP. This in
turn is fused at the C-teminus with the Gαi2 subunit with a NotI site after the STOP
codon at the C-terminal end [184]. Fluorescent proteins derived from EGFP contain a
native BsrGI site at their C-terminal end.
In a ﬁrst step a SpeI site was introduced towards the N-terminus of ECFP (residues
15-17) by site directed mutagenesis using the primers fw-XFP-mut and rv-XFP-mut.
The amino acid sequence of the resulting plasmid, pECFP(SpeI)-Gi2, was not altered
by the insertion of the SpeI site (silent mutation).
In a second step the the gene encoding for Cit was ampliﬁed by PCR using the
forward primer fw-SpeI-frCit and the reverse primer rv-BsrGI-frCit introducing SpeI
and BsrGI restriction sites at the same position as the SpeI and BsrGI restriction
sites in the ECFP of the pECFP(SpeI)-Gi2 plasmid. The SpeI /BsrGI cut and puriﬁed
fragment was ligated into the SpeI /BsrGI cut pECFP(SpeI)-Gi2 plasmid yielding pCit-
Gi2.
In a third step, Gαi2 was replaced by mouse Gαq. Therefore, the gene encoding
for Gαq was was ampliﬁed by PCR on the template pSFV1::Gq using the forward
primer fw-BsrGI-Gq and the reverse primer rv-NotI-Gq introducing a BsrGI and the
last 2 nucleotides of Cit (TGTACAAG) without STOP codon at the 5’ end, and a NotI
restriction site at the 3’ end. The BsrGI /NotI cut and puriﬁed fragment was ligated
into the BsrGI /NotI cut pCit-Gi2 plasmid yielding pCit-Gq. To construct pCFP-
Gq, the BsrGI /NotI cut and puriﬁed fragment was ligated into the BsrGI /NotI cut
pECFP-mem::Gαi2 plasmid.
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wtGβ, wtGγ, Cit-Gβ and Cit-Gγ
The BspEI /BamHI fragments from pEYFP::Gβ1 and pEYFP::Gγ2 were cloned into
BspEI /BamHI cut pCit-C1 plasmid yielding Cit-Gβ and Cit-Gγ. The AgeI /BspE1
fragments from pEYFP::Gβ1 and pEYFP::Gγ2, containing the Cit-gene fragment, were
removed by restriction digest with the corresponding restriction enzymes and the vector
was religated (compatible sticky ends) to yield wtGβ and wtGγ, respectively.
8.2.3 Absorption and Emission of Fluorescent Proteins
HEK293 cells expressing cytosolic ECFP, EYFP or Cit were homogenized with a Ultra-
Turrax T25 homogenizer (Janke & Kunkel, Staufen, D) to release the cytosolic pro-
teins. Remaining cells end cell fragments were pelleted by centrifugation for 5min at
14’000 rpm in a 5415D centrifuge (Eppendorf, Hamburg, D). The supernatant with sol-
uble ECFP, EYFP or Cit was stored at -80◦C. Optical density at 434 nm for ECFP, and
515 nm for EYFP and Cit was measured on a spectrophotometer DU 640 (Beckman,
Fullerton, CA, USA). Emission was measured on a SPEX Fluorolog II (Instruments S.A.,
Stanmore, UK) with 434 nm excitation and 480 nm emission for ECFP and 510 nm ex-
citation and 530 nm emission for EYFP and Cit. Excitation and emission band pass
was 1.8 nm. All measurements were done at room temperature.
AlF−4 solution is freshly prepared by mixing 800µl 0.5mM NaF, 2.4µl 0.5mM AlCl3
and 197.6µl H2O.
8.2.4 Calcium Response on LSM
Gαq/11 deﬁcient ﬁbroblast cells were grown in DMEM supplemented with 10% FCS on
glass coverslips in 6-well plates. Fibroblasts (60-80% conﬂuent) were transfected using
EﬀecteneTM lipofection (Qiagen, Hilden, D). Transfection solution for one well (2ml
medium) contained a total amount of 0.8µg plasmid DNA in H2O (1µg/ml) mixed
with 6.4µl Enhancer in 50µl EC buﬀer; it was incubated for 3 minutes at RT. 8µl
Eﬀectene was added, and after 10 minutes incubation at RT, the solution was added to
the cells in FCS free DMEM. 24-55 hours after transfection, the cells were loaded with
a calcium-sensitive dye (Calcium 3 assay kit, Molecular Devices) in 400µl during 30
minutes at 37◦C. The loading solution was replaced by D-PBS with 0.1% BSA, placed
on the Zeiss LSM 510 microscope, and time series were recorded with addition of 100 nM
SP.
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8.2.5 FRET Spectrometry and Microscopy
For FRET spectroscopy with cell suspensions, HEK293 cells or the stable NK1R-ECFP
cell line were transfected according the protocol described in Chapter 3. For FRET
between receptor and G protein or between G protein subunits the DNA mixture con-
tained always all three subunits of the heterotrimeric G protein: 10 parts of Gq(Cit)
or wtGq, 1 part of wtGβ or wtGγ, and 0.2 part of Cit-Gβ or Cit-Gγ. 48 hours after
transfection, cells were washed in PBS and detached from the plates using PBS contain-
ing 0.5mM EDTA. The cells from one 10-cm culture dish were resuspended in isotonic
buﬀer (137.5mM NaCl, 1.25mM MgCl2, 1.25mM CaCl2, 6mM KCl, 5.6mM glucose,
10mM HEPES, 0.4mM NaH2PO4, pH 7.4) to a concentration of about 106 cells/ml.
Fluorescence spectra of cell suspensions were recorded on a SPEX Fluorolog II (In-
struments S.A., Stanmore, UK). Samples were placed in a 10 × 4mm2 quartz cuvette
(Hellma, D) and continuously stirred by a magnetic stirrer. For FRET spectroscopy on
single cells and FRET microscopy HEK293 cells were grown on 0.17mm thick, 25mm
diameter glass coverslips (Assistent, D) deposited in 6-well plates (TPP, CH) and trans-
fected in the same way as described above. Further details and FRET calculations are
described in Section 4.4.
The DA molar ratio (rDA) was estimated from corresponding spectra according to
rDA =
εA
εD
φA
φD
ddonorSD,donor
aacceptorSA,donor
. (8.1)
The molar extinction coeﬃcients at donor excitation wavelength for the acceptor is
εA and for the donor it is εD. φA and φD are the quantum yields of acceptor and
donor,. ddonor, aacceptor, SD,donor and SA,donor are the ﬁtting coeﬃcients and their cor-
responding spectra as described in Chapter 4.4. Note that ddonorSD,donor = FDA and
aacceptorSA,donor = FA. FDA is used instead of FD, because the real donor intensity (FD)
can not be determined correctly due to quenching by FRET. Therefore, rDA is only a
rough estimate of the real DA ratio.
8.3 Results and Discussion
8.3.1 Halide Sensitivity of EYFP and Citrine
In this work, the mutation Q69M has been introduced into EYFP by site directed
mutagenesis to yield Citrine (Cit), which is supposed to be less sensitive to ﬂuoride [183]
(Figure 8.2A). Introducing this point mutation was necessary, because a AlF−4 -solution,
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EYFP 21.1 ± 0.1 23.0 ± 0.1
Cit 271 ± 15 201 ± 21
Figure 8.2: Citrine versus EYFP. A, detailed view of residue 69 and surrounding
residues from EYFP and Citrine (Cit) (taken from [183]). The mutation from Gln69 to
Met69 reduces the cavity where the halide can bind (here a iodide), and thereby blocks the
binding. B, normalized absorption versus ﬂuoride concentration of ECFP (full circles), Cit
(empty circles) and EYFP (crossed circles). C and D, normalized ﬂuorescence intensity
(C) and Stern-Volmer plot (D) of EYFP and Cit against ﬂuoride and AlF−4 -solution.
EYFP vs. ﬂuoride (full circles), EYFP vs. AlF−4 (empty circles), Cit vs. ﬂuoride (full
triangles), and Cit vs. AlF−4 (empty triangles). The Table represents K
−1
s values from
the Stern-Volmer plot ﬁtted with Eq. 8.2 (± 95% conﬁdence interval).
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which is used for direct activation of the Gαq contains free ﬂuoride anions, which quench
the EYFP ﬂuorescence. Quenching of EYFP further leads to artifacts in the FRET
signal and make it impossible to distinguish if changes in FRET are due to quenching
or real distance changes.
To compare the eﬀect of ﬂuoride and a AlF−4 -solution on the absorbance and ﬂuores-
cence emission of ECFP, EYFP and Cit, the soluble FPs were extracted from HEK293
cells transfected with the respective plasmid. The ﬂuorescence emission of EYFP was
strongly dependent on the amount of ﬂuoride (NaF) or an AlF−4 -solution (Figure 8.1C).
The ﬂuorescence emission of Cit decreased only very little as compared to EYFP. This
small decrease might be due to photobleaching. The ﬂuorescence emission of ECFP was
not quenched by ﬂuoride (data not shown).
Whether the observed quenching of EYFP is due to dynamic (collisional) or static
quenching, can be distinguished by examination of the absorption. Dynamic quenching
aﬀects the excited state of the ﬂuorophore and therefore no change in absorption is
expected. In contrast, complex formation in static quenching usually results in the
perturbation of the absorption spectrum of the ﬂuorophore.
The strong decrease in absorption found for EYFP (Figure 8.1B), indicates static
quenching, and the Stern-Volmer equation therefore is
F0/F = 1 + Ks[Q], (8.2)
where F and F0 are the ﬂuorescence intensities of the ﬂuorophore in absence and pres-
ence of the quencher, respectively, Ks is the association constant of the quencher and
[Q] is the concentration of quencher [86]. K−1s is the quencher concentration at which
F0/F = 2, or 50% of the intensity is quenched. Figure 8.1D represents the Stern-Volmer
plot from ﬂuorescence intensity measurements and the corresponding K−1s values are
found in the Table in Figure 8.1.
A K−1s value of about 20mM was measured for EYFP, which is in agreement with
the 6mM reported by Jayaraman et al. [182]. The point mutation Q69M (Cit) led
to a 10-fold decrease in ﬂuoride sensitivity. This makes Cit more suitable for FRET
measurements when working with AlF−4 for G protein activation, although on the cost
of a lower Förster distance R0, which was calculated from the absorption and emission
spectra and the spectral characteristics of ECFP, EYFP and Cit given in Table 8.2.
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Absorption Emission Quantum Molar R0
Maximum Maximum yield Extinction with ECFP
ECFP 434 476 0.42 23’900 -
EYFP 514 527 0.61 83’400 49.2
Citrine 516 529 0.76 77’000 40.5
Table 8.2: Spectral characteristics of ECFP, EYFP and Cit. Absorption and
emission maximum are in nm. Quantum Yield and molar extinction (M−1cm−1) for
ECFP and EYFP were from [123], and for Cit from [183]. The Förster distance R0
(Å) with ECFP as donor was calculated from absorption and emission spectra according
Eq. 4.8 and 4.9.
8.3.2 Fluorescent Labelling of NK1R and G Protein Subunits
After having produced the ﬂuoride-insensitive Cit, we constructed the diﬀerent fusion
proteins in order to measure FRET between receptor and G protein in vivo. Therefore,
ECFP has been fused to the cytosolic C-terminus of NK1R. This brought the ECFP
in closer proximity to the G protein than would have a fusion to the extracellular N-
terminus. Construction and characterization of NK1R-ECFP has been described in
Chapter 5. The labelling of Gαq turned out to be more diﬃcult. Fusion of a ﬂuorescent
protein (FP) to either N-terminus or C-terminus did not yield a functional construct
(Susanna Cotecchia, personal communication). Therefore, another approach for the FP
fusion had to be found.
Gα-subunits consist of two domains: the GTPase domain containing the GDP/GTP
binding site and the helical domain. Little is known about the function of the helical
domain of Gα-subunits. It is unique to the heterotrimeric G proteins, whereas the
GTPase domain is present in all members of the GTPase superfamily. Among the
postulated functions of the helical domain are (1) increasing aﬃnity of GTP binding,
(2) acting as a tethered intrinsic GTPase activating protein, (3) participating in eﬀector
recognition [13, 185]. Comparison of diﬀerent mammalian Gα-subunits with the Gα
from Saccharomyces cerevisiae (Gpa1p) reveals a striking diﬀerence within the helical
domain (Figure 8.3). Gpa1p has large insertions of 110 amino acids in total, the largest
part (∼90aa) being between the helices αA and αB.
As Gpa1p from Saccharomyces cerevisiae with an insert of 110 amino acids is func-
tional, there was reason to believe that the FP can be inserted here in the helical domain
of Gαq without altering its functionality. In addition, the helical domain seems not to
interfere directly with the conserved nucleotide binding motifs in the GTPase domain
(G-1 to G-5), the receptor coupling sites at the C- and N-terminus, the palmitoylation
sites at the N-terminus, and the PLC interaction sites (Figure 8.4), further supporting
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Figure 8.3: Alignment of Gα-subunits. mG12, mouse Gα12 (P27600); mG15, mouse
Gα15 (P30678); rGi1, rat Gαi1 (P10824); hGo1, human Gαo1 (P09471); mGq, mouse Gαq
(NP032165); hGs, human Gαs (P04895); hGt, human Gαt (P11488); hGz, human Gαz
(P19086); Gpa1p, Gα from Saccharomyces cerevisiae (AAB68432). In brackets are the
corresponding database accession numbers of the protein sequences. The secondary struc-
ture (from αA to αF) corresponding to Gαt and Gαi1 [185] is shown below the aligned
sequences. The alignment was done with clustalW (http://www.ebi.ac.uk/clustalw/) us-
ing default settings.
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the idea of FP insertion between αA and αB. Therefore, the site between Tyr103 and
Glu104 in front of the αB helix (i3 in Figure 8.4) was chosen for insertion. The detailed
cloning steps of Gq(EGFP)-BM are described in Section 8.2.
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Figure 8.4: Crystal Structure of a Gαβγ and scheme of diﬀerent domains in
mouse Gαq. A, crystal structure of Gαi2 complexed with Gβ1γ2 (PDB:1GG2) [15]. Ct
and Nt indicate C-terminus and N-terminus, respectively. B, Cys9/10, palmitoylation
sites [186]; α2 to α5 and αA to αG represent α-helices; β1 to β6 represent β-strands
(from alignments with protein sequences with known structures); G-1 to G-5, conserved
nucleotide binding motifs [13]; R, receptor coupling sites [20,187]; PLC, domains required
for PLC activation [188]. i1, site of FP insertion in Gαs before helical domain [189]; i2,
site of FP insertion in Gα2 from D. discodeum (Lys97 in Gαq) [118]; i3, site of FP inser-
tion (Tyr103,Glu104) yielding Gq(EGFP)-BM; i4, site of FP insertion (Phe124,Glu125)
yielding Gq(ECFP) or Gq(Cit) (same as [190]).
Although this construct later turned out to be non-functional, the strategy was
heading in the right direction. In the meantime, Hughes et al. [190] inserted EGFP
between mouse Gαq residues Phe124 and Glu125, located towards the end of the loop
between helices αB and αC (i4 in Figure 8.4). Furthermore, Janetopoulos et al. [118]
inserted ECFP towards the beginning of the loop between the helices αA and αB of
Gα2 from Dictyostelium discoideum. The insertion site corresponds to residue Lys97 in
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mouse Gαq (i2 in Figure 8.4) and is close to our insertion point. Another insertion of
EGFP just before the helical domain has been reported for Gαs by Yu et al. [189] (i1
in Figure 8.4).
A diﬀerent approach for labelling Gα was taken by Leaney et al. [184]. They de-
scribed a functional ECFP fusion to the N-terminus of Gαi1-3 and Gαo, based on the
ECFP-Mem vector (Clontech), which contains the ﬁrst 20aa of GAP43 as a membrane
targeting sequence at the C-terminus of ECFP. The stop codon of ECFP has been
removed and the Gα-subunits were genetically fused to the N-terminus of ECFP.
For further experiments a ECFP (Gq(ECFP)) and EYFP (Gq(EYFP)) fusion with
mouse Gαq was constructed in Susanna Cotecchia’s lab after the protocol from Hughes
et al. [190]. The EYFP in Gq(EYFP) has been further mutated to citrine (Gq(Cit)).
Furthermore, the Gαi2 in pECFP-mem::Gαi2 (a gift from Andrew Tinker [184]) was
exchanged for Gαq yielding ECFP-Gq and Cit-Gq. In addition, the EYFP in the ﬂu-
orescently labelled subunits EYFP-Gβ1 and EYFP-Gγ2 (gift from Susanna Cotecchia)
was either removed or exchanged for Cit to yield wild type Gβ1 and Gγ2 and the Cit-
labelled subunits, Cit-Gβ1 and Cit-Gγ2.
8.3.3 Functionality of Fluorescent Gαq and Coupling to NK1R-
ECFP
To measure any interactions between NK1R and Gαq it was necessary to know whether
the fusion proteins are well expressed and are correctly assembled. Therefore, the new
ﬂuorescent Gα-subunits were expressed in HEK293 cells and confocal micrographs were
recorded (Figure 8.5A-C). Gq(Cit) and Cit-Gq were found to partly localize in the
plasma membrane, whereas Gq(EGFP)-BM showed a cytoplasmic localization indicat-
ing that this construct, although expressed, might not be functional.
It was shown before, that activation of the NK1R-ECFP led to a calcium response
when expressed in HEK293 cells. Because of endogenous Gαq in HEK293 cells, the
calcium response resulting from interactions between NK1R-ECFP and ﬂuorescently
labelled Gαq had to be measured in a Gαq/11-deﬁcient ﬁbroblast cell line. Transfection
eﬃciencies of these ﬁbroblast where too low to measure concentration response curves
on the FLEX station, as it was done for NK1R-ECFP in HEK293 cells (see Chapter 5).
Therefore, calcium response was measured on single cells expressing both the NK1R-
ECFP and one of the three Gαq fusion proteins. For Gq(EGFP)-BM no response to
SP was observed (data not shown), which we already expected due to the cytoplasmic
localization. In contrast, the addition of 100nM SP to cells with Gq(ECFP) or Cit-Gq
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Figure 8.5: Localization of ﬂuorescently labelled Gαq and calcium response.
A-C, confocal micrographs of HEK293 cells expressing Gq(EGFP)-BM (A), Gq(Cit) (B),
Cit-Gq (C). Scale bars represent 10µm. D, time course of the ﬂuorescence intensity
of calcium sensitive probes inside Gαq/11-deﬁcient ﬁbroblast cells after SP stimulation
of NK1R-ECFP coexpressed with either Gq(Cit) (solid) or Cit-Gq (dotted), and non-
transfected cells (dashed). SP concentration used was 100nM. The ﬂuorescence signal
increased steeply, reﬂecting an increase of the intracellular calcium ion concentration.
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resulted in a typical intracellular calcium response (Figure 8.5D). The response was
not detected from non-transfected cells or cells with only NK1R. This conﬁrmed that
Gq(Cit) and Cit-Gq were functional with respect to calcium signaling and able to couple
to the ﬂuorescently labelled NK1R-ECFP.
It seems that the site of FP insertion into the helical domain of Gα is critical.
Insertion of FP between the helices αB and αC yielded a functional Gαq [190] and
insertion of FP between αA and αB also yielded a functional Gα2-subunit [118]. But
the insertion of FP only 6 residues further downstream, still between αA and αB, yielded
a non-functional Gαq-subunit.
Another interesting ﬁnding is, that the fusion of FP to the N-terminus of Gαq was
not functional. The reason therefore might be that palmitoylation of Gαq, required for
its functional expression [186], is blocked by the FP fusion. But addition of a membrane
targeting sequence with a palmitoylation site targets the fusion construct to the plasma
membrane again and restores the functionality.
Although Cit-Gq was functional, we did not use it for FRET studies, because single-
molecule experiments performed in our lab (Perez et al., in preparation) showed that
Cit-Gq is directly translocated to the plasma membrane without Gβγ. Therefore, the
protein will mostly be present as a monomer, meaning that it would not interact with
the receptor but lead to a high ﬂuorescence background signal in FRET experiments.
For the Gβ- and Gγ-subunits there was no functional assay available in the lab. But
because there are several reports of functional Gβ- and Gγ-subunits with a N-terminal
fusion of FPs [31,117,118,191,192], we could assume that our constructs are functional
as well.
8.3.4 FRET between NK1R and Gαβγ Subunits
With functional ﬂuorescent receptor and G protein subunits tools are now available to
measure FRET in whole cells. In a ﬁrst attempt, FRET was measured in cell suspensions
using a spectrometer (see Chapter 4.4). The feasibility of the method was shown with
a ECFP-EYFP fusion protein, and by co-expressin ECFP and EYFP in the same cell.
Measurements on cells suspensions yielded FRET eﬃciencies of 45.6% ± 0.4 for the
ECFP-EYFP fusion protein and of 4.8%± 1.2 for co-expressed ECFP/EYFP (mean of
3 samples ± S.D.). The almost 5% eﬃciency for the co-expression of ECFP and EYFP
is attributed to possible aggregation or high protein expression levels and not an artefact
from the method, because a mixture of cells expressing ECFP alone and EYFP alone
resulted in 0.9% FRET eﬃciency.
It is likely that transiently overexpressed ﬂuorescently labelled G protein subunits
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are in excess over endogenous free G protein subunits. Because the interaction with
Gβγ-subunits is required for functionality and membrane targeting of Gαq [193], the
complementary untagged subunits were always co-transfected to promote heterotrimeric
complex formation and plasma membrane localization. This meant, that a mixture of
three diﬀerent plasmids had to be used for transient transfection of the stable NK1R-
ECFP or wtNK1R cell lines. The DNA ratios of the plasmids for transfection were
adjusted to get as close as possible to a 1:1 stoichiometry of expressed donor and acceptor
labelled proteins. But even when keeping this DNA ratio constant the estimated DA
ratios in the cells varied between diﬀerent experiments in the range from about 0.1 to
10.
Table 8.3 reﬂects the range of apparent eﬃciencies measured in cell suspensions
for NK1R-ECFP with Gq(Cit), Cit-Gβ or Cit-Gγ, and for Gq(ECFP) with Cit-Gβ or
Cit-Gγ. FRET was detected for all combinations, but for NK1R-ECFP/Cit-Gγ and
Gq(ECFP)/Cit-Gγ the apparent eﬃciencies where rather low and could also be due to
overexpression or aggregation of FPs, as it was the case for co-expressed ECFP/EYFP,
which showed an apparent eﬃciency of 5%. In general, the large diﬀerences in apparent
FRET eﬃciencies from experiment to experiment were probably due to high variability
in transfection eﬃciencies, expression levels, DA ratios and the fraction of DA complexes.
Although FRET could be measured, no changes in FRET could be observed when adding
SP or AlF−4 to activate the NK1R or directly the Gα-subunit, respectively.
Gq(Cit) Cit-Gβ Cit-Gγ
NK1R-ECFP 5-45% 5-20% 1-10%
Gq(ECFP) - 10-30% 5-10%
Table 8.3: Range of apparent FRET eﬃciencies of cell suspensions.
The next approach was to use laser scanning confocal microscopy and investigate
single cells (see Chapter 4.4). This oﬀers the advantage to select cells of appropriate ex-
pression levels and membrane localization of the labelled proteins. Again, the apparent
eﬃciency of the ECFP-EYFP fusion protein and the ECFP/EYFP co-expression was
measured and yielded 36%±1.0 and 1.4%±3.5, respectively. This showed the feasibility
of the approach for cytosolic proteins with a 1:1 DA stoichiometry.
Unfortunately, this approach did not improve the FRET measurements for NK1R
and its G proteins. The main reasons were: (i) the excitation of the donor was only
possible at 458 nm meaning that the factor εA/εD for ECFP and Cit is 0.3. This leads
to high direct excitation of the acceptor and in consequence reduces the dynamic range
of the measured FR ratio (see Section 4.4.3). (ii) because of misfocusing deviations due
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to chromatic aberrations, the donor and acceptor images were eﬀectively taken from
slightly diﬀerent planes in the cells. Therefore, donor and acceptor images did not
spatially overlap leading to pixels with extremely high and low FRET.
Because of these problems, we moved to a home-built setup based on a wide-ﬁeld
microscope with a CCD camera coupled to a spectrometer. Here, the deviations due to
misfocusing could be avoided by wide-ﬁeld illumination. Furthermore, the possibility of
recording the entire donor and acceptor spectrum should facilitate monitoring FRET
changes by simply calculating the ratio between donor and acceptor intensities.
Unfortunately, this approach did not work well either. The main problem here was
the ﬁeld of illumination for the two excitation wavelengths used. Donor and acceptor
excitation for a cell or a group of cells of about the size of the illumination ﬁeld did
not overlap, leading to diﬀerent FRET signals depending on the position of the cells in
the ﬁeld of illumination. Nevertheless, the ECFP-EYFP fusion protein yielded a FRET
of 45% ± 6.7, and FRET was also detected between NK1R-ECFP/Gq(Cit), NK1R-
ECFP/Cit-Gβ and Gq(ECFP)/Cit-Gβ for some cells, but no changes upon receptor
activation were observed.
Taking all this together, we can conclude that there is a FRET signal due to inter-
acting NK1R and Gαβγ and also between Gαq and Gβγ. The reason why no changes
could be detected remains unclear. Apart from technical problems, it could also mean,
that NK1R and Gαq form a stable complex, which does not dissociate upon activation.
The same could be true for Gαq and Gβγ as it was seen in the case of Gαi [31]. This
of course is speculation and deﬁnite conclusions need further investigations. A setup
with wider illumination ﬁeld and excitation at 430 nm should be used to improve FRET
measurements. In addition, the proteins investigated by Bünemann et al. [31] and Gales
et al. [117] could be used as a control for receptor-G protein and Gα-Gβγ interaction.
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Chapter 9
Ligand Binding to NK1R in
Tethered Cell Membranes
9.1 Abstract
G protein-coupled receptors (GPCRs) constitute a large class of seven transmembrane
proteins, which bind selectively agonists or antagonists with important consequences
for cellular signaling and function. Comprehension of the molecular details of ligand
binding is important for the understanding of receptor function and in turn for the
design and development of novel therapeutic compounds. Here we show how ligand-
receptor interaction can be investigated in situ with high sensitivity on sensor surfaces
by total internal reﬂection ﬂuorescence (TIRF) measurements. A generally applicable
method for the surface immobilization of membrane proteins was developed using the
prototypic seven transmembrane neurokinin-1 receptor. The receptor was expressed
as a biotinylated protein in mammalian cells. Membranes from cell homogenates were
selectively immobilized on glass surfaces covered with streptavidin. TIRF measurements
showed that a ﬂuorescent agonist binds to the receptor on the sensor surface with similar
aﬃnity as to the receptor in live cells. This approach oﬀers the possibility to investigate
minute amounts of membrane protein in an active form and in its native environment
without puriﬁcation.
9.2 Introduction
G protein-coupled receptors (GPCRs) play a central role in cellular signaling. Be-
cause this class of proteins comprises the most important targets of presently used
medicines [194], there is an increasing demand for reliable and fast methods to probe
105
106 CHAPTER 9. LIGAND BINDING TO IMMOBILIZED NK1R
the function of GPCRs [195] both for investigating the molecular basis of cellular sig-
naling reactions and for developing novel therapeutic compounds [196]. Among the
membrane proteins known to belong to the GPCR superfamily, there are only a few
with well characterized ligands. Orphan GPCRs, for which no ligands have been iden-
tiﬁed yet, represent therefore important potential drug targets [197,198].
Probing the function of large numbers of receptors or libraries of active compounds
can be performed either in suspension using microvolume samples [155] or on surfaces,
taking advantage of optical surface-sensitive detection, which allows on-line distinc-
tion between free and bound molecules without additional separation steps. Typical
methods and devices used are infrared spectroscopy [199–201], surface plasmon reso-
nance (SPR) [202–205], reﬂectometric interference spectroscopy [206], and total inter-
nal reﬂection ﬂuorescence (TIRF) [207,208]. The detection of molecular interactions of
surface-immobilized receptors by ﬂuorescence (either using ﬂuorescent proteins or ﬂu-
orescent ligands) is in general much more sensitive than by SPR, where variations of
eﬀective refractive index at the surface are detected. Although these techniques have
been widely used to investigate DNA molecules and water-soluble proteins, they have
been rarely applied to membrane proteins, mainly because of diﬃculties to obtain large
amounts of these proteins and to keep them under physiological conditions (whole cells,
plasma membranes) in a functionally active form at sensor surfaces.
Surface-sensitive techniques require the immobilization of one of the interacting part-
ners. Apart from chemical cross-linking of the protein to the surface, several surface
immobilization strategies have been used based on high aﬃnity interactions between
oligohistidine sequences and nitrilotriacetic acid (NTA) [209], glutathion-S-transferease
and glutathione, antibody and antigen [210], streptavidin and biotin [202], or com-
plementary oligonucleotides [211]. Presently the combination of biosensing [212] with
microarray technology is of great interest in proteomics since it allows highly parallel
investigation of many proteins [213].
To probe the function of proteins of low abundance, it is prerequisite to reduce pro-
tein consumption to the nano- to picogram region and perform fast, highly sensitive
measurements. In the case of membrane proteins, the investigation can be performed
under physiological conditions, using either whole cells or plasma membranes, but also
on puriﬁed samples using detergent-solubilized proteins or reconstituted proteins in arti-
ﬁcial lipid membranes [214–216]. Membrane protein puriﬁcation is generally very time-
consuming and not trivial since it requires solubilization without altering the function
of the protein.
In this paper,we describe a novel approach to immobilize minute amounts of recombi-
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nant, biotinylated membrane receptor proteins in a uniform orientation on streptavidin
coated sensor surfaces. Using the very sensitive TIRF technology, we show that it is pos-
sible to perform the ﬂuorescent measurements under physiological conditions using non
puriﬁed cell homogenates. This is demonstrated in the case of the neurokinin-1 receptor
(NK1R), a representative GPCR [5,217], investigating ligand-receptor interactions.
9.3 Experimental Procedures
9.3.1 Materials
Bovine serum albumin (BSA), biotinylated BSA (BSA-biot), and biotin were pur-
chased from Sigma (St. Louis, MO). Fluorescein-labelled BSA (BSA-ﬂu), streptavidin,
ﬂuorescein-labelled streptavidin (Strep-ﬂu), and ﬂuorescein-labelled substance P (SP-
ﬂu) were purchased from Molecular Probes (Eugene, OR). Competitive antagonist L-
732,138 was purchased from Tocris Cookson Ltd. (Langford, UK), and [3H]-SR 140333
from NEN (Boston, MA). Phosphate-buﬀered saline (PBS) was used (10mM phosphate,
138mM NaCl, 2.7mM KCl, pH 7.4), supplemented with MgCl2 (3mM) when investi-
gating NK1R-biot.
9.3.2 Neurokinin-1 Receptor
Biotinylated NK1R-biot and wild-type NK1Rs were overexpressed in CHO cells, upon
infection with recombinant Semliki Forest virus encoding for the respective proteins as
described earlier [218]. NK1R-biot comprises a C-terminal biotin tag. This tagged re-
ceptor protein was previously shown to display similar aﬃnity for radioactive substance
P ([3H]-SP) as the wild-type protein and to activate calcium signaling as measured by
intracellular Ca2+ release in Semliki Forest virus infected BHK and CHO cells [218]. Cell
pellets were homogenized with a Dounce homogenizer in PBS prior to storage at -80◦C.
Puriﬁed membranes were prepared from cell pellets according to Mazina et al. [219].
The quantity of NK1Rs in the cell membranes was estimated by radioligand binding
experiments using NK1R antagonist [3H]-SR 140333.
9.3.3 TIRF Measurements
TIRF measurements were performed using a homemade instrument described else-
where [208]. Fluorophores at the quartz-water interface were excited by a laser beam
of 488 nm and 10µW (argon-ion laser 163C, Spectra- Physics, Mountain View, CA) at
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an angle of incidence of 72◦ using a quartz prism (Wisag, Zürich, CH) [208] to cou-
ple the light into the quartz plate (corresponding penetration depth of the evanescent
wave of 100 nm [207]). The prism and plate were kept in optical contact by index
matching ﬂuid (Cargille, Cedar Grove, NJ). The emitted ﬂuorescence was collected by
a water immersion objective (40×, 0.75NA,Zeiss, Oberkochen, D) of an inverted Zeiss
Axiovert ﬂuorescence microscope, passed a dichroic mirror (510nm) and an emission
ﬁlter (band-pass 515-565 nm), and was ﬁnally measured by a photomultiplier (R928,
Hamamatsu, Bridgewater, NJ), using a PC-controlled photoncounting system (System
DM3000, Spex, Middlesex, UK). The sample chamber covered 19.6mm2 of the total
internal reﬂection glass element and had a volume of 33µl. It was connected to a
peristaltic pump allowing a purge of 500µl/min ﬂuid.
9.3.4 Surface Modiﬁcation
Microscope quartz slides (37 × 25 × 1mm3, Wisag) were cleaned successively in Hell-
manex, water, and ethanol at 60◦C for 30 min, followed by 2 min sonication, and ﬁnally
stored in water. For each experiment, a dried quartz slide was assembled in the TIRF
chamber and was incubated for 30 min at room temperature (RT) with a solution of
a mixture of BSA/BSA-biot (each 0.05mg/ml in PBS). The quartz slide sensor sur-
face was then washed with 20ml of PBS prior to addition of a 10µg/ml solution of
streptavidin, supplemented with 0.5% Strep-ﬂu. After 20 min, the detection chamber
was washed with 20ml of PBS prior to addition of the cellular extracts. The cellular
extracts were freshly thawed and sonicated for 3 min at 4◦C in a bath sonicator prior to
resuspension in PBS supplemented with MgCl2 (3mM) to reach a ﬁnal concentration
of 9 nM of NK1R-biot. They were then injected into the detection chamber and left for
1 hour at RT prior to washing of the detection cell with 20ml of buﬀer.
9.3.5 Estimation of the Protein Density on Surface
The amount of BSA adsorbed on the surface was estimated based on its molecular
dimensions [220], assuming a densely packed layer of BSA as expected from the exper-
imental conditions [221, 222]. The solutions of BSA/BSA-biot and streptavidin were
supplemented with a deﬁned amount of homologous ﬂuorescently labelled proteins.
To prevent self-quenching at the surface, low concentration of labelled proteins were
used (2-10% for BSA-ﬂu and 0.5% for Strep-ﬂu). The ratios BSA/streptavidin and
streptavidin/SP-ﬂu were estimated by comparison of the respective signals taking into
account their respective labelling stoichiometry and ﬂuorescence quantum yields.
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9.3.6 Binding of Strep-ﬂu to BSA-biot on Glass Surfaces
Binding of Strep-ﬂu (S) to BSA-biot (B) adsorbed on glass surfaces was measured
by TIRF. The TIRF intensities measured at diﬀerent concentrations of S in the bulk
medium are directly proportional to the number of molecules of Strep-ﬂu bound to the
BSA-biot, allowing one to establish a binding isotherm. Data were ﬁtted according to
the chemical equilibrium B + νS  BSν using a Hill equation, neglecting nonspeciﬁc
binding and depletion,
BS∗ =
SνT
KνSd + S
ν
T
. (9.1)
BS∗ is the normalized measured ﬂuorescence intensity of S bound to B and is propor-
tional to the concentration of BSν . ST is the total molar concentration of Strep-ﬂu
injected, ν is the Hill coeﬃcient, and KSd is the apparent dissociation constant of the
considered complex between Strep-ﬂu and BSA-biot.
9.3.7 Binding of SP-ﬂu to Surface-Immobilized NK1R-biot
TIRF measures total binding (speciﬁc plus nonspeciﬁc) of SP-ﬂu to immobilized NK1R-
biot. The nonspeciﬁc binding of SP-ﬂu was estimated using two methods. In the ﬁrst
approach, increasing concentrations of SP-ﬂu were introduced in the ﬂow chamber, al-
ways in the presence of the same concentration of non-ﬂuorescent SP (at least a 100-fold
excess). The resulting ﬂuorescence signal was shown to be linearly dependent on the
SP-ﬂu concentration in the surrounding medium. The second method for estimating the
nonspeciﬁc binding of SP-ﬂu consisted of an "internal" measurement, which was system-
atically performed in all binding experiments. The total binding of SP-ﬂu was measured
by the stepwise increase of SP-ﬂu concentration. After measuring the ﬂuorescence at
the highest concentration of SP-ﬂu (usually 90 nM), an excess of the non-ﬂuorescent
competitive antagonist L-732,138 [223] was added to remove the speciﬁcally bound SP-
ﬂu at this particular concentration, and the nonspeciﬁcally bound SP-ﬂu was deduced.
Assuming that the nonspeciﬁc binding of SP-ﬂu depends linearly on its concentration
in the surrounding medium, we calculated the amount of nonspeciﬁcally bound SP-ﬂu
for each concentration of ligand tested. The two approaches gave similar values.
The intensities measured at diﬀerent ligand concentrations are directly proportional
to the number of molecules of bound SP-ﬂu. The binding curves of SP-ﬂu (L) to NK1R-
biot (R) were established on various sensor chips. After normalization of their intensities
for 90 nM SP-ﬂu, they were averaged and the average binding isotherm was analyzed
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taking into account the reaction R + L RL, described by
RL∗ =
LT
KLd + LT
. (9.2)
RL∗, the measured normalized ﬂuorescence intensity of the ligand bound to surface-
immobilized receptor is assumed to be proportional to the molar concentration of the
ligand-receptor complex (RL), LT is the total molar concentration of ligand injected,
and KLd is the apparent dissociation constant of the complex RL.
9.4 Results and Discussion
9.4.1 Preparation of Sensor Surfaces
Cell membranes comprising GPCRs were immobilized on quartz surfaces as follows. Our
method is based on the high aﬃnity of streptavidin for biotin [224,225]. As illustrated in
Figure 9.1, the sensor surface is ﬁrst covered by a mixed layer of BSA/BSA-biot to which
an additional layer of streptavidin is bound speciﬁcally. This surface acts as a template
for the controlled tethering of cell membrane fragments comprising biotinylated GPCRs.
BSA-biot NK1R-biot
StreptavidinBSA Ligand
Figure 9.1: Molecular architecture of the functionalized sensor surface. The
quartz slide is ﬁrst covered with a mixed layer of BSA/BSA-biot. An additional layer
of streptavidin is bound speciﬁcally to BSA-biot. Cell membrane fragments comprising
NK1R-biot are ﬁnally assembled on top of the streptavidin layer. Protein concentrations
for BSA, streptavidin, and NK1R-biot were estimated to be 1.8− 5.5× 104, 5− 15× 103,
and 100− 400 molecules/µm2, respectively.
Co-adsorption of a 1:1 molar mixture of BSA and BSA-biot to the quartz surface
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was monitored by TIRF using BSA-ﬂu as a ﬂuorescent probe (2-10mol %). At a con-
centration of 0.1mg/ml total BSA, the formation of the protein layer was completed
within 25 min. 71% of the surface adsorbed layer could not be removed by extensive
wash with buﬀer, which is in agreement with published reports [221,222].
The functional activity of the surface-immobilized mixed BSA/BSA-biot layer was
investigated by quantifying the binding of streptavidin in the presence of 0.5mol %
of Strep-ﬂu by TIRF. A KSd value of 1.27 ± 0.07 nM (Figure 9.2) was obtained. This
value is in agreement with published data for the interaction of streptavidin with protein-
coupled biotin (KSd = 1-10 nM for BSA-biot/streptavidin, depending on the presence
or absence of a spacer between the protein and the biotin-tag [225]) and is considerably
higher than KSd values for the interaction of free biotin with streptavidin (typically
10−15M [225]). A molar ratio between streptavidin and BSA-biot of 0.55 ± 0.13 was
estimated from the TIRF signals.
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Figure 9.2: Binding of streptavidin to surface-immobilized BSA. A mixed layer
of BSA/BSA-biot (1:1) on the sensor surface was purged with solutions of the indicated
concentrations of Strep-ﬂu. Binding of streptavidin to BSA-biot was quantiﬁed by mea-
suring the TIRF signal of speciﬁcally bound Strep-ﬂu after 30 min of incubation. The
insert shows a typical example for the case of 10 nM Strep-ﬂu. The speciﬁc binding of
Strep-ﬂu (continuous line) is about 16 times higher than the corresponding unspeciﬁc
binding (dashed line), which was measured after saturating all binding sites accessible
on streptavidin by non-ﬂuorescent biotin. Fitting (dashed line) the data (•) with a Hill
equation results in a KSd of 1.27± 0.07nM and a Hill coeﬃcient ν of 1.4± 0.1. Data are
presented as mean ± standard deviation of three measurements.
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In our experience, the use of a BSA-biot cushion oﬀered a number of advantages
over a direct immobilization of streptavidin to the glass surface: (i) Functional activ-
ity of streptavidin molecules was improved in a reproducible manner, most probably
by preservation of its structure (no direct interaction with the potentially denaturing
surface [226]) and by controlling its orientation, that is, its accessibility, and its sur-
face concentration. (ii) Nonspeciﬁc binding of proteins and membrane fragments was
minimized (data not shown).
9.4.2 Immobilization of NK1R-biot
We used cell homogenates containing NK1R-biot, which is biotinylated in vivo in its
C-terminal intracellular domain [218]. NK1R-biot was immobilized on the streptavidin-
coated quartz surface by incubating the sensor surface with a cell homogenate comprising
the recombinantly expressed receptors. The sensor surface was then extensively washed
to remove part of the nonspeciﬁcally bound membranes. The tethered membranes
showed high mechanical stability, withstanding extensive washing steps with diﬀerent
buﬀer solutions.
We determined the amount of speciﬁcally immobilized receptor using the ﬂuorescent
agonist substance P ﬂuorescein (SP-ﬂu) [143,154] as a marker for the NK1R-biot at the
surface. As shown in Table 9.1, the presence of the biotin tag on the receptor yielded a
4-fold increase of the signal-to-background ratio, suggesting an improved immobilization
speciﬁcity of cell homogenates on the streptavidin coated quartz surface. It is also re-
markable that no signiﬁcant improvement of the immobilization was observed if puriﬁed
plasma membranes were used instead of crude cell homogenates.
speciﬁc signal/
binding background
biological sample of SP-ﬂua ratiob
cell homogenates + NK1R-biot 63 ± 16% 4.2 ± 0.7
plasma membranes + NK1R-biot 54 ± 17% 2.9 ± 0.5
cell homogenates + wild-type NK1R 32 ± 5% 1.2 ± 0.2
biotin + cell homogenates + NK1R-biot 29 ± 3% 1.0
Table 9.1: Immobilization of NK1R to sensor surfaces covered with BSA/BSA-
biot and streptavidin. a Determined as the percentage of SP-ﬂu removed upon addition
of an excess of competitive antagonist L-732,138. b Ratio of speciﬁc binding/nonspeciﬁc
binding normalized to the ratio of negative control in line 4.
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9.4.3 Binding of SP-ﬂu to NK1R-biot on the Sensor Surface
TIRF was used to measure the binding of the ﬂuorescein-labelled agonist SP-ﬂu [143,154]
on surface-immobilized cell membranes. The dependence of TIRF intensities versus
free ligand concentration can be evaluated assuming a single binding site per receptor
yielding a dissociation constant KLd = 27±9 nM (Figure 9.3). This is in agreement with
values reported [143, 154] showing that neither the biotin tag nor the immobilization
of the protein aﬀect receptor activity signiﬁcantly. According to Tota et al. [143], the
receptor has a low aﬃnity for the agonist SP-ﬂu in the absence (KLd = 48.6 nM) and a
high aﬃnity in the presence of its G protein (KLd = 1.2 nM). The KLd values obtained
here from our TIRF measurements indicate that the majority of NK1R-biot does not
interact with G proteins. This is reasonable since the receptor was overexpressed in
CHO cells in the presence of a low natural abundance of G proteins. However we
cannot exclude a perturbation of the G protein binding to the immobilized receptor.
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Figure 9.3: Binding of SP-ﬂu to NK1R-biot on the sensor surface. Binding of the
ﬂuorescent agonist SP-ﬂu to NK1 receptors (NK1R-biot) in cell membranes on the sensor
surface was measured by TIRF increasing stepwise the concentration of the ﬂuorescent
ligand in the bulk. After incubation with the highest concentration (90 nM) of SP-ﬂu used,
the sensor surface was purged with a solution of a nonﬂuorescent competitive antagonist
(L-732,138) replacing the speciﬁcally receptor-bound SP-ﬂu. The TIRF signal (0.011/nM)
stemming from nonspeciﬁcally bound SP-ﬂu was subtracted from the corresponding total
TIRF signal, obtaining the ﬂuorescence intensity (•) of the speciﬁcally bound ligand.
Fitting a Langmuir isotherm (dashed line) to the data, shown for a typical experiment,
yields a KLd value of 30 nM. Averaged data of four experiments were best ﬁtted by a
Langmuir isotherm with KLd = 27± 9nM.
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9.4.4 Down-Scaling Receptor Consumption
Cell membranes were immobilized on sensor surfaces by using homogenates of CHO
cells, where each cell on average comprised about 1 million receptors. According to
the high signal-to-noise ratio of the measured TIRF signals, experiments on membranes
containing 10 times fewer receptors (100’000 receptors per cell) can be envisaged. From
the normalized ﬂuorescence intensities of Strep-ﬂu and the speciﬁcally bound SP-ﬂu at
saturating concentrations, we estimated the molar ratio of streptavidin/NK1R-biot on
the sensor surface to be 43± 13. This corresponds to a surface concentration of 100-400
receptors/µm2. The measured area on a TIRF sensor was 2000 µm2 (the cross section
of the laser beam on the sensor surface), which corresponds to less than an attomole of
immobilized GPCRs.
9.5 Conclusion
Although the streptavidin (or avidin)-biotin technology is well established for the im-
mobilization of water-soluble biopolymers [227], it is used here in a novel approach for
membrane proteins [202,228]. In this context, our method oﬀers a number of interesting
features summarized as follows.
Previous reports have described immobilization of puriﬁed, detergent-solubilized
GPCRs, which have or have not been subjected to lipid reconstitution [202,228]. Here, it
was demonstrated for the ﬁrst time that biotinylated membrane proteins, here GPCRs,
could be immobilized on a streptavidin-coated quartz sensor surface, using cell ho-
mogenates, without prior puriﬁcation. The selective, high-aﬃnity interaction between
biotin and streptavidin allowed a template-directed puriﬁcation of the receptor uni-
formly oriented on the support.
The NK1R-biot showed fully preserved ligand-binding activity in the tethered mem-
branes. Due to the surface-selective and highly sensitive TIRF ﬂuorescence detection, 1
attomol of receptor molecules was suﬃcient to fully characterize binding of a ﬂuorescent
agonist to the receptors. According to the measured high signal-to-noise TIRF signals,
it is reasonable to extrapolate that ligand receptor interactions can be observed using
tethered membranes comprising at least 10 times fewer functional receptor molecules,
that is, less than 1 attomol of nonpuriﬁed receptor proteins. This opens the possibility
to miniaturize further the size of the sensing regions and also to reduce the amount of
required receptor proteins substantially.
The procedure is of course not limited to biotinylated recombinant membrane pro-
teins. By artiﬁcially integrating biotinylated lipid molecules into the plasma membrane
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of cells prior to homogenization, our procedure can be extended to the immobilization
and functional investigation of any native or recombinant membrane receptor protein
as far as a sensitive procedure is available to characterize the properties of interest.
Alternatively, it is possible to use any biotinylated membrane protein for the selective
immobilization of cell membranes even if other non-biotinylated membrane proteins are
to be investigated. Additional methods for the formation of biotinylated surfaces are
based on thiols [202] or poly(ethylene glycol) polymers [229].
This approach for the selective immobilization of native cell membranes on solid
supports will be of interest for many applications of membrane protein research [174]
such as investigating the function and the biochemical network of membrane proteins
as well as for screening how potential therapeutic compounds might inﬂuence receptor-
mediated cellular functions.
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Chapter 10
Summary and Outlook
In this thesis ﬂuorescence resonance energy transfer (FRET) and total internal reﬂec-
tion ﬂuorescence (TIRF) were used for the investigation of G protein-coupled receptors
(GPCR). The presented data provide new insight into GPCR signal transduction and
have potential for future studies. The thesis includes all the steps from cloning of
genetic constructs through cell culturing and biochemistry to the investigation of the
recombinant proteins by biophysical methods.
NK1R was ﬂuorescently labelled and shown to be functional with respect to ligand
binding and calcium signaling. These ﬂuorescent NK1R constructs can be used for
several diﬀerent studies such as ligand binding, traﬃcking, oligomerization, and protein-
protein interactions. Especially the novel ACP labelling technique has been shown
suitable for FRET experiments, but can also be applied for single molecule studies or
ﬂuorescence correlation spectroscopy, where low concentrations of labelled proteins are
required.
It was shown that the ACP labelling was superior to the labelling with EGFP for
a FRET-based speciﬁc ligand binding assay on single cells. This ligand binding assay
is suitable to measure fast binding kinetics and could be also interesting for screening
assays, because it can be miniaturized and there is no washing step needed.
Exploiting the advantages of the ACP labelling, mainly the multiple labelling at a
desired dye ratio, it was shown by FRET studies that the NK1R does not form homo-
oligomers. The observed FRET signal was strongly dependent on receptor concentration
and therefore indicated that the NK1R is present in microdomains. The method used
here can give further insight into the many open questions in GPCR oligomerization.
Furthermore, it can be applied for other membrane proteins.
The FRET methodology described in this thesis was also used to investigate inter-
actions between NK1R and Gαqβγ-complexes or between Gαq and Gβγ. With most
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combinations, a FRET signal could be detected, but no changes were observed upon
activation of the system. The reason therefore is not obvious. Using a wide-ﬁeld micro-
scope with optimal donor excitation (e.g. 430 nm for ECFP) would increase the signal
to noise ratio and make it possible to detect even small changes in FRET. Furthermore,
receptors and G proteins, where FRET changes upon activation have been detected
before (e.g. β2AR/Gαs and Gαs/Gβγ), should be used as a control.
In general, the FRET methodology established in the laboratory will give new in-
sight into GPCR signal transduction processes. The ACP labelling or other labelling
techniques allowing the precise control of DA ratios will have an impact on the quality
of FRET data and e.g. questions about oligomerization can be answered more precisely.
Furthermore, a novel approach was developed to immobilize NK1R on a surface
and to measure ligand binding by TIRF. The procedure is not limited to biotinylated
recombinant membrane proteins. By artiﬁcially integrating biotinylated lipid molecules
into the plasma membrane of cells, the procedure can be extended to the immobilization
and investigation of any native or recombinant membrane protein. The method can be
miniaturized and is of use for high-throughput screening assays, which is interesting for
the pharmaceutical industry.
Abbreviations and Symbols
Abbreviations and Acronyms
5HT3 Mouse serotonin receptor type 3A
A Acceptor
ACP Acyl carrier protein
AcpS Phosphopantetheine transferase (PPTase) from Escherichia coli
AcSP SP analogue with a N-terminal acetyl group instead of the amino group
BRET Bioluminescence resonance energy transfer
BSA Bovine serum albumin
C-terminus Carboxy-terminus
cAMP Cyclic adenosinemonophosphate
Cit Citrine (EYFP with mutation Q69M)
CoA Coenzyme A
D Donor
D-PBS Dulbecco’s phosphate-buﬀered saline
DMEM Dulbecco’s modiﬁed Eagle medium
DOPG 1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)]
DPPE-Cy5 N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine labelled with Cy5
ECFP Enhanced cyan ﬂuorescent protein
EGFP Enhanced green ﬂuorescent protein
EYFP Enhanced yellow ﬂuorescent protein
FCS Fetal calf serum
FP Fluorescent protein
FRET Fluorescence resonance energy transfer
GDP Guanosinediphosphate
GFP Green ﬂuorescent protein
GPCR G protein-coupled receptor
GTP Guaninetriphosphate
G protein Heterotrimeric GTP-binding protein
HEK293 Human embryonic kidney cells
IP3 Inositol-trisphosphate
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N-terminus Amino-terminus
NK1R Neurokinin 1 receptor, substance P receptor, or NK1 receptor
NK2R Neurokinin 2 receptor
NK3R Neurokinin 3 receptor
NKA Neurokinin A, the physiological agonist for NK2R
NKB Neurokinin B, the physiological agonist for NK3R
PCR Polymerase chain reaction
PPTase Phosphopantetheine transferase
ROI Region of interest
SP Substance P, the physiological agonist for NK1R
TIRF Total internal reﬂection ﬂuorescence
TM Transmembrane helix
Physical Symbols
ηA Detection eﬃciency for the acceptor
ηD Detection eﬃciency for the donor
κ Factor describing the relative orientation in space of the transition dipoles
between the donor and acceptor
λ Wavelength in nm
ΦDT Quantum yield of energy transfer from the donor
φA Fluorescent quantum yield of the acceptor
φD Fluorescent quantum yield of the donor
σCy5 DPPE-Cy5 surface density on vesicle
σr Receptor surface density
τDA Lifetime of the donor in presence of the acceptor
τD Lifetime of the donor in absence of the acceptor
FR FRET ratio: FAD/FA
εA Molar extinction coeﬃcient of the acceptor
εD Molar extinction coeﬃcient of the donor
cA Reduced acceptor concentration (acceptor surface density normalized by
R20
E Eﬃciency of energy transfer
Eapp Apparent eﬃciency of energy transfer
EC50 Half-maximal response. Molar concentration of an agonist that produces
50% of the maximal possible eﬀect of that agonist
FA Fluorescence intensity of acceptor emission in the absence of donor (di-
rect excitation of acceptor only)
fa Fraction of acceptor in complex with donor
FD Fluorescence intensity of donor emission in the absence of acceptor
fD Molar ﬂuorescence of donor emission in the absence of acceptor
fd Fraction of donor in complex with acceptor
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FAD Fluorescence intensity of acceptor emission in the presence of donor (con-
sisting of ﬂuorescence arising from energy transfer and from direct exci-
tation of the acceptor)
FDA Fluorescence intensity of donor emission in the presence of acceptor
fDA Molar ﬂuorescence of donor emission in the presence of acceptor
J(λ) Spectral overlap of the donor emission with the acceptor absorption
Kd Dissociation constant
kc Rate constant of internal coversion
kf Rate constant of radiative decay to the ground state
kisc Rate constant of intersystem crossing to a triplet state
kQ Rate constant of collisional quenching
kr Rate constant of vibrational relaxation
kT Rate constant of long-range resonance dipole energy transfer
n Refractive index of the medium or number of units in a oligomeric com-
plex
NA Avogadro’s number (6.022 · 1023)
pEC50 Negative logarithm of EC50
r Distance between donor and acceptor molecule
R0 Förster Distance (distance at which FRET is 50% eﬃcient)
Rc Distance of closest approach of donor and acceptor
x′DU Mole fraction of donor labelled and unlabelled receptors together
x′U Mole fraction of unlabelled receptors
xA Acceptor mole fraction
xD Donor mole fraction
xmono Mole fraction of monomers
xoligo Mole fraction of oligomers
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